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ABSTRACT OF THE DISSERTATION 
 
Spray Techniques and Lung Cancer Chemoprevention 
by 
Huijing Fu 
Doctor of  Philosophy in Energy, Environmental, & Chemical Engineering 
Washington University in St. Louis, 2011 
Research Advisor:  Professor Da-Ren Chen 
 
Chemoprevention is a promising approach to decrease the incidence of  lung cancer in 
current and former smokers. Directly delivering drugs to the lung could lead to a high 
concentration in the target organ with a lower dose compared to other means of  
administration. The primary advantages of  aerosol delivery in treating lung diseases include 
improving the bioavailability of  the drug in the lung, decreasing the medicine dose, rapid 
action, and reducing the systemic toxicity as well as side effects. Spray techniques are widely 
used for aerosol delivery. Two spray techniques were evaluated in this study for their 
applications in lung cancer chemoprevention. One is the spray-drying process which was 
used to study the inhibitory effects of  chemopreventive agents in lung tumorigenesis using 
the A/J mice model. The other is a twin-head electrospray (THES) to generate 
chemopreventive agent particles. Six single agents and three combinational agents, both 
natural and synthetic compounds, were investigated in the first part of  this dissertation work. 
Polyphenon E and Polyphenon E without EGCG, which are mixtures of  tea catechins, were 
 iii 
 
studied to investigate the prevention mechanism of  the mixture. Resveratrol was delivered in 
aerosol form to improve its efficacy, because it did not show any inhibitory effects in the 
dietary form due to its low bioavailability in the lung. Gefitinib and erlotinib were delivered 
via aerosols to decrease the dose to prevent severe skin toxicities associated with high 
dosages. The effect of  aerosolized budesonide was studied. It was further combined with 
diet Polyphenon E, diet indole-3-carbinal, or oral pioglitazone in the animal study for the 
inhibitory effects over lung carcinogenesis. Aerosol characterization and drug concentration 
in different organs of  mice, after exposure to the drug aerosols, were also carried out to 
facilitate the data interpretation. In the second part of  this work, a twin-head electrospray 
system was developed to be used as an aerosol generator in animal studies of  lung cancer 
chemoprevention. The system consists of  two electrospray heads: one producing positively 
charged particles and the other for negatively charged ones. The coagulation between 
oppositely charged droplets generated by the THES was verified in three ways. The size 
evolution due to coagulation was studied for particles from 10 nm to 710 nm. The effect of  
the initial charge level on the coagulation process was investigated using dual-capillary ES. 
The residual charges on coagulated particles were measured. The particle transmission 
efficiency through the THES system was also characterized. The effect of  particle mixing on 
the coagulation process was also investigated. The THES was then used to generate PLGA-
based controlled release drug particles. Two drugs, budesonide and pioglitazone, were coated 
with PLGA using dual-capillary heads in the THES. Particles in various sizes and different 
drug-to-polymer ratios were prepared. The release profiles of  prepared drug particles before 
and after coagulation were compared to investigate the release characteristics of  THES-
prepared drug particles. A promising application of  the THES, as an electrospray inhaler, 
was also proposed.  
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Chapter 1 
Introduction and Overview  
  
   2 
1.1 Introduction 
Pulmonary drug delivery is an attractive, noninvasive drug administration method 
for many reasons. These include accessing very large absorption area in the lung, 
avoiding metabolism in the liver, decreasing the required dosage, and minimizing 
systemic effects (Gagnadoux et al. 2008). Inhalation is the preferred route of  delivering 
drugs for the treatment and prevention of  lung diseases, especially asthma, chronic 
obstructive pulmonary disease (COPD), and lung cancer (Hohenegger 2010). Through 
inhalation, drug particles are delivered directly to the target organ, which can greatly 
reduce the required dose compared with systemic delivery, offer a more rapid response, 
and minimize the systemic toxicity and side effects. Also, inhalation treatment provides 
an alternate route to introduce drugs systemically, especially for those drugs that can be 
absorbed efficiently from the lung, such as insulin.  
The effectiveness of  the inhalation therapy highly depends on the particle 
deposition efficiency in the target site. The target deposition site varies with the disease. 
For example, for the prevention of  lung cancer, the drug particles need to be spread all 
over the lung, including alveoli, while for the treatment of  lung cancer, the drug 
particles are preferably target-delivered to lung tumor cells. For the treatment of  COPD 
and asthma, the goal is to deliver most of  the drug aerosols to a patient’s 
bronchopulmonary tree and lower airways. The deposition efficiency is affected by 
many factors, including the particle size distribution, inhalation pattern (e.g., flow rate, 
volume, and breath-holding time), airway geometry, and properties of  the inhaled 
particles as well as the carrier. The particle size distribution is controlled by the aerosol 
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generator. There are many techniques to generate drug particles for pulmonary drug 
delivery, with spray technique being an important one.  
Chemoprevention is believed to be a promising approach to control cancer at 
various sites (Sporn and Suh 2002). Although significant improvement has been 
achieved in the prevention of  breast cancer (Chang 1998), no successful lung cancer 
chemoprevention is available. Aerosol delivery of  chemopreventive agents for lung 
cancer attracted more and more attention, especially after the failure of  clinical trials 
using retinoids (Spinella and Dmitrovsky 2000). Animal studies showed that two major 
issues believed to be responsible for the failure, low bioavailability at the target site and 
high systemic toxicity, could be solved by using aerosol delivery. An important step in 
research regarding lung cancer chemoprevention is to select effective chemopreventive 
agents with low systemic toxicity or side effects using animal models. Thus, to use 
aerosolized drugs in animal studies provides direct and important guidance for future 
research. 
The overall objective of  this dissertation is to advance our current knowledge on 
using spray techniques in lung cancer chemoprevention. Accordingly, it has two major 
parts: (1) investigation of  chemopreventive agents using aerosol delivery in mice model 
and (2) design and evaluation of  a twin-head electrospray system which could 
potentially be used in lung cancer chemoprevention study. The motivations for each 
part are explained in the following sections. 
   4 
1.2 Part I: Aerosol Delivery and Evaluation of  Agents 
for Lung Cancer Chemoprevention 
The aerosol route has many advantages compared to traditional routes of  
administration, such as oral, intravenous and intraperitoneal. Experiments using 
aerosolized chemopreventive agents had been carried out by different groups (Anderson 
et al. 2008; Kohlhaufl et al. 2002; Wattenberg et al. 2000; Wattenberg et al. 1997). 
However, most animal inhalation studies used devices which generate super-micrometer 
particles, mainly due to the lack of  suitable generators for animal studies. All drugs need 
to be first tested in animal models before moving to human clinical trials. Besides 
particle size, deposition efficiency is also related to the geometry of  the respiration 
pathway, which is much smaller in animals like mice or rats than in humans. Figure 1.1 
shows the deposition efficiency in the respiratory system as a function of  particle size in 
mice and human. The deposition is related to both particle diameter and the target site. 
For lung cancer chemoprevention, the agents need to be delivered to deep lung region 
including alveolus. As shown in Figure 1.1, the highest deposition efficiency in alveoli 
was particles less than 0.1 µm. For mice, the smallest particle size tested in the 
experiment was 0.27 µm, which had the highest deposition in alveoli than larger 
particles. Meanwhile, 0.27 µm particles have a higher deposition in the alveoli of  mice 
compared to human, indicating that small particles are more suitable in studies using 
mice. Instead of  using devices designed to generate super-micrometer particles, new 
devices are needed in animal studies to generate particles with diameters in sub-
micrometer and nanometer ranges with stable performance. 
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Figure 1.0.1 Particle deposition efficiency as a function of  particle size in various sites of  the respiratory 
system of  CF1 mice (a) (Raabe et al. 1988) and human lung (b) (ICRP 1994). 
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The main goal of  lung cancer chemoprevention is to identify the effective agents. 
The studies on molecular and cell levels provide the information on the mechanisms, 
which are the first step in identifying the effective agents. Next, the drugs need to be 
investigated using animal models. Most of  the animal studies use traditional route of  
administration. However, the same drug may show a different efficacy when it is 
delivered differently. In aerosol delivery, drug particles are directly introduced to the 
target site without going through the first-pass metabolism. It is an effective method for 
those drugs that have low bioavailability in the lung when introduced orally. However, it 
may not work for those drugs whose active form is the metabolites. The drugs which 
may potentially be used in aerosolized form need to be first studied in animal models. 
  A major cause of  lung cancer is long term exposure to cigarette smoke. Due to the 
complexity of  the composition of  the cigarette smoke, it is unlikely to prevent lung 
cancer by only inhibiting one pathway. Thus, using more than one agent at the same 
time has a larger opportunity to successfully prevent the incidence of  lung cancer. 
Different agents for the combination study can be administrated in different routes. The 
combinational effects also need to be investigated in animal models. 
The major objectives for the first half  of  the dissertation are: 
1. To design a mice dosing system for the evaluation of  chemopreventive agents 
using aerosol delivery. 
2. To study the chemopreventive effects of  single aerosolized agents using A/J 
mice model. 
3. To study the combination effects of  agents administrated by aerosol and oral 
delivery using A/J mice model. 
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1.3 Part II: Design and Evaluation of  a Twin-head 
Electrospray (THES) System 
Electrospray is capable of  generating highly charged monodisperse particles in a 
wide range of  particle sizes. The highly charged particles are most likely deposited if  the 
charge level is not reduced. The common techniques to reduce the charges are corona 
discharge, radioactive materials, and soft X-ray (Chen et al. 1995; Ebeling et al. 2000; 
Hogan et al. 2004). When two electrosprays are operated at the same time, with one 
spray generating positive charged particles and the other generating negative ones, 
collisions between oppositely charged particles occur when the two aerosol flows meet. 
The collision serves as a charge neutralization process. Also, the collision can be used 
for various applications. 
 The idea of  using two sprays to generate countercharged droplets was first 
proposed in 1965 to study the collision of  two charged droplets (Schneider et al. 1965).  
It was later used to encapsulate solid particles with liquid droplets using electrostatic 
attractions (Langer and Yamate 1969). Several studies using the twin-head electrospray 
had been carried out after that. The twin-head electrospray was designed and the 
application in powder production was evaluated (Borra et al. 1999; Camelot et al. 1999). 
Based on the application, the experiments only focused on supermicrometer particles. 
No systematic characterization about the operation conditions and the coagulation 
process was carried out. A direct observation of  the interaction between the counter-
charged droplets was done by Almekinders et al.(Almekinders and Jones 1999). Two 
multi-jet electrohydrodynamic atomizers were used to generate counter charged droplets, 
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which were attracted by electrostatic force. No characterizations were carried out 
regarding the particles formed after the charge-enhanced coagulation. The interactions 
between fibers and particles generated by countercharged electrospinning and 
electrospray were studied (Morozov and Vsevolodov 2007; Park et al. 2008) Morozov et 
al. used eletrospinning to generate polymer fibers, and electrospray to generate ions to 
neutralize the charged fiber indirectly. No interactions between oppositely charged 
particles were observed in the system designed by Park et al.  
Although twin-head ES has been designed and studied previously, no systematic 
characterization of  the system and the droplets coagulation process was done. Further, 
most of  the particles generated by the previous twin-head ES systems were 
supermicrometer particles. All the previous studies only used single capillary ES. Dual-
capillary ES has many advantages over single capillary ES, especially on the synthesis of  
controlled release drug particles. The coagulation between droplets generated by two 
spray heads with dual-capillary provides more variations in the generation of  drug-
loaded polymer particles for controlled drug delivery. 
The major objectives of  the second half  of  the dissertation are: 
1. To design a twin-head electrospray system. 
2. To systematically evaluate the performance of  the twin-head ES. 
3. To synthesize and characterize controlled-release drug particles using the twin-
head ES system. 
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1.4 Dissertation Structure 
In addressing the two major components, the whole dissertation contains nine 
chapters. The first part, including chapters 2, 3, 4 and 5, focuses on aerosol delivery and 
evaluation of  lung cancer chemopreventive agents in animal models. The second part, 
including chapters 6, 7, and 8, focuses on the design and evaluation of  the twin-head 
electrospray. Brief  descriptions of  each chapter are as follows. 
In chapter 1, a general introduction in which the background, the motivations and 
objectives of  this study are given. 
PART I: 
Chapter 2 first introduces the background of  lung cancer chemoprevention and the 
standard approaches in evaluating the chemopreventive agents. The advantages of  
aerosol delivery are summarized. Previous studies using aerosol delivery in lung cancer 
chemoprevention studies are overviewed. The combination treatments in lung cancer 
chemoprevention are reviewed. 
In chapter 3, a nose-only mice dosing system was developed. The protocols of  
animal experiment used in this study are introduced. All the chemopreventive agents 
tested in this study are summarized. 
Chapter 4 gives the results of  the evaluation of  aerosolized single agents for their 
inhibitory effects on lung tumorigenesis using A/J mice model. First, Polyphenon E and 
Polyphenon E without EGCG were compared, with the objective of  determine the role 
of  EGCG, which is the main component of  Polyphenon E, in the chemopreventive 
effects of  the mixture form (Polyphenon E). Another natural agent, resveratrol, was 
also studied as a chemopreventive agent for lung cancer by aerosol delivery. Three 
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synthetic agents, gefitinib, erlotinib and budesonide, all of  which are approved by FDA 
for use in humans, were investigated for their efficacy in inhibiting lung carcinogenesis 
separately.  
In chapter 5, the combination treatments of  aerosolized budesonide and oral 
Polyphenon E, indole-3-carbinol, and pioglitazone were studied for lung cancer 
chemoprevention. The inhibitory effects of  single agents as well as the combination 
groups are compared. 
PART II: 
In chapter 6, a general introduction on electrospray, electrostatic coagulation and the 
adhesive forces between particles are given. Previous studies regarding twin-head 
electrospray system are summarized. A potential application of  twin-head ES as an 
inhaler is discussed. 
In chapter 7, a twin-head electrospray system was designed. The performance was 
evaluated. First, the coagulation between counter charged particles were verified by 
particle size distribution, particle morphology, and fluorescence tracers. The particle size 
distributions before and after coagulation were compared. The initial particle size 
ranged from 10 nm to over 700 nm. The effects of  initial charge levels on the size 
distribution evolution were studied by using dual-capillary ES in each spray head. The 
residual charge of  particles exiting the system after coagulation was studied by an 
electrostatic precipitator. The ratios of  neutral, positively and negatively charged 
particles were compared for three particle sizes. A second coagulation chamber with the 
two spray heads facing each other was also designed and its performance was evaluated 
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and compared with the 90 degree chamber. At last, the particle transmission efficiency 
through the system was characterized by fluorescence analysis. 
In chapter 8, the twin-head ES system was used to generate drug-loaded polymer 
particles. The particle size distribution and morphology with or without coagulation was 
characterized. The in vitro release profile was characterized by high performance liquid 
chromatography. Two drugs, budesonide and pioglitazone, were used for this study. The 
release profiles of  particles generated by one spray head were compared to that of  
particles generated by both spray heads with different solution and liquid feed flow rate. 
A biexponential kinetic model was used to facilitate the comparison. The possibility of  
using the THES system as an inhaler was discussed. 
In chapter 9, the accomplishments of  this dissertation are summarized, as well as 
the issues and challenges that deserve future research efforts. 
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Chapter 2  
Review of  Lung Cancer 
Chemoprevention 
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2.1 Chemoprevention of  Lung Cancer 
Cancer is a major public health problem in many countries of  the world, accounting 
for 23.2% of  death in the United States in 2010 (Jemal et al. 2010). Although scientists 
have made great achievements on both the basic understandings of  the nature of  cancer 
and the clinical treatments of  certain types of  cancer, the death rates from some 
common cancers still have not decreased (Sporn and Suh 2000). Lung cancer is the 
most common form of  cancer in the world and the leading site of  cancer-related death 
in both men and women (Jemal et al. 2010). The current therapies of  lung cancer are 
surgery, radiation and chemotherapy. Despite improvements in traditional therapies, the 
5-year survival rate is still low. About 90% of lung cancer patients die from their disease 
(Minna et al. 2002). Instead of  trying to cure lung cancer, another approach, named 
chemoprevention, controls lung carcinogenesis (Hecht et al. 2009).  
Chemoprevention is defined as the use of  natural or synthetic agents to reverse, 
prevent, or delay carcinogenic progression to invasive cancer. Chemoprevention 
approaches target the carcinogenic process at early and potentially reversible stages, 
focusing on the inhibition of  one or many elements in the stepwise progression toward 
cancer (Minna et al. 2002; Soria et al. 2003). Chemoprevention is considered to be an 
important approach to decrease the incidence of  lung cancer in current and former 
smokers. It has been applied with some early success to individuals at high risk for 
breast, prostate, and colon cancer, but chemoprevention for lung cancer is not currently 
available.  
An important objective of  lung cancer chemoprevention research is to identify 
active agents. Two major criteria of  a successful agent are effectiveness and tolerable 
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toxicity. In chemoprevention study, it is important to verify the efficacy and safety of  
the tested agents in cell culture and animal models before clinical trials. The most 
common animal model in evaluating chemopreventive agents for lung cancer is the 
carcinogen-treated A/J mice model. The A/J mouse is susceptible to both 
spontaneously-occurring and carcinogen-induced lung tumors. The tumors induced by 
carcinogens in A/J mice are similar to human lung adenocarcinoma in morphological, 
histological and molecular features. More than 50 chemicals have been tested for the 
chemopreventive efficacy in the A/J mouse (Hecht et al. 2009). 
Chemoprevention can be considered at three different major strategy levels: primary, 
secondary and tertiary (Cohen and Khuri 2002; Soria et al. 2003). Primary prevention 
intends to delay the development of  cancer or hinder its progression in healthy 
individuals who are at high risk, such as current and former smokers. Besides 
chemoprevention drugs, approaches such as smoking prevention and cessation 
treatments are also considered as primary chemoprevention. Secondary 
chemoprevention aims at persons with evidence of  early disease, but without the 
symptoms of  cancer. Tertiary prevention targets patients who had previous cancers, 
trying to prevent the development of  second primary tumors, to prevent the recurrence, 
and to decrease the morbidity of  established disease. Since the stages of  tumor 
progression of  each level are quite different, chemopreventive agents with different 
action mechanisms are used at each level. As a result, researchers developed different 
protocols in mice models. 
Based on the three chemoprevention strategies, three protocols are commonly used 
in the A/J mice model: complete, post-initiation and tumor progression (Figure 2.1) 
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(Wang et al. 2006). In the complete chemoprevention protocol, the treatment begins 
one to two weeks before carcinogen initiation and continues until the termination 
(usually 20-24 weeks), which corresponds to the primary prevention in healthy 
individuals. This model is usually used to examine agents that either block carcinogen 
initiation or suppress tumor growth. The post-initiation chemoprevention protocol 
begins intervention two to three weeks after carcinogenic initiation and continues 
thereafter. The whole protocol usually lasts for 20-24 weeks. Postinitiation mimics the 
situation in ex-smokers. It can determine the tumor suppressing effects after the tumor 
initiation, which mainly corresponds to the secondary chemoprevention. The tumor 
progression chemoprevention protocol begins treatment 12-20 weeks after carcinogen 
initiation and continues until approximately 40 weeks post-carcinogen initiation. This 
protocol determines the inhibitory effects of  preventive agents on the progression from 
adenomas to carcinomas.  
 
Figure 2.1 Three commonly used chemoprevention protocols in A/J mice model. (a) complete protocol; 
(b) post-initiation protocol; (c) tumor progression protocol. The arrow indicates carcinogen initiation; the 
dot indicates the beginning of  intervention 
There are four commonly used carcinogens in mouse study to induce lung tumors: 
benzo[a]pyrene (B(a)P), 4‑(methylnitrosamino)‑1‑(3‑pyridyl)‑1‑butanone (NNK), 
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ethyl carbamate (urethane) and vinyl carbamate (VC). B(a)P and NNK present in 
cigarette smoke and are highly carcinogenic. The tumors induced by B(a)P and NNK at 
about 20 weeks after initiation are all adenomas. Urethane is a constituent of  some 
cigarette smoke. VC, which is a carcinogenic metabolite of  urethane, has not been 
analyzed in cigarette smoke or in smokers as a metabolite. Generally, urethane and VC 
could induce more tumors than B(a)P and NNK even with a smaller dosage. Besides, 
adenocarcinoma appears earlier when urethane or vinyl carbamate are used as the 
carcinogen (Gunning et al. 2000). 
2.2 Administrations by Aerosol 
Typical administrations used in animal models include oral, intravenous, 
intraperitoneal, and aerosol routes (Francis et al. 1994). In order to reach a good 
inhibitory effect, higher doses of  chemopreventive agents are often required, which may 
cause systemic toxicity and adverse effects. Targeting chemopreventive agents to specific 
areas within the body can result in better efficacy and lower toxicity (Lippman et al. 
1998).  
Inhaling medications are widely accepted as the optimal route of  administration in 
treating lung diseases. Directly delivering drugs to the lung could lead to a high 
concentration in the target organ with a lower dose compared with other means of  
administration. Aerosol delivery for therapy of  lung cancer in humans has been 
reported to be effective without adverse effects (Tatsumura et al. 1993; Verschraegen et 
al. 2004).  
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The pioneer work using aerosolized agent for lung cancer chemoprevention was 
done by Wattenberg et al. (Estensen et al. 2004; Wattenberg and Estensen 1997; 
Wattenberg et al. 2000; Wattenberg et al. 1997). Budesonide, which is currently used in 
the treatment of  asthma through inhalation, was investigated for its chemopreventive 
effects on lung carcinogenesis by aerosol delivery.  Aerosolized budesonide at low dose 
inhibited all stages of  progression from hyperplasia formation to cancer in B(a)P 
induced mice lung carcinogenesis without systemic toxicity. 
Retinoids are natural occurring or synthetic vitamin A metabolites and analogs 
(Cohen and Khuri 2002; van Zandwijk 2005). Their effectiveness in human cancer 
chemoprevention was associated with systemic vitamin A toxicities. Also, retinoids can 
be easily bound to serum proteins or be cleared in gut and liver, which highly limited the 
delivery of  retinoids to lung tissues when they are orally administrated (Cohen and 
Khuri 2005). The clinical studies regarding retinoids in the prevention of  lung cancer 
did not show enough efficacies (Toma et al. 1999). Through aerosol inhalation, retinoids 
can be delivered locally at low dosage without compromising the antitumorigenic 
responses (Spinella and Dmitrovsky 2000). Aerosol delivery of  a liposomal formulation 
of  all-trans-retinoic acid to the lungs of  mice effectively retained its biological activity 
without observable adverse effects (Parthasarathy et al. 1999). Inhalation of  isotretinoin, 
which showed protective effects against second aerodigestive tumors in a randomized 
clinical trial, could reduce tumor multiplicity at a relatively low dose without obvious 
toxic signs (Dahl et al. 2000). A preliminary clinical study using aerosolized vitamin A 
suggested that inhalation of  retinyl esters could be a promising therapeutically approach 
for chemoprevention of  lung cancer (Kohlhaufl et al. 2002). 
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2.3 Combination treatment 
Cigarette smoking, both active and passive, is the main epidemiologically proven 
cause of  lung cancer (Staempfli and Anderson 2009). Cigarette smoke is a complex 
mixture of  carcinogens and toxicants. Lung cancer caused by long-term exposure to 
cigarette smoke is unlikely to be prevented through intervention in a single pathway. 
Combinations of  drugs that act through different mechanisms may achieve greater 
chemopreventive efficacy (Hecht et al. 2009).  
The combination approach for cancer chemoprevention has many advantages. By 
carefully selecting the combinational agents, a better preventive efficacy can be reached 
with a lower dose of  each agent. However, additive or synergistic toxicities of  the agents 
should also be investigated (Castonguay 1992).  
The combination treatment in lung cancer chemoprevention has been investigated 
using multiple agents in animal models. ElBayoumy et al. compared the efficacy of  four 
agents (1,4-phenylenebis(methylene)selenocyanate (p-XSC), phenethyl isothiocyanate 
(PEITC), indole-3-carbinol (I3C), and d-limonene (d-L)) individually and in 
combination using complete protocol in A/J mice (ElBayoumy et al. 1996). All single 
agents and the combination group inhibited tumor multiplicity significantly. No statistic 
difference in the inhibitory effects was observed between the mixture and single agents. 
Dietary myo-inositol and dexamethasone were found to inhibit tobacco smoke-induced 
lung tumors in A/J mice (Witschi et al. 1999). However, the average tumor number 
induced by tobacco smoke was relatively low (2.1 for control group). Dietary myo-
inisitol was also combined with aerosolized budesonide or dietary N-acetyl-S-(N-2-
phenethylthiocarbamoyl)-L-cysteine (PEITC-NAC) (Hecht et al. 2002; Wattenberg et al. 
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2000). The combination groups showed better efficacy than either single agents. Further, 
the combination of  PEITC-NAC, myo-inositol and I3C or 3,3'-diindolylmethane (DIM), 
showed significant inhibition on tumor multiplicity (Kassie et al. 2010b). Dietary I3C 
and silibinin were studied for  combinatorial treatment with in A/J mice (Dagne et al. 
2011). Enhanced inhibition of  lung adenocarcinoma was observed in the combination 
group with low doses without causing obvious loss of  body weight. Green tea 
polyphenols and atorvastatin were found to have synergistic inhibition on lung 
tumorigenesis (Lu et al. 2008). Another study investigated the effects of  dietary green 
tea extract and aerosolized difluoromethylornithine (DFMO) during lung tumor 
progression in A/J mice (Anderson et al. 2008). However, no additive or synergetic 
effects were observed due to the lack of  efficacy of  aerosolized DFMO. Synthetic 
triterpenoids (CDDO-Methyl ester or CDDO-Ethyl amide) and rexinoids (LG100268 
or NRX194204) were combined for the prevention and treatment of  lung cancer (Liby 
et al. 2009). The combination groups showed significant inhibition on tumor load over 
each single agents as well as the control group in both post-initiation and progression 
protocol. 
The results of  animal studies confirmed that by selecting appropriate agents, the 
combination treatment may achieve better inhibitory effects than single agents. The 
successful animal experiments provide guidance and potential candidates for future 
studies. 
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Chapter 3  
Experimental Setup and Protocols 
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3.1 Animal Experiments 
In this study, we used the post-initiation protocol in carcinogen-treated A/J mice to 
test the efficacy of  chemopreventive agents. Female A/J mice at 6 weeks of  age were 
obtained from Jackson Laboratories (Bar Harbor, ME). The use of  animals was 
approved by the Washington University’s Institutional Animal Care and Use Committee. 
The mice were housed at a constant temperature and humidity and received a standard 
diet and water. 
At the age of  8 weeks, carcinogen was given to mice to initiate the tumor growth. 
Either a single intraperitoneal (i.p.) dose of  B(a)P (100 mg/kg body weight) in 0.2 ml of  
tricaprylin, or two doses of  VC by i.p. injection once a week for two consecutive weeks 
(0.32 mg per injection in 0.2 mL sterile saline without adjusting pH) were used. Two 
weeks after the first dose of  carcinogen, the mice were randomly divided into control 
and treatment groups with 12 or 16 mice per group to reach the enough sample size. 
Each treatment group had a corresponding control group. The only difference between 
the treatment group and its corresponding control group was that the treatment group 
received chemopreventive agent while the control group was treated with the same 
procedure but with only the vehicle containing no drug. Daily treatments were then 
began, and continued till the end of  the experiment (Figure 3.1). All solutions were 
prepared just before use and stored on ice until use. Ethanol and dimethyl sulfoxide 
were used to dissolve the chemopreventive agents used in the aerosol delivery. 
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Figure 3.1 Treatment protocol 
Three different administration methods were used. For aerosol delivery, the mice 
were exposure to aerosols for 2 min, 8 min, or 15 min per day, 5 times per week. The 
dose time varied with the tested drug. An air control group was included in the first 
animal study. The mice in the air control group were placed in the chamber for 8 
minutes without aerosol treatment to control for potential stress factors affecting 
tumorigenesis. No difference was observed between the air control group and the 
solvent control group, so no air control group was included in the later studies. The 
inhalation exposures were conducted using a custom-built nose-only 12-mice exposure 
chamber (Figure 3.2). The design of  the chamber ensures that the mice place their 
noses into the cone of  each exposure port in the chamber. Mice were randomly placed 
into exposure ports to minimize any bias inside the chamber.  
   23 
 
Figure 3.2 Nose-only mice exposure chamber used in the animal study (with mice loaded in the chamber) 
For diet treatment, the drug was well mixed with AIN-76A purified powder diet 
(Dyets, Inc., Bethlehem, PA) and 3% sugar with a KitchenAid (St. Joseph, MI) for one 
hour. Diet was prepared twice per week. Fresh diet in the cages was changed daily. For 
gavage treatment, the mice received gavage once per day, five days per week. 
The body weights of  the mice were measured every week for the duration of  
treatments. Mice were sacrificed 20 or 22 weeks after exposure to carcinogen by CO2 
asphyxiation. Lungs from each mouse were fixed in Tellyesniczky’s solution (Zhang et al. 
2000) overnight, followed by 70% ethanol. The fixed lungs were evaluated under a 
dissecting microscope to obtain fixed surface tumor count and individual tumor size. 
Tumor volume (V) was calculated using tumor diameter (r) based on the following 
formula: V (mm3) = 4πr3/3 (Zhang et al. 2000). The total tumor volume in each mouse 
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was calculated by the sum of  all tumors. Tumor load was determined by averaging the 
total tumor volume of  each mouse in each group. 
3.2 Aerosol Procedure 
Drug solution was atomized into droplets by a custom-made Collison Type atomizer. 
The flow rate was 2.27 l/min. Aerosol flow was then passed through two diffusion 
dryers containing silica gel to remove water from droplets and/or two scrubbers with 
active carbon which was used to remove organic solvent. The resulting dry aerosol flow 
with only desired chemicals was then introduced into the nose-only exposure chamber 
from the top inlet. Effluent aerosol was discharged from an opening at the bottom of  
the chamber. The schematic diagram is shown in Figure 3.3. 
 
Figure 3.3 Schematic diagram of  aerosol delivery system used in animal study 
The size distribution of  the aerosol was determined by scanning mobility particle 
sizer (SMPS) spectrometer, which includes an Electrostatic Classifier (TSI model 3080), 
Filter 
Compressed Air 
Diffusion Dryer  
Atomizer 
Scrubber  Mice Exposure Chamber 
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a Differential Mobility Analyzer (DMA, TSI model 3081) and a Condensation Particle 
Counter (CPC, TSI model 3025). Geometric median diameter (GMD), mass median 
diameter (MMD), geometric standard deviation (GSD) and particle concentration were 
obtained. Online samples were taken inside the chamber right at the place where mice 
were supposed to inhale aerosols. Different sample points were used to monitor the 
concentration uniformity inside the chamber.  
The mass of  inhaled drug was calculated as follows: 
[ ] tRMVCM aerosolinhaled ⋅⋅= ,                                              (3.1) 
where [C]aerosol is the aerosol concentration of  drugs (mg/l), RMV is the respiratory 
minute volume of  the mouse (0.025 l/min, based on Guyton’s formula), and t is the 
exposure time.  
The deposition ratio of  aerosol within the lung was estimated by the following 
equation:  
%100% ×=
inhaled
tissue
M
M
Deposition ,                                           (3.2) 
where Mtissue (mg) is the mass of  drug that deposited in lung.  
The dose could be estimated by: 
body
aerosol
body
inhaled
M
tRMVC
M
M
Dose
××
== ,                                       (3.3) 
where bodyM  
is the body weight which was taken to be 0.020 kg. However, in reality, 
the deposition ratio is always less than 1, so the actual dose is less than the estimate 
value. 
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3.3 Tissue Assay Method 
Lung, liver, and spleen tissues were weighed, frozen in liquid nitrogen, and crushed 
with a precooled hammer. The tissue homogenate was collected in a tube with 0.2 ml 
DMSO. Then the samples were vortexed for 2 minutes and centrifuged at 13,000 rpm 
for 15 minutes at 4 °C. Supernatants were tested by HPLC. The serum was extracted as 
above for lung tissue homogenate. 
Drug concentrations in tissue and serum samples were determined by HPLC. The 
HP 1100 series HPLC system consisted of  an autosampler, a binary pump, a 
thermostatted column compartment, and a diode array detector (Agilent Tech, Santa 
Clara, CA). The HPLC column was 4.6 × 75 mm Zorbax SB-C18 3.5 µm column. The 
column temperature was maintained at room temperature (20 °C). The flow rate of  the 
mobile phase was 1 ml/min. The detection conditions are summarized in Table 3.1. 
Polyphenon E and Polyphenon E without EGCG are mixtures. The largest peak of  
Polyphenon E and Polyphenon E without EGCG was used for quantification, 
respectively. EGCG peak was used for Polyphenon E and EC peak was used for 
Polyphenon E without EGCG.  
For certain drugs, a pre-experiment was carried out to determine the dosed mass in 
the lung. Mice were exposed to the drug aerosols for 10 minutes. Following exposure, 
the animals were sacrificed by cervical dislocation at designated time points with the end 
of  the exposure marked as time zero. Blood was obtained by retro-orbital sinus 
sampling, and collected into plastic centrifuge tubes. The lung was severed at the carina, 
the esophagus and trachea were removed. All samples were stored in liquid nitrogen 
until assayed. 
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Table 3.1 HPLC methods for drugs used in this study 
Drug Mobile Solution A 
Mobile 
Solution B 
Volumetric 
Ratio of  
A:B 
Detection 
Wavelength 
(nm) 
Polyphenon E 0.1% Trifluoroacetic acid Methanol 75:25 254 
Budesonide 20 mM Sodium phosphate, pH=2 Acetonitrile 45:55 254 
Gefitinib 50 mM ammonium acetate, pH=2.2 Acetonitrile 80:20 348 
Erlotinib 0.1% Trifluoroacetic acid Acetonitrile 65:35 348 
Resveratrol 50 mM ammonium acetate, pH=2.2 Acetonitrile 70:30 308 
Pioglitazone 20 mM Sodium phosphate, pH=2 Acetonitrile 70:30 269 
Indole-3-Carbinol H2O Acetonitrile 40:60 280 
3.4 Statistical Analysis 
Tumor multiplicity and tumor load were analyzed by two sided Student’s t test using 
Microsoft Excel 2007 (Microsoft, Redmond, WA) to determine differences in the 
number and in the size of  lung tumors per mouse between groups. In all t-tests, the 
level of  statistical significance was set at P < .05. For combination treatment, tumor 
multiplicity and tumor load were analyzed by one-way analysis of  variance (ANOVA) 
followed by the Tukey’s multiple comparisons to determine differences in the number 
and in the size of  lung tumors per mouse between groups. The level of  statistical 
significance was set at p < 0.05. 
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3.5 Summary of  Chemopreventive Agents Evaluated 
in This Study 
Four sets of  experiments were carried out. Eight drugs of  different concentrations, 
including natural and synthesis chemicals, individually or combined with others, were 
tested for their inhibitory effects on lung tumorigenesis using A/J mice model and 
postinitiation protocol. Table 3.2 summarized the chemopreventive agents and the 
evaluation conditions. The chemical structures of  the agents or their main component 
are shown in Figure 3.4. 
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Table 3.2 Chemopreventive agents evaluated using postinitiation protocol in A/J mice model 
Agents Administration Concentration Carcinogen Complete Time 
Polyphenon E Aerosol 15 mg/ml B(a)P Jul. 2008 
Polyphenon E 
without EGCG 
Aerosol 15 mg/ml B(a)P Jul. 2008 
Budesonide Aerosol 
1 mg/ml 
B(a)P 
Jul. 2008 
6 mg/ml Jul. 2008 
3 mg/ml Nov. 2009 
Iressa Aerosol 
1 mg/ml 
VC Feb. 2009 
5 mg/ml 
5 mg/ml B(a)P Nov. 2009 
10 mg/ml 
B(a)P Sep. 2010 
15 mg/ml 
Tarceva Aerosol 
1 mg/ml 
VC Feb. 2009 
5 mg/ml 
5 mg/ml B(a)P Nov. 2009 
Resveratrol Aerosol 
7.5 mg/ml 
VC Feb. 2009 
15 mg/ml 
15 mg/ml B(a)P Nov. 2009 
Budesonide + Poly E 
Aerosol + 
Diet 
3 mg/ml + 
1.5% 
B(a)P Nov. 2009 
Budesonide + I3C 
Aerosol + 
Diet 
3 mg/ml + 
10 µmol/g 
B(a)P Nov. 2009 
Budesonide + 
Pioglitazone 
Aerosol + 
Gavage 
3 mg/ml + 
10 mg/kg 
B(a)P Nov. 2009 
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Figure 3.4 The chemical structures of  evaluated chemopreventive agents   
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4.1 Polyphenon E and Polyphenon E without EGCG 
The cancer preventive activity of  tea polyphenols has received more attention in 
recent years. The inhibitory activities of  tea constituents against carcinogenesis at 
different organ sites have been demonstrated in many animal models (Clark and You 
2006; Ju et al. 2007). Polyphenon E is a well-defined pharmaceutical-grade mixture of  
polyphenols that contain at least five different catechins: epicatechin (EC), epicatechin 
gallate (ECG), epigallocatechin (EGC), gallocatechin gallate (GCG), and (–)-
epigallocatechin-3-gallate (EGCG), with EGCG being the most abundant (Chang et al. 
2003; Clark and You 2006). EGCG was thought to be the most active component in 
Polyphenon E (Clark and You 2006). However, our previous results showed that 
aerosolized EGCG failed to show significant inhibition on both tumor multiplicity and 
tumor load, while at the same concentration, aerosolized Polyphenon E inhibited lung 
tumorigenesis significantly (Yan et al. 2007). This indicates that EGCG alone can not 
show chemopreventive activity by aerosol administration, which means that either 
EGCG is not the active compound in Polyphenon E, or EGCG will show its antitumor 
activity only when other components in Polyphenon E are present. The capacity of  
other tea catechins to prevent lung tumorigenesis needs to be further investigated to 
understand the role of  EGCG in chemoprevention of  lung cancer. This work was 
initiated to compare the inhibitory activities of  Polyphenon E and Polyphenon E 
without EGCG by aerosol administration.  
Since 65 w.t.% (weight percent) of  Polyphenon E is EGCG, the daily delivery time 
for Polyphenon E without EGCG group was 2.8 min/day with the agent and 5.2 
min/day with only air. The total exposure time of  Polyphenon E without EGCG group 
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was also 8 min/day, which was the same as other groups. Therefore, mice in treatment 
groups were exposed to similar amount of  tea catechins other than EGCG. 
4.1.1  Composition Analysis for Polyphenon E and 
Polyphenon E without EGCG.  
The chromatogram of  Polyphenon E and Polyphenon E without EGCG are 
comparatively shown in Figure 4.1. Eight different catechins were identified in 
Polyphenon E, with EGCG being the most abundant. EGCG accounted for 65 w.t.% 
of  Polyphenon E, while no other catechins accounted for more than 10 w.t.%. The 
concentrations of  the various catechins in Polyphenon E without EGCG were: 
epicatechin (EC), 44%; epigallocatechin (EGC), 28% and the other six catechins, 7%. 
Small amount (1.4%) of  EGCG was also detected in Polyphenon E without EGCG. 
The composition of  Polyphenon E and Polyphenon E without EGCG are given in 
Table 4.1. Although the ratios among different catechins were different, the main 
difference between Polyphenon E and Polyphenon E without EGCG was in the 
amount of  EGCG.  
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Figure 4.1 Chromatogram of  Polyphenon E and Polyphenon E without EGCG. Data provided by Mitsui 
Norin Co., Ltd. (Japan) 
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Table 4.1 Composition of  Polyphenon E and Polyphenon E without EGCG 1 
  Abbreviation Polyphenon E 
(w.t.%) 
Polyphenon E 
without EGCG 
(w.t.%) 
Caffeine - 0.7 0.8 
(+–)-gallocatechin (+–)-GC 0.2 1.7 
(–)-epigallocatechin (–)-EGC 3.8 28.2 
(+–)-catechin (+–)-C 1.0 3.3 
(–)-epigallocatechin gallate (–)-EGCG 65.0 1.4 
(+–)-epicatechin (+–)-EC 9.1 43.9 
(–)-gallocatechin gallate (–)-GCG 3.5 0.1 
(–)-epicatechin gallate (–)-ECG 6.6 0.3 
(–)-catechin gallate (–)-CG 0.2 0.2 
Total catechins - 89.4 79.1 
 
4.1.2  Aerosol Characteristics  
The typical size distributions of  Polyphenon E and Polyphenon E without EGCG 
inside chamber are given in Figure 4. Polyphenon E and Polyphenon E without EGCG 
yielded similar particle size distribution with geometric median diameter (GMD) of  0.13 
µm and geometric standard deviation (GSD) of  1.6. The mass median diameter (MMD) 
of  Polyphenon E and Polyphenon E without EGCG was around 0.3 µm. Two sample 
points were chosen inside the exposure chamber to measure the size distribution. No 
difference in GMD, MMD and GSD was found among measurements at each sample 
point. 
                                                        
1 Data provided by Mitsui Norin Co., Ltd. (Japan). 
  
Figure 4.2 Size distributions of  Polyphenon E (a) and Polyphenon E without EGCG (b) in exposure 
chamber. The mean size of  (a) and (b) was 0.13 µm, with the geometric standard derivation around 1.65.
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4.1.3  Deposition Dose  
In Figure 4.3, the concentrations of  EGCG in Polyphenon E and EC in 
Polyphenon E without EGCG in the lung were given as a function of  time following 
aerosol exposure. The concentration of  EGCG or EC immediately following the 
exposure was taken as time 0. Because the catechins in Polyphenon E other than 
EGCG are in really small mass ratio (less than 10 %) and the dose mass of  aerosol was 
much lower than that achieved by other administrations such as oral, the concentrations 
of  other catechins in Polyphenon E were lower than the detection limit. For 
Polyphenon E without EGCG, EC was detected and used for quantification. Since 
EGCG is 65% of  Polyphenon E in mass and EC is 44% of  Polyphenon E without 
EGCG in mass, the concentrations of  Polyphenon E and Polyphenon E without 
EGCG were estimated. The concentration of  Polyphenon E was 0.042 µg/mg in lung 
at time 0, and decreased with time slowly. After 50 minutes, the concentration was 0.023 
µg/mg. The half-life of  elimination of  Polyphenon E from the lung, t1/2,lung, was 
estimated to be 48 minutes. The concentration of  Polyphenon E without EGCG 
showed similar trend as Polyphenon E. The dosed mass and delivery ratio were 
summarized in Table 4.3. The concentration of  all the tea catechins in Polyphenon E 
and Polyphenon E without EGCG in the serum was much lower (less than 0.04 µg/ml) 
for both cases.  
Using an average body weight of  0.020 kg, the inhaled dose of  was calculated to be 
4.19 mg/kg for Polyphenon E and 1.83 mg/kg for Polyphenon E without EGCG. The 
dose level was much lower than oral administration previously reported (Yan et al. 
2006b). The deposited mass in lung was calculated from assayed lung concentration, 
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given as deposited mass versus body weight. The deposition ratios of  Polyphenon E and 
Polyphenon E without EGCG group were 5.2% and 5.4%, respectively (Table 4.3). 
Pharmocokinetic parameters of  EGCG in Polyphenon E and EC in Polyphenon E 
without EGCG are given in Table 4.2. The following parameters were estimated as 
described earlier (Liao et al. 2004b): maximum lung concentration (Cmax); the mean area 
under the lung concentration-time curve (AUC); the area arising from the last measured 
time point to infinity (AUC∞); the mean resident time (MRT∞) and the lung half-life (t1/2). 
The residence time of  EC in Polyphenon E without EGCG was shorter than that of  
EGCG in Polyphenon E, which showed that EGCG has a longer half-life than EC 
when EGCG was in mixture form. 
 
Figure 4.3 Concentration of  EGCG in Polyphenon E (circle) and EC in Polyphenon E without EGCG 
(triangle) in the lung following aerosol inhalation. The concentration of  EGCG in Polyphenon E and EC 
in Polyphenon E without EGCG in mice lung decreased with time slowly. Bar: SD. 
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Table 4.2 Pharamacokinetic parameters of  EGCG in Polyphenon E and EC in Polyphenon E without 
EGCG for aerosol administration (Data shown in Mean ± SD) 
Parameters 
EGCG in  
Polyphenon E 
EC in Polyphenon E 
without EGCG 
Cmax (µg/g) 27.3 ± 2.6 20.2 ± 2.2 
AUC (µg/g  h) 16.2 ± 1.9 9.8 ± 1.3 
AUC∞ (µg/g  h2) 28.0 ± 2.5 14.1 ± 1.2 
MRT∞ (h) 1.15 ± 0.11 0.64 ± 0.07 
t1/2 (min) 48.1 ± 7.2 34.7 ± 5.2 
 
4.1.4  Chemoprevention Effects 
Mice were treated by aerosol for 18 weeks after the injection of  B(a)P. During the 
experiment, all mice showed great tolerance to treatment with either Polyphenon E or 
Polyphenon E without EGCG. No significant difference in body weight was observed 
(Figure 4.4).  
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Figure 4.4 Body weight monitoring during the treatment duration. The body weights of  mice were 
measured every week. During the whole treatment duration, the body weights of  mice increased slowly, 
no signs of  systemic toxicities and adverse effects were found. 
Table 4.3 Effects of  aerosolized Polyphenon E and Polyphenon E without EGCG on lung tumorigenesis 
in female A/J mice (Data shown in Mean ± SE) 
Group 
Deposited 
mass 
(µg/kg) 
Deposi-
tion (%) 
Final Body 
Weight (g) 
Tumor 
Multiplicity  
Inhibi
-tion 
Tumor 
Load 
(mm3) 
Inhibit
-ion 
Air Control - - 22.6 ± 1.9 5.69 ± 0.83 - 1.78 ± 0.33 - 
Solvent Control - - 22.3 ± 1.8 5.88 ± 0.55 - 1.74 ± 0.21 - 
Polyphenon E 
without EGCG 
80 ± 22 5.4 ± 1.6 23.2 ± 1.8 4.73 ± 0.70 20.0%  1.36 ± 0.31 21.8%  
Polyphenon E 222 ± 51 5.2 ± 1.3 23.1 ± 1.7 2.79 ± 0.64 52.5%  0.66 ± 0.24 62.1%  
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 Effects of  aerosolized Polyphenon E and Polyphenon E without EGCG on lung 
tumorigenesis in female A/J mice are summarized in Table 4.3. B(a)P induced an 
average of  5.69 ± 0.83 (n=16) tumors per mouse in air control group and 5.88 ± 0.33 
(n=16) tumors per mouse in solvent control group. Results in tumor multiplicity and 
tumor load showed no significant difference in Air control group and Solvent control 
group. Mice treated with Polyphenon E showed a significant decrease in both tumor 
multiplicity [53%; 2.79 ± 0.64 (n=14)] and tumor load [62%; 0.66 ± 0.24] when 
compared to the solvent control group (P < 0.001), while Polyphenon E without 
EGCG treatment exhibited statistically non-significant reduction in tumor multiplicity 
[20%; 4.73 ± 0.70 (n=15)] and tumor load [22%; 1.36 ± 0.31].  
Green tea has been shown to be able to inhibit the development of  lung cancer in 
several animal models (Cao et al. 1996; Liao et al. 2004a; Mimoto et al. 2000; Yang et al. 
1998b; Zhang et al. 2000). Polyphenon E, which is a mixture of  polyphenols containing 
at least five tea catechins, is believed to be the effective agent. Among tea catechins, 
EGCG, which is believed to have the highest antioxidant activity, is the most abundant 
catechin in Polyphenon E. However, our previous results showed that Polyphenon E 
could decrease tumor load by 59%, while at the same concentration, EGCG did not 
show any significant inhibition on tumor multiplicity and tumor load (Yan et al. 2007). 
Results also showed that inhalation of  EGCG did not modulate tobacco smoke-induced 
tumorigenesis (Witschi et al. 2004). Herein, by aerosol administration, Polyphenon E 
without EGCG was compared to Polyphenon E on their chemopreventive efficacies 
under the same condition. The results showed that Polyphenon E inhibited lung 
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tumorigenesis, which agreed to our previous results, while Polyphenon E without 
EGCG failed to inhibit lung tumor growth.  
In this study, the aerosolized Polyphenon E inhibited tumor multiplicity by 53% and 
tumor load by 62%, respectively (Table 4.3). The results show that by aerosol delivery, 
Polyphenon E could both cause the regression of  the tumorigenesis once the tumor 
progression was initiated by carcinogen, and inhibition of  tumor growth during tumor 
progression. This indicates that Polyphenon E is preventive at all stages of  
carcinogenesis, which agrees with previous results (Wang et al. 1992). However, at the 
same concentration as catechins besides EGCG in Polyphenon E, Polyphenon E 
without EGCG did not show statistically significant effects in both the tumor 
multiplicity (20%) and tumor load (22%) (Table 4.3).  
Based on HPLC analysis, the main difference between the chemical composition of  
Polyphenon E and Polyphenon E without EGCG was the content of  EGCG. 65% of  
Polyphenon E was EGCG, while in Polyphenon E without EGCG, there was only 1.4% 
EGCG left, compared to 44% of  EC and 28% of  EGC (Table 4.1). Although there 
were differences in the ratios among other tea catechins in Polyphenon E and 
Polyphenon E without EGCG, the difference became minor when compared to the 
difference in the amount of  EGCG. The difference in tumor multiplicities between 
Polyphenon E group and Polyphenon E without EGCG group was attributed to the 
presence of  EGCG.  
It is believed that EGCG is the main active compound in tea catechins. However, in 
our previous study, aerosol administration of  EGCG alone at the same concentration 
for 18 weeks in a similar way as this study did not show significant effects in the tumor 
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load (Yan et al. 2007). Combined previous results without this study, EGCG in purified 
form and Polyphenon E without EGCG both showed no significant effect on lung 
tumorigenesis, while Polyphenon E inhibited tumor multiplicities by 53%. This indicates 
that EGCG or other tea catechins alone are not as active as the combined form, 
Polyphenon E, in lung tumor inhibition. Both EGCG and other tea catechins need to 
be present in order to show inhibitory effect on lung cancer. One possible reason might 
be that the presence of  other tea catechins may affect the absorption (Yang et al. 1998a), 
biologic activity, or other properties of  EGCG. Because tea catechins have similar 
chemical structure, they compete for any resources they need, such as binding sites, and 
thus the metabolic conversion of  EGCG is retarded and the residence time of  EGCG 
increases when compares to the case in which pure EGCG was administrated. 
Comparison of  pharmacokinetic properties of  both decaffeinated green tea (DGT) and 
purified EGCG in rat administrated by intravenous injection showed that other 
components in DGT could affect the plasma concentration and elimination of  EGCG 
(Chen et al. 1997). In our study, the half-life of  EGCG in Polyphenon E in lung after 
aerosol administration was longer than that of  EC in Polyphenon E without EGCG 
(Table 4.2). Detailed information on EGCG and Polyphenon E administrated by 
aerosol is not available so far. More studies are expected in the future. 
4.1.5 Aerosol Generation  
Compared to other methods of  administration, aerosol inhalation could reach 
higher efficacy at the primary target sites in the lung with relatively low dose level (Liao 
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et al. 2004b). In this study, an improved aerosol delivery system was used to give a stable 
size distribution with smaller particle mean size and standard deviation.  
Particle size is always a key factor which affects lung deposition of  an aerosol. In 
general, for humans, aerosols with a MMAD less than 3 µm have a higher chance of  
reaching the lower airways and being deposited in the alveoli (Labiris and Dolovich 
2003). Because of  the smaller size of  respiration tract, the optimal particle size for mice 
inhalation study is much smaller. Study showed that for CF1 mice, 0.27 µm particles 
reached a higher deposition ratio in lung (45.4%) than larger particles (dp > 1.09 µm, 
deposition ratio less than 9.7%) (Raabe et al. 1988). Most of  previous studies on 
aerosolized chemopreventive agents used different types of  nebulizer to generate 
aerosol. Although nebulizer has a high mass throughput, it usually generates particles in 
a relatively wide size range with large geometric standard deviations (Dahl et al. 2000; 
Liao et al. 2004b; Yan et al. 2007). In this study, we used a custom-built atomizer, which 
gave a much narrower particle size distribution. The MMAD of  Polyphenon E and 
Polyphenon E without EGCG were both around 0.3 µm, which was more favorable in 
mice inhalation study. Besides, both Polyphenon E group and Polyphenon E without 
EGCG group used the same concentration (15 mg/ml), which assured that the MMAD 
were similar for both cases.  
In this study, diffusion dryer and scrubber were used to remove water and ethanol 
from droplets formed by atomizer before aerosol flow entering the exposure chamber, 
which guaranteed that mice were exposed to only the desired agents and air. Each 
diffusion dryer contained two concentric cylinders formed by an inner wire screen 
cylinder and an acrylic outer cylinder. The annular volume between cylinders was filled 
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with silica gel. As aerosol flowed through the inner cylinder, water vapor diffused 
through the wire screen and into the silica gel. Scrubber worked similarly with diffusion 
dryer, except that scrubber had four inner wire screen cylinder to enhance removal 
efficiency. In diffusion dryer, particle loss was minimized because the particles did not 
come into contact with the silica gel or active carbon. Compared to diffusion dryer, the 
evaporation-condense method, which was commonly used in previous studies (Liao et 
al. 2004b; Yan et al. 2007), introduced extra particle loss because of  thermophoresis 
(Zheng 2002), which reduced the deposition ratio in lung.  
The in-situ size distribution measurement showed that the inhalation system 
provided aerosol with stable size distribution. In this study, the SMPS system was used 
to provide the high-resolution size distribution in the exposure chamber. Through the 
sample hole at the bottom of  the chamber, two sample points were selected. Each 
sample point was at the height where mice nose would be. Thus, the exact size 
distribution information of  the aerosol in the chamber could be collected. No 
significant difference in size distributions indicates that the aerosol inside exposure 
chamber was uniform and stable. All mice were exposed to particles with the same size 
distribution. Furthermore, mice had been put into the chamber randomly throughout 
the treatment. So, mice in the same group could be considered to receive similar 
treatment.  
4.2 Resveratrol 
Using naturally occurring compounds as potential cancer chemopreventive agents in 
human populations is a promising approach. Researchers have observed that a lower 
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risk of  lung cancer among consumers of  wine compared with consumers of  other 
alcohol beverages, which may be partly attributed to the high resveratrol content, 
particularly in red wine (Athar et al. 2007). Resveratrol, a polyphenol found in numerous 
plant species, including mulberries, peanuts, and grapes, has been shown to have anti-
inflammatory, antioxidant, antitumor, neuroprotective, and immunomodulatory 
activities. As a chemoprevention agent, resveratrol has been shown to inhibit tumor 
initiation, promotion, and progression (Jang et al. 1997). Although evidence regarding 
gene expression has been found in cell studies, dietary resveratrol failed to show 
inhibitory effect on B(a)P induced tumorigenesis in A/J mice (Berge et al. 2004; Hecht 
et al. 1999). No resveratrol or resveratrol conjugates were detectable by HPLC in the 
lung tissue of  animals receiving a resveratrol-supplemented diet, which means 
resveratrol given in the diet might not be able to reach the lung tissue in sufficient 
concentrations, or in a biologically active form. Aerosol administration could deliver 
resveratrol directly to the lung despite the poor bioavailability of  resveratrol, which 
makes it possible to utilize resveratrol as a chemopreventive agent for lung cancer.  
In this study, aerosolized resveratrol was investigated in female A/J mice model and 
post-initiation protocol. Two sets of  experiments were carried out, with different 
carcinogens, B(a)P and VC. Two concentrations of  reveratrol, 7.5 mg/ml and 15 mg/ml, 
corresponding to estimated doses at 4.15 mg/kg and 8.30 mg/kg, were compared in the 
first set of  experiment using VC as carcinogen. 
The average body weight of  all groups are shown in Figure 4.5. In general, the body 
weight of  mice receiving resveratrol was close to the control groups. There was no 
statically significant difference. Resveratrol was well tollerented under the given dose. 
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The concentrations of  resveratrol in the lung and serum of  the B(a)P treated 
groups were obtained using the method described in section 3.2. The concentration in 
the lung was 0.56 ± 0.42 µg/g lung. Low concentration of  resveratrol was also detected 
in the serum samples. The average concentration was 0.075 ± 0.005 µg/ml. 
The inhibitory effects of  aerosolized resveratrol are given in Figure 4.6. Aerosolized 
resveratrol showed no effects on tumor multiplicity in VC-treated groups. Significant 
inhibition on tumor load was achieved. The decrease in tumor load was 26.3% (P<0.05) 
and 36.0% (P<0.01). The inhibitory effects increase with the increase of  dose. For 
B(a)P treated groups, only the high dose was tested. The average tumor multiplicity and 
tumor load were decreased by 37.1% (P<0.01) and 72.0% (P<0.05), respectively.  
 
Figure 4.5 Body weight during the treatment duration 
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(b) 
Figure 4.6 Chemopreventive effects of  resveratrol in femail A/J mice model. (a)VC was used as 
carcinogen; (b) B(a)P was used as carcinogen. *, P < 0.05; **, P < 0.01; bar, SE 
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The mechanisms of  the anti-tumor effects of  resveratrol have been well studies in 
cell models (Shankar et al. 2007; Ulrich et al. 2005; Whyte et al. 2007). However, 
previous studies using diet resveratrol did not show effects on lung tumorigenesis 
(Berge et al. 2004; Hecht et al. 1999). Animal studies and limited human studies showed 
that resveratrol was mainly accumulated in liver and kidney following its ingestion 
(Wenzel and Somoza 2005). And it has been observed that resveratrol has a very short 
half  life resulting in low bioavailability. In this study, resveratrol was directly introduced 
into the lung through inhalation. The presence of  resveratrol in the lung was confirmed 
by HPLC analysis. The tumor load was decreased by aerosolized resveratrol at both 
doses in B(a)P or VC treated mice. The results indicate that aerosol delivery is a 
promising approach to delivery the drug to the lung for lung cancer chemoprevention, 
especially for those drugs with low bioavailability. 
4.3 Gefitinib (ZD1839, Iressa) 
Gefitinib (ZD1839, Iressa) is orally active inhibitors of  the intracellular tyrosine-
kinase domain of  the epidermal growth factor receptor (EGFR). EGFR is a tyrosine 
kinase (TK) receptor of  the ErbB family that is activated in a variety of  cancers, which 
makes it a promising target for anticancer therapy. Selective blockade of  the EGFR via 
newly developed agents has been an exciting area of  research and can be an effective 
therapeutic approach, specifically in non-small-cell lung cancer (NSCLC) (Hida et al. 
2009). 
Gefitinib is the first molecularly targeted agent to be registered for advanced 
NSCLC. In preclinical studies of  cell lines and human tumor xenografts, gefitinib 
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produced growth inhibition in a variety of  solid tumor types, including lung cancer. 
Four phase I clinical trials showed that gefitinib had durable clinical benefit, and it was 
well tolerated. In two phase II trials in Japan, Europe and United States, the overall 
response rate was 10% to 18%. Higher response rate and longer survival were achieved 
in Asian patients and never-smokers. Based upon these data, gefitinib received approval 
in May 2003 in the United States as third-line monotherapy treatment of  patients with 
this disease. (Pao and Miller 2005) Gefitinib is now approved in 36 countries worldwide 
as a first-, second-, or third-line treatment option of  NSCLC (Hida et al. 2009).  
The possibility of  using gefitinib as a chemopreventive agent was studied using the 
female A/J mice model (Yan et al. 2006a). Gefitinib, which is administrated by diet, 
significantly inhibited both tumor multiplicity and tumor load. However, higher doses 
(larger than 200 mg/kg) caused light alopecia, especially at the region near the eyelid, in 
some treated mice. The dose level could be reduced by administrating gefitinib by 
aerosol.  
4.3.1 Aerosol Characteristics 
Figure 4.7 shows the size distribution of  gefitinib which were obtained using 
scanning mobility particle sizer (SMPS). In our study, the diameter of  gefitinib particles 
ranged from 0.02 µm to 0.6 µm, with over 95% of  the particles smaller than 0.3 µm, 
which is more favorable for aerosolized drug delivery in mouse model (Raabe et al. 
1988). The calculated dose was 0.55 mg/kg, 2.77 mg/kg, 5.53 mg/kg, and 8.30 mg/kg 
for gefitinib concentration of  1 mg/ml, 5 mg/ml, 10 mg/ml, and 15 mg/ml, 
respectively. The recommended dose for human is 250 mg/day, corresponding to 4.17 
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mg/kg using a 60 kg body weight. Note that the calculated dose for aerosol delivery is 
much higher than the real dose. When estimating the dose, one assumption is that all 
the particles being inhaled deposit in the lung, which is hardly the case. The deposition 
ratio varies with particle size. No 100% deposition can be achieved for the particle sizes 
covered in the given size distribution. 
 
Figure 4.7 The size distribution of  Gefitinib particles (5 mg/ml solution) used in the mice experiment. 
4.3.2 Pharmacokinetics of  Gefitinib 
A pre-experiment was first carried out to determine the pharmacokinetics of  
gefitinib in the lung. Gefitinib was dissolved in 1:1 Dimethyl Sulfoxide/Ethanol 
solutions at a concentration of  5 mg/ml. Mice were exposed to gefitinib particles for 15 
minutes. Following exposure, the animals were sacrificed at designated time points with 
the end of  the exposure marked as time zero. Blood and lung samples were obtained, 
assayed and analyzed using HPLC.  
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In Figure 4.8, the concentrations of  gefitinib in the lung were given as a function of  
time following aerosol exposure. The pharmacokinetic parameters are shown in Table 
4.4. The maximum concentration was achieved at time 0. The concentration in lung 
decreased with time. The half-life of  gefitinib in the lung was about 90 min. Gefitinib 
was not detected in blood until the last time point, which was 1 hour after exposure. 
The results indicated that by aerosol route, gefitinib was mainly accumulated in the lung 
1 hour after delivery. Hence, the systemic effects of  gefitinib could be highly reduced by 
aerosol delivery. 
 
Figure 4.8 Concentration of  Gefitinib in the lung following 15 min aerosol inhalation. Bar, SD. 
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Table 4.4Pharamacokinetic parameters of  gefitinib for aerosol administration (Data shown in Mean ± SD) 
Parameters Gefitinib 
Cmax (µg/g) 1.81 ± 0.38 
AUC (µg/g  h) 2.37 ± 0.83 
AUMC∞ (µg/g  h2) 2.14 ± 1.11 
MRT∞ (h) 0.90 ± 0.52 
t1/2 (min) 1.33 ± 0.60 
4.3.3 Experimental Design 
The treatment protocol was shown in Figure 5(a). Female A/J mice at 8 weeks of  
age were used in this experiment. Three sets of  experiments were carried out. Two 
carcinogens, B(a)P and VC were compared. Two weeks after the i.p. injection of  
carcinogen, mice were randomly divided into control and treatment groups with 12 
mice per group: (1) VC solvent control group (DMSO: Ethanol = 1:1); (2) Gefitinib-VC 
1 mg/ml; (3) Gefitinib-VC 5 mg/ml; (4) B(a)P solvent control group 1 (DMSO: 
Ethanol = 1:1); (5) Gefitinib-B(a)P 5 mg/ml; (6) B(a)P solvent control group 2 (DMSO: 
Ethanol = 1:1); (7) Gefitinib-B(a)P 10 mg/ml; (8) Gefitinib-B(a)P 15 mg/ml.  
All the mice were exposed to aerosols for 15 min/day and 5 days/week. The 
treatment began two week after the carcinogen injection and continued for 18 (VC 
treated groups) or 20 weeks (B(a)P treated groups (Figure 4.9). 
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Figure 4.9 Experiment protocol 
4.3.4 Chemopreventive Effects 
There were no significant body weight differences between gefitinib treated groups 
and their corresponding control groups for all the experiments (Figure 4.10), indicating 
that at the given concentrations, aerosolized gefitinib was well-tolerated. 
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Figure 4.10 The average body weight of  mice during the treatment: (a) VC treated groups; (b) B(a)P 
treated groups. 
The results of  tumor number and tumor load in all the groups were shown in 
Figure 4.11 (a), (b), (c), and (d). VC induced an average of  43.3 ± 1.5 (n=12) tumors per 
mouse in the solvent control group. The average tumor load was 21.6 ± 5.6 mm3. 
Gefitinib showed no inhibitory effects on tumor number. However, the tumor load was 
decreased with the increase of  gefitinib concentration. The 1 mg/ml gefitinib decreased 
the tumor load by 26% (p<0.05), and the 5 mg/ml gefitinib decreased tumor load by 33% 
(p<0.05). B(a)P induced an average of  5.0 ± 0.63 (n=12) tumors per mouse in the 
solvent control group 1 and 4.1 ± 0.62 (n=12) tumors per mouse in solvent control 
group 2. The average tumor load in B(a)P solvent control group 1 and 2 were 0.30 ± 
0.07 mm3 and 0.78 ± 0.17 mm3, respectively. Similar to the VC groups, aerosolized 
gefitinib (5 mg/ml, 10 mg/ml and 15 mg/ml) did not show significant inhibitory effects 
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on tumor multiplicity, while the decrease in tumor load were 39%, 46%, and 56%, 
respectively, when compared with the corresponding solvent control group.  
   
  
Figure 4.11 (a) Tumor number of  VC-treated groups. (b) Tumor load of  VC-treated groups. (c) Tumor 
multiplicity and tumor load of  the first set of  B(a)P treated groups. (d) Tumor multiplicity and tumor load 
of  the second set of  B(a)P treated groups. Bar, SE. *, P<0.05. 
In this study, both B(a)P and VC were used to induce lung carcinogenesis. B(a)P 
mainly induces lung adenomas, while VC mainly induces lung adenocacinomas and 
carcinomas (Gunning et al. 2000). As shown in Figure 5, aerosolized gefitinib decreased 
the tumor load in both B(a)P and VC treated groups, which indicates that although 
gefitinib could not cause tumor regression once the tumor progression was initiated by 
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carcinogens, it can significantly inhibit the growth of  adenomas, adenocacinomas and 
carcinomas. The HPLC results confirmed that gefitinib was mainly concentrated in the 
lung. Furthermore, there was no alopecia observed on any of  the aerosolized gefitinib-
treated mice, while when gefitinib was administrated orally,  alopecia was observed at 
the region near eyelid (Yan et al. 2006a). By using aerosol delivery, the desired dose 
could be highly reduced comparing with oral route. In the mean time, the systemic 
toxicity could be minimized by directly introducing the drug to the target organ. Thus, 
aerosol delivery of  gefitinib could be a promising approach in lung cancer 
chemoprevention. 
4.4 Erlotinib (OSI-774, Tarceva) 
Erlotinib, which is also an orally available reversible ATP-competitive inhibitor of  
the wild-type EGFR TK, showed positive response in clinical trials. A randomized, 
placebo-controlled Phase III trial (BR.21) conducted by National Cancer Institute of  
Canada Clinical Trials Group, in which the overall survival was 6.7 months for erlotinib 
versus 4.7 months for placebo (Shepherd et al. 2005), directly led to the approval of  
erlotinib by the US Food and Drug Administration in 2004 for treatment of  patients 
with locally advanced or metastatic NSCLC after failure of  at least one previous 
chemotherapy regimen (Pao and Miller 2005). More clinical trials using erlotinib for the 
treatment of  early stage, locally advanced and metastatic NSCLC have carried out. The 
results have been well summarized (Gridelli et al. 2010; Iyer and Bharthuar 2010). 
Pharmacoeconomic analysis indicated that in patients with advanced NSCLC, second- 
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or third-line treatment with erlotinib is clinically effective in improving survival (Lyseng-
Williamson 2010). 
The mechanisms of  erlotinib are similar to gefitinib. Erlotinib competes with 
adenosine triphosphate (ATP) for the ATP-binding sites localized on the EGFR 
intracellular domain and inhibits autophosphorylation by EGFR-tyrosine kinase, which 
results in blockage of  downstream EGFR signal transduction pathways, cell cycle arrest 
and inhibition of  angiogenesis ((Iyer and Bharthuar 2010)).  
The major side effects of  erlotinib are skin rash and diarrhea, similar to gefitinib. 
The recommended daily dose for human is 150 mg/day. The possibility of  using 
erlotinib as a chemopreventive agent was studied using the female A/J mouse model. 
4.4.1 Aerosol Characteristics 
First, the aerosol characteristics of  erlotinib generated by the aerosol delivery system 
were determined by SMPS system. The size distribution of  erlotinib particles generated 
by the atomizer using 5 mg/ml erlotinib solution is shown in Figure 4.12.  
 
Figure 4.12 Size distribution of  5 mg/ml Erlotinib 
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The geometric median diameter (GMD) was 0.118 µm, and the geometric standard 
deviation (GSD) was 1.6. The aerosol mass concentration aerosolC was 132 µg/liter. 
Similarly, for 1 mg/ml erlotinib solution, the GMD and aerosolC  decreased with the 
solution concentration. The GMD was 0.07 µm, and the aerosol mass concentration 
aerosolC was 26.4 µg/liter. The custom-made Collison type atomizer could provide stable 
aerosol size distribution, which ensured that the mice received the same dose everyday 
throughout the experiment. As shown in Figure 4.12, the diameters of  erlotinib 
particles generated by the system ranged from 0.02 µm to 0.6 µm. 90% of  the particles 
were 0.03 to 0.4 µm in diameter, which was in the favorable ranges for mice inhalation 
study (Raabe et al. 1988). 
4.4.2 Parmacokinetics of  erlotinib 
A pre-experiment was carried out to determine the pharmacokinetics of  erlotinib in 
the lung. Mice were exposed to erlotinib (5 mg/ml solution) for 15 min. In Figure 4.13, 
the concentrations of  erlotinib in the lung were given as a function of  time following 
aerosol exposure. Pharmocokinetic parameters of  aerosolized erlotinib were calculated 
based on Figure 4.13. The following parameters were estimated as described earlier 
(Liao et al. 2004b): maximum lung concentration (Cmax); the mean area under the lung 
concentration-time curve (AUC); the area under first moment curve (AUMC∞); the 
mean resident time (MRT∞) and the lung half-life (t1/2). The data are given in Table 4.5. 
The half-life of  erlotinib in the lung was about 29 min, while the mean resident time 
was 42 min. Low concentration in the serum (0.11 µg/ml) was detected 1 hour after 
exposure. The results indicate that after aerosol delivery, erlotinib mainly stayed in the 
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lung for the first hour after being inhaled. Compared with gefitinib, erlotinib had a 
shorter MRT∞ and t1/2 in the lung. 
 
Figure 4.13 Concentration of  erlotinib in the lung following aerosol inhalation Bar, SD. 
Table 4.5 Pharamacokinetic parameters of  erlotinib for aerosol administration. (Data shown in Mean ± 
SD) 
Parameters Tarceva 
Cmax (µg/g) 4.59 ± 0.70 
AUC (µg/g  h) 2.92 ± 0.52 
AUMC∞ (µg/g  h2) 2.06 ± 0.23 
MRT∞ (h) 0.71 ± 0.21 
t1/2 (min) 28.88 ± 1.31 
4.4.3 Chemoprevention Effects 
Mice were treated by aerosol for 18 or 20 weeks after carcinogen injection. During 
the experiment, all mice showed good tolerance to treatment with erlotinib. No 
significant difference in body weight was observed (Figure 4.14). 
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Figure 4.14 Body weight monitoring during the treatment duration.  
The results of  tumor multiplicity and tumor load for each group are shown in 
Figure 4.15. VC induced an average of  43.3 ± 1.5 (n=12) tumors per mouse in the 
solvent control group. The average tumor load was 21.6 ± 5.6 mm3. The tumor number 
in groups treated by 1 mg/ml erlotinib and 5 mg/ml erlotinib were 40.6 ± 2.5 and 45.3 
± 3.0, respectively. No inhibitions on tumor multiplicity were achieved by aerosolized 
erlotinib. The tumor load was decreased with the increase of  erlotinib concentration. 
The decrease in tumor load was 24.5% (P<0.05) and 35.7% (P<0.01). Similar results 
were observed for B(a)P treated groups. The mice received erlotinib at a solution 
concentration of  5 mg/ml had an average tumor number of  4.73 ± 0.3, while the 
control group had an average of  5.0 ± 0.6 tumors per mouse. No decrease in tumor 
number was achieved. For tumor load, erlotinib inhibited by 63.8% (P<0.05) compared 
to control group. 
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Figure 4.15 Chemopreventive effects of  Erlotinib in femail A/J mice model. (a)VC was used as 
carcinogen; (b) B(a)P was used as carcinogen. *, P<0.05; **, P<0.01; bar, SE. 
Erlotinib has been investigated in all stages of  NSCLC, including early stage, locally 
advanced, metastatic stage, and recurrent NSCLC. The results of  clinical trials suggest 
that erlotinib has beneficial effects in treating certain types of  NSCLC patients, the 
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main characteristic of  whom are never- or light smokers, having adenocarcinoma and 
bronchioloalveolar carcinoma, female gender, and Asians. Many reviews have 
summarized the current status regarding erlotinib recently (Gridelli et al. 2010; Iyer and 
Bharthuar 2010; Laack et al. 2010). Herein, the chemopreventive effects of  erlotinib had 
been investigated using female A/J mice model and post-initiation protocol. Two 
carcinogens were used separately to induce lung tumorigenesis. Erlotinib had shown on 
effects on tumor multiplicity. The average tumor numbers were similar with the 
corresponding control groups. However, significant inhibition on tumor load, which 
increased with the dose, was observed for all erlotinib treated groups. The results 
indicated that although erlotinib could not cause the regression of  the tumorigenesis 
once the tumor was initiated by carcinogens, it can inhibit tumor growth during tumor 
progression for both adenomas and adenocarcinomas. The effectiveness of  EGFR 
inhibitors, such as gefitinib and erlotinib, associates with acute toxicity, especially the 
skin rash, in clinical trials. The occurrence of  skin reactions is considered as a potential 
surrogate marker for anti-EGFR drug efficacy (Gridelli et al. 2010). However, such 
toxicity is not acceptable if  erlotinib is used as a chemopreventive agent. By aerosol 
delivery, the necessary dose could be reduced without sacrificing the effects. Our studies 
showed that the tumor growth was inhibited with no obvious side effects observed. So, 
aerosol delivered erlotinib can be a good candidate for lung cancer chemoprevention. 
4.5 Budesonide 
Budesonide is a glucocorticoid steroid for the treatment of  asthma, the treatment of  
non-infectious rhinitis, and the treatment and prevention of  nasal polyposis. Animal 
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studies showed that synthetic glucocorticoids have lung cancer chemopreventive 
efficacy (Wang et al. 2003; Wattenberg et al. 1997; Yao et al. 2004). Budesonide was first 
shown to have inhibitory effects on B(a)P induced pulmonary adenoma formation in 
the female A/J mouse model through administrations by both diet and aerosol in 1997 
(Wattenberg and Estensen 1997; Wattenberg et al. 1997). In order to further minimize 
the systemic effects and potential side effects, Wattenberg et al. examined aerosol 
administration of  budesonide with low doses. The inhibitory effect decreased with 
lower dose level (Wattenberg et al. 2000). By using different mouse models, Wang et al. 
showed that budesonide has both chemopreventive and chemotherapy effects on lung 
tumors in mice with different germline mutations and that the degree of  efficacy 
depends on genotypes of  mice (Wang et al. 2003). Gene expression array analysis 
indicated that the chemopreventive effects of  budesonide in the mouse lung 
tumorigenesis assay involved increased and decreased expression of  a wide variety of  
genes in multiple signaling pathways (Yao et al. 2004). 
In our study, the chemopreventive effects of aerosolized budesonide were examined 
using female A/J mice. Two concentrations, 1 mg/ml and 6 mg/ml were compared. 
The corresponding dose of  budesonide was estimated to be about 72.8 µg/kg body 
weight for 1 mg/ml solution and 437µg/kg body weight for 6 mg/ml solution. 
The average body weights of  each group during treatment are given in Figure 4.16. 
The low concentration of  budesonide had no effects on body weight. The body weight 
was close to that of  control group for the treatment duration. However, the body 
weight of  mice receiving high concentration budesonide decreased significantly since 
the second week of  treatment. The average body weight was about 11% lower than the 
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control group. Similar results were observed by Wattenberg et al. (Wattenberg et al. 
1997). The decrease in body weight indicated that even though budesonide was 
introduced directly to the lung through inhalation, at higher concentration, budesonide 
still caused systemic effect. The dose should be kept lower than this for future studies. 
The results of  tumor multiplicity and tumor load for each group are shown in 
Figure 4.17. Both tumor multiplicity and tumor load were decreased by aerosolized 
budesonide. The inhibitory effects increase with the increase of  budesonide 
concentration. The decrease in tumor number was 35.4% (P<0.01) and 41.5% (P<0.01) 
for budesonide concentration of  1 mg/ml and 6 mg/ml, respectively. The decrease in 
tumor load was 40.7% (P < 0.05) for low dose and 72.4% (P < 0.001) for high dose. 
 
Figure 4.16 Body weight monitored during treatment 
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Figure 4.17 Inhibitory effects of  aerosolized budesonide on tumor number (left) and tumor load (right). *, 
P<0.05; **, P<0.01; ***, P<0.001. Bar, SE. 
4.6 Summary 
Six aerosolized chemopreventive agents were tested for their inhibitory effects on 
lung tumorigenesis using female A/J mice and post-initiation protocol. This study 
showed that Polyphenon E was an effective chemopreventive agent on inducing tumor 
regression and inhibiting tumor growth, while Polyphenon E without EGCG was 
ineffective. EGCG is thought be the most active component in Polyphenon E, but it 
has to be with other tea catechins to show chemopreventive activity on lung 
tumorigenesis in aerosolized form. Resveratrol, which showed no effects on lung 
tumorigenesis previously when it was given in diet, inhibit tumor growth significantly. 
HPLC analysis confirmed the existence of  resveratrol in the lung. Two EGFR inhibitors, 
gefitinib and erlotinib, inhibited the growth of  tumors initiated by either B(a)P or VC. 
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No skin toxicity, which was commonly associated with the effectiveness in both animal 
study and human clinical trials, was observed throughout the treatment. Budesonide 
inhibited both tumor multiplicity and tumor load. The inhibitory effects increased with 
the dose. However, higher dose cause severe decrease in body weight. Lower dose was 
recommended for future testing. 
In summary, the delivery by aerosol of  chemopreventive agents has been 
demonstrated to be a novel method for providing the powerful efficacies in 
chemoprevention of  lung tumorigenesis. Aerosol delivery can decrease the dose while 
remaining the efficacy, minimize the toxicity, and improve the bioavailability in the lung. 
The inhalation system used in this study is capable of  providing aerosol with stable size 
distribution which was suitable for chemoprevention study using mice. The aerosol 
delivery is an effective approach of  chemoprevention, which could be considered for 
further studies in animal models as well as clinical trials. 
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Chapter 5  
Chemoprevention of  lung carcinogenesis 
by the combination of  aerosolized and 
oral delivered agents in A/J mice 
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5.1 Introduction 
Target populations for lung cancer chemoprevention include those who are at high 
risk of  developing lung cancer, e.g. current and former smokers. Cigarette smoke is a 
complex mixture of  carcinogens and toxicants. Thus, lung cancer caused by years of  
smoking is unlikely to be prevented through intervention in a single pathway. 
Combinations of  drugs that act through different mechanisms may achieve greater 
chemopreventive efficacy (Hecht et al. 2009). 
As introduced in section 4.5, budesonide, which is a glucocorticoid steroid for the 
treatment of  asthma, has inhibitory effects on B(a)P induced pulmonary adenoma 
formation in the female A/J mouse model through administrations by both diet and 
aerosol in 1997 (Wattenberg and Estensen 1997; Wattenberg et al. 1997). Our 
experiments also confirmed this. By introducing a second chemopreventive agent, myo-
inosital, in diet, in addition to aerosol administration of  budesonide, a better efficacy 
was achieved compared with single agent treatment (Wattenberg et al. 2000). In order to 
further investigate the inhibitory effects by combining budesonide with other effective 
chemoprevention agents, we carried out more experiments, including the combination 
of  aerosolized budesonide with diet Polyphenon E, diet Indole-3-carbinol, and gavage 
pioglitazone, respectively.  
As introduced in section 4.1, Polyphenon E is a well-defined green tea extract 
containing at least five tea catechins, with (–)-epigallocatechin-3-gallate (EGCG) being 
the most abundant (Chang et al. 2003; Clark and You 2006). Polyphenon E has been 
shown to have inhibitory effects on lung carcinogenesis in animal models (Clark and 
You 2006; Yan et al. 2006b). It is believed that EGCG, which can bind to various 
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proteins, is the most active compound in polyphenon E although the direct targets of  
EGCG have not been identified yet. 
Indole-3-carbinol (I3C) is a glucobrassicin derivative found at high concentration in 
cruciferous vegetables. As a nutritional supplement, I3C has been considered as a 
promising preventive and treatment agent for breast and other types of  cancers 
(Bradlow 2008; Grubbs et al. 1995; Jin et al. 1999; Manson et al. 1998; Plate and 
Gallaher 2006; Souli et al. 2008; Srivastava and Shukla 1998; Tanaka et al. 1992; Yu et al. 
2006). I3C may cause induction of  phase I and phase II enzymes, inhibition of  
proliferation and induction of  apoptosis in tumor cells, and modulation of  estrogen 
metabolism (IARC 2004). In lung cancer chemoprevention, the dose-dependent and 
post-carcinogen tumor-inhibitory activities of  I3C was examined lately using A/J mice 
model (Kassie et al. 2008b). Diet administration of  I3C at 10 µmol/g or higher showed 
over 50% inhibition efficiency. I3C had been combined with other drugs for the 
treatment of  lung tumorigenesis (Dagne et al. 2011; Kassie et al. 2010b). The inhibition 
on tumor multiplicity of  the combination groups was higher than single agents. 
The peroxisome proliferator-activated receptors γ (PPARγ) is a member of  the 
nuclear hormone receptor superfamily of  ligand-activated transcription factors. It has a 
critical role in the regulation of  multiple cellular processes including lipid metabolism 
and differentiation (Lehrke and Lazar 2005; Michalik et al. 2004; Nemenoff  2007). 
PPARγ expression was increased in non-small cell lung cancer (NSCLC) and PPARγ 
expression correlated with lung cancer histologic type and grade (Theocharis et al. 2002). 
PPARγ is a molecular target for thiazolidinediones (TZDs), such as troglitazone, 
rosiglitazone, and pioglitazone. Pioglitazone and rosiglitazone are synthetic PPARγ 
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ligands used clinically to treat type II diabetes. Recent epidemiological studies indicated 
a significant decrease in lung cancer risk in patients receiving TZDs to treat diabetes, 
suggesting that TZDs may have chemopreventive effects on lung cancer (Nemenoff  
2007). The mechanisms of  the inhibitory effects of  TZDs on NSCLC were reviewed 
recently (Keshamouni et al. 2004). Troglitazone has been shown to inhibit the growth 
of  NSCLC cells in vitro and in vivo (Keshamouni et al. 2004; Satoh et al. 2002). 
Pioglitazone has a favorable safety profile compared to other TZDs in regards to 
cardiovascular side effects (Shah and Mudaliar 2010). This is a strong rationale for 
testing pioglitazone versus rosiglitazone or troglitazone (Gegick and Altheimer 2001; 
Stafylas et al. 2009). Pioglitazone induced apoptosis and inhibited tumor growth in 
xenograft models of  lung cancer (Keshamouni et al. 2004). In a lung adenocarcinoma 
model using mice, Wang et al. found that oral dose of  pioglitazone inhibited tumor load 
by 50% or higher (Wang et al. 2010). 
The four drugs have shown good inhibitory effects in lung cancer individually using 
animal models without causing systemic toxicity or weight loss, which indicates they are 
good candidates for chemoprevention study. Here, the chemopreventive effects of  the 
combination of  Polyphenon E, I3C, and pioglitazone with aerosolized budesonide for 
the inhibition of  B(a)P induced lung tumorigenesis in A/J mice was studied and 
compared with single agents.  
5.2 Experimental Design 
The experimental design is summarized in Table 5.1. There were 12 groups, total 
140 mice included in this study. Each treatment group had a corresponding control 
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group. The only difference between the treatment group and the control groups was 
that no drug was used in the control groups.  
Table 5.1 Experimental design of  the combination treatment 
# Groups Dose Administration 
1 Diet Control AIN-76A diet Diet 
2 Gavage Control 
polyethylene glycol : 0.5 g/L carboxy-
methylcellulose in PBS = 1:1 
Gavage 
3 Solvent Control  50% DMSO / EtOH Aerosol 
4 
Solvent +  
Diet Control 
50% DMSO / EtOH + 
AIN-76A diet 
Aerosol 
Diet 
5 
Solvent + 
Gavage Control 
50% DMSO / EtOH + 
Solvent for Gavage 
Aerosol 
Gavage 
6 Budesonide 2.25 mg/ml in DMSO/EtOH Aerosol, 2 min 
7 Polyphenon E 1.5 % in AIN-76A diet Diet 
8 Pioglitazone 10 mg/kg body weight Gavage 
9 
Indole-3-
carbinol (I3C) 
10 µmol/g in AIN-76A diet Diet 
10 
Budesonide + 
Poly E 
2.25 mg/ml budesonide in DMSO/EtOH 
+ 1.5% PolyE in AIN-76A diet 
Aerosol 2 min 
+ Diet 
11 
Budesonide + 
Pioglitazone 
2.25 mg/ml budesonide in DMSO/EtOH 
+ 10 mg pioglitazone/kg body weight 
Aerosol 2 min 
+ Gavage 
12 
Budesonide + 
I3C 
2.25 mg/ml budesonide in DMSO/EtOH 
+ 10 µmol/g I3C in AIN-76A diet 
Aerosol 2 min+ 
Diet 
 
Figure 5.1 shows the experiment protocol. The post-initiation A/J mice model was 
used. All treatment began 2 weeks after the i.p. injection of  B(a)P. All solvent control 
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groups and all groups receiving budesonide were subjected the aerosol delivery 
treatment for 2 minutes per day, 5 days per week. All gavage control groups and 
pioglitazone groups received oral gavage 5 days per week. All diet treatment groups 
received AIN-76 diet with drugs and 3% sugar. The total treatment duration continued 
for 20 weeks. All mice were sacrificed 22 weeks from the B(a)P injection. 
 
Figure 5.1 Treatment Protocol 
5.3 Results 
5.3.1 Aerosol Characteristics 
We first determined the aerosol characteristics of  budesonide generated by our 
aerosol delivery system. The custom-made Collison type atomizer could provide stable 
aerosol size distribution, which ensured that the mice received the same dose everyday 
throughout the experiment. The size distribution of  budesonide particles generated by 
the atomizer is shown in Figure 5.2. The geometric median diameter (GMD) was 0.078 
Aerosol Treatment (solvent control, budesonide), 5 times/week, 2 min/day. 
Gavage Treatment (gavage control, pioglitazone), 5 times/week. 
Diet Treatment (AIN-76A) (diet control, polyphenon E, indole-3-carbinol) 
 
2 weeks 0 week 
B(a)P (100 mg/kg) 
Start of  treatments Termination 
22 weeks 
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µm, and the geometric standard deviation (GSD) was 1.7. The mass median diameter 
(MMD) was 0.12 µm. The aerosol mass concentration aerosolC was 83.7 µg/liter.  
 
Figure 5.2 Size distribution of  budesonide particles in exposure chamber. The diameter of  budesonide 
particles ranged from 0.01 µm to 0.4 µm, which was in the favorable ranges for mice inhalation study 
(Raabe et al. 1988). 
5.3.2 Dose for All Drugs 
Tissue distributions of  drugs were also examined. At the end of  the study, 4 mice 
from each group were randomly selected and the left lobe of  the lung was homogenized 
to analyze agent concentration. Serum, liver and spleen tissue were obtained for the 
same purpose. Tissue concentrations of  each agent are summarized in Table 5.2. The 
concentration of  budesonide was 2.7 µg/g of  lung. Budesonide was not detected in 
serum, liver or spleen tissue via HPLC. Assuming that there were no budesonide 
accumulated in other unanalyzed organs, the total concentration of  budesonide in mice 
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was thus estimated to be 20.25 µg/kg body weight. In contrast to aerosolized 
budesonide, orally administered polyphenon E and pioglitazone, were detected in all 
analyzed tissues. Serum concentrations were significantly higher than concentrations in 
lung tissue. The difference in drug distribution between aerosol and oral delivery 
indicated that aerosol delivery achieved an elevated lung tissue concentration while 
minimizing systemic drug levels. 
Table 5.2 Accumulated concentrations of  chemopreventive agents after 20 weeks treatment 
Groups Drug 
Admini-
stration 
Concentrations in 
 Lung (µg/g) 
Blood 
(µg/ml) 
 Liver (µg/g) 
 Spleen 
(µg/g) 
Budesonide Budesonide Aerosol 2.66 ± 0.17 ND2 ND ND 
Polyphenon E Polyphenon E Diet 12.57 ± 3.86 31.58 ± 9.15 44.84 ± 3.94 42.88 ± 2.91 
Pioglitazone Pioglitazone Gavage 2.51 ± 0.41 5.24 ± 2.60 1.50 ± 0.18 3.25 ± 0.45 
Budesonide & 
Polyphenon E 
Budesonide Aerosol 2.67 ± 0.32 ND ND ND 
Polyphenon E Diet 10.73 ± 2.84 31.91 ± 4.42 46.38 ± 3.60 36.67 ± 4.47 
Budesonide & 
Pioglitazone 
Budesonide Aerosol 2.73 ± 0.35 ND ND ND 
Pioglitazone Gavage 1.44 ± 0.17 4.03 ± 2.01 1.62 ± 0.21 4.40 ± 0.53 
However, no I3C was detected for all the samples. It was reported that I3C was 
rapidly absorbed, distributed, and eliminated within one hour after oral administration 
(Anderton et al. 2004). In our case, I3C was mixed in the daily diet. No directly dose 
was introduced right before sacrifice. As a result, no I3C was detected by HPLC. I3C, 
which is susceptible to oligomerization under acidic conditions, is converted into several 
                                                        
2 ND, Not detected. 
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condensation products after ingestion. It has been suggested that the observed 
biological activity may be attributable mainly to the acid condensation products, in 
particular, 3,3’-diindolylmethane (DIM), which has shown promising cancer 
chemopreventive properties in vitro and in vivo (Bhatnagar et al. 2009; Kim et al. 2010; 
Rahman et al. 2009). However, the sample collection process we used here was not 
capable of  extracting DIM from tissues.  
5.3.3 Chemopreventive Effects of  Aerosolized Budesonide 
Mice were treated with aerosolized budesonide for 20 weeks. The initial dose of  
budesonide was estimated to be about 209 µg/kg body weight. The body weight in all 
budesonide-treated groups decreased slowly during the first 7 weeks of  treatment. The 
average body weight in budesonide-treated groups was about 8% less than the 
corresponding control group by the end of  7th week. As a result, we decreased the dose 
of  budesonide by 25% (about 157 µg/kg body weight) for the duration of  treatment. 
After the dose adjustment, body weight increased in budesonide treated mice, indicating 
that the budesonide was well tolerated at this dose. There were no significant body 
weight differences between budesonide treated groups and their corresponding control 
groups at the end of  the experiment.  
In the solvent control group, B(a)P induced an average of  5.0 ± 0.63 (n=12) tumors 
per mouse. The average tumor load in control group was 0.30 ± 0.07 mm3. Aerosolized 
budesonide alone significantly decreased both tumor multiplicity [56.7%; 2.17 ± 0.47 
(n=12)] and tumor load (78.4%; 0.07 ± 0.02 mm3) when compared to the control group, 
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shown in Figure 5.3. The tumor incidence was 100% for solvent control group, and 83.3% 
for budesonide group. 
 
Figure 5.3 Effects of  budesonide on lung tumorigenesis in female A/J mice. (a) Tumor number; (b) 
Tumor load. ** P<0.01, Bar: SE 
5.3.4 Combination of  Budesonide and Polyphenon E  
Polyphenon E has been reported to be effective in lung cancer chemoprevention 
(Wattenberg et al. 1997; Yan et al. 2006b). Since it targets different proteins and 
pathways compared with budesonide, we thus tested the combination effect of  
aerosolized budesonide and diet polyphenon E using A/J mice model. Single dose of  
B(a)P at the concentration of  100 mg/kg was used to induce lung tumors. Two weeks 
after carcinogen injection, budesonide was given by aerosol while Polyphenon E (15 
g/kg diet) was given in diet for 20 weeks. As shown in Table 5.3, Polyphenon E did not 
show inhibitory effects on tumor number, while it decreased tumor size by 82.9%. The 
combination of  budesonide and Polyphenon E further decreased the tumor load by 
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88.8%, while no improvement was observed in tumor multiplicity when compared to 
the case of  budesonide only. Tumor incidence was 90% for budesonide and 
Polyphenon E group, while it was 100% for all other groups shown in Table 5.3.  
Table 5.3  Effects of  combined budesonide and polyphenon E on lung tumorigenesis in female A/J mice  
Group 
Final Body 
Weight (g)3 
Tumor 
Multiplicity4 
Inhibition  
Tumor Load 
(mm3)5 
Inhibition  
Diet Control 27.3 ± 4.2 14.67 ± 1.62 - 3.90 ± 1.37 - 
Polyphenon E  23.9 ± 1.8 10.75 ± 1.16 26.7% 0.67 ± 0.15 82.9%6 
Solvent & Diet 
Control 
23.3 ± 1.5 8.64 ± 1.03 - 1.28 ± 0.38 - 
Budesonide & 
Polyphenon E 
18.3 ± 1.3 3.60 ± 0.54 58.3%7 0.09 ± 0.04 88.8%8 
 
5.3.5 Combination of  Budesonide and Indole-3-carbinol 
Indole-3-carbinol was given at the concentration of  10 µmol/g by diet two weeks 
after carcinogen initiation. For this combination group, the mice were also subjected to 
aerosolized budesonide in addition to receiving I3C in diet. As shown in Table 5.4, after 
20 weeks’ treatment, I3C alone decreased tumor number by 35.8% and tumor load by 
83.2% compared with the diet control group. By combining aerosolized budesonide and 
diet I3C, the tumor load was further decreased by 85%, while there was no 
improvement in tumor number.  
                                                        
3 Data shown as Mean ± SD, similar for Table 5.4 and 5.5 
4 Data shown as Mean ± SE, similar for Table 5.4 and 5.5 
5 Data shown as Mean ± SE, similar for Table 5.4 and 5.5 
6 P<0.01 versus diet control group 
7 P<0.001 versus diet & solvent control group 
8 P<0.01 versus diet & solvent control group 
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Table 5.4  Effects of  combined budesonide and I3C on lung tumorigenesis in female A/J mice 
Group 
Final Body 
Weight (g) 
Tumor 
Multiplicity 
Inhibition 
Tumor Load 
(mm3) 
Inhibition 
Diet Control 27.3 ± 4.2 14.67 ± 1.62 - 3.90 ± 1.37 - 
I3C  26.1 ± 3.3 9.42 ± 1.12 35.8%  0.66 ± 0.16 83.2%9 
Solvent & 
Diet Control 
23.3 ± 1.5 8.64 ± 1.03 - 1.28 ± 0.38 - 
Budesonide 
& I3C 
20.3 ± 2.5 5.00 ± 0.85 42.1%  0.12 ± 0.04 84.9%10 
5.3.6 Combination of  Budesonide and Pioglitazone 
Pioglitazone was given by oral gavage at the concentration of  10 mg/kg body 
weight. When compared to the gavage control group, no inhibitory effects on tumor 
number were observed while the tumor size was significantly decreased by 63%.  
Pioglitazone was also studied for its chemoprevention effects when combined with 
aerosolized budesonide. We observed a 90% inhibition in tumor load compared to the 
corresponding control group. 87% of  all the tumors observed in the combination group 
were smaller than 0.5 mm in diameter, compared to 42% in budesonide treated group 
and 51% in pioglitazone treated group. The combination of  pioglitazone and 
budesonide did not significantly affect tumor multiplicity compared to budesonide alone. 
The results are summarized in Table 5.5. 
 
 
                                                        
9 P<0.01 versus diet control group 
10 P<0.01 versus diet & solvent control group 
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Table 5.5  Effects of  combined budesonide and pioglitazone on lung tumorigenesis in female A/J mice 
Group 
Final Body 
Weight (g) 
Tumor 
Multiplicity 
Inhibition 
Tumor Load 
(mm3) 
Inhibition 
% tumors  
< 0.5 mm 
Gavage Control 20.9 ± 1.9 4.33 ± 0.62 - 0.36 ± 0.13 - 23.1% 
Pioglitazone  23.0 ± 2.5 4.08 ± 0.61 5.8%  0.13 ± 0.03 63.3%11 50.8% 
Solvent & 
Gavage Control 
20.1 ± 2.5 4.70 ± 0.69 - 0.26 ± 0.07 - 39.2% 
Budesonide & 
Pioglitazone 
19.2 ± 1.7 2.09 ± 0.44 55.5%12 0.03 ± 0.01 89.6%13 87.0% 
5.4  Discussion 
Chemoprevention using combinations of  agents targeting different pathways may 
offer significant advantages compared with single agents by increasing efficacy. In 
addition, this approach may allow the use of  lower doses with the potential to reduce 
adverse side effects. Budesonide inhibits all stages of  lung tumorigenesis induced by 
B(a)P in the A/J mouse model (Wattenberg and Estensen 1997; Wattenberg et al. 1997) 
and is a good candidate for combinational studies (Alyaqoub et al. 2007; Wattenberg et 
al. 2000). Three agents (i.e., Polyphenon E, indole-3-carbinol, and pioglitazone), which 
were shown to have inhibitory effects on lung carcinogenesis under different 
mechanisms, were selected as combination agents with aerosolized budesonide. Using a 
post-initiation protocol, we determined the effect of  combination treatment on lung 
adenoma prevention in A/J mice.  
                                                        
11 P<0.05 versus gavage control 
12 P<0.05 versus solvent & gavage control, P<0.01 versus pioglitazone group 
13 P<0.05 versus solvent & gavage control, P<0.01 versus pioglitazone group 
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In this study, budesonide was introduced through aerosol delivery using an aerosol 
generation and exposure system which could ensure that mice received constant dose of  
drug throughout the experiment (Fu et al. 2009). Since mice have much smaller 
respiratory tract than human, the optimal particle size for mice inhalation studies is less 
than 0.3 µm (Raabe et al. 1988). In our study, the diameter of  budesonide particles 
ranged from 0.01 µm to 0.4 µm, with the mass median diameter at 0.12 µm (Figure 5.2), 
which is more favorable for aerosolized drug delivery in mouse model compared with 
previous studies in which nebulizers was used for generating aerosolized agents (Dahl et 
al. 2000; Liao et al. 2004b).  
After 20 weeks treatment, aerosolized budesonide alone inhibited tumor multiplicity 
by 57% and tumor load by 78%, similar to what has been observed previously 
(Wattenberg et al. 1997). As expected, aerosol delivery achieved high budesonide 
concentrations in lung tissue but undetectable amounts in other tissues tested. Thus, by 
delivering agent particles directly to the mouse lung, the systemic dose could be 
significantly reduced without affecting efficacy. This in turn should reduce the risk of  
side effects and minimize systemic toxicity. Since chemoprevention targets healthy 
people with a high risk of  developing lung cancer, efficacy and safety are two key 
criteria for the selection of  chemopreventive agents. Compared to other means of  
administration, aerosol delivery has distinct advantages in satisfying the above two 
criteria.  
Polyphenon E, which is a mixture of  polyphenols containing at least five tea 
catechins, has been shown to be able to inhibit the development of  cancer at different 
target sites in several animal models. For lung cancer chemoprevention, Polyphenon E 
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shows good inhibitory effects (Fu et al. 2009; Yan et al. 2006b; Zhang et al. 2010), 
suggesting that Polyphenon E is a good candidate for lung cancer chemoprevention. In 
this study, by adding 15 g/kg Polyphenon E in diet, the tumor load was decreased by 83% 
when compared with the control group. The inhibition on tumor load was further 
increased to 89% when combining budesonide with Polyphenon E. No significant 
effect on the tumor multiplicity was observed when comparing Polyphenon E alone 
group with the control group. Similarly, for the combinational group, the inhibition on 
tumor number was at the same level with the budesonide only group. Our previous 
study showed that aerosolized polyphenon E could inhibit tumor growth without 
showing significant decrease in body weight (Fu et al. 2009). Thus, introducing both 
agents by aerosol in the combinational study at the same time could be an alternative 
approach to further decease the agent dose level while minimizing the side effects. 
Indole-3-carbinol is well-accepted as a nutritional supplement. Kassie et al. studied 
the inhibition of  I3C on VC-induced lung adenocarcinoma as well as 4-
(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) plus B(a)P-induced lung 
tumorigenesis in A/J mice model (Kassie et al. 2010a; Kassie et al. 2008b). In their study, 
by receiving I3C in diet for more than 10 µmol/g beginning at 50% of  carcinogen 
treatment, the mice had at least 50% less tumor number compared with the control 
group. However, using postinitiation protocol and VC as carcinogen, the effective dose 
of  I3C was 70 µmol/g diet. In our study, for the I3C treatment group, the mice received 
10 µmol/g I3C in diet for 20 weeks starting 2 weeks after the carcinogen treatment. The 
tumor load was significantly decreased by 83%, while the inhibition on the tumor 
number was around 36%, indicating that, at the test dose, I3C could not effectively 
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cause the regression of  tumorigenesis using this protocol. As a result, the tumor 
number of  combination group was not further reduced when compared with the result 
of  individual agent treatment group. The tumor load was decreased by 85% for the 
combinational group, while the decrease was 83% for the I3C treatment group and 78% 
for the budesonide treatment group. The mechanisms through which I3C or 
budesonide suppress tumorigenesis have been extensively investigated in cell culture 
models as well as in animal models (Kassie et al. 2008a; Kassie et al. 2010a; Tao et al. 
2002; Wu et al. 2005; Yao et al. 2004). Different targeting pathways for I3C and 
budesonide suggest that combination of  these two agents might achieve better 
inhibitory effects, which is consistent with our experimental results.   
Pioglitazone is a synthetic PPARγ ligand which has been approved by the Food and 
Drug Administration (FDA) for the treatment of  type II diabetes. PPARγ agonists have 
anticancer effects on cell lines by binding with PPARγ receptor which then forms an 
active heterodimer with the retinoid X receptors (Ondrey 2009). Pioglitazone acts via 
distinct mechanisms (Han and Roman 2006; Hazra et al. 2007; Keshamouni et al. 2005) 
and was selected as a combination agent with aerosolized budesonide. After 20 week 
administration of  pioglitazone by oral gavage, the number of  tumors in the pioglitazone 
treatment group was not affected. In contrast, tumor load was decreased by 63%. When 
combined with budesonide, pioglitazone did not enhance the inhibition of  tumor 
multiplicity compared to the budesonide treated group. However, tumor load in the 
combination group was decreased by ~90% compared to its corresponding control 
group. Approximately 87% of  total tumors were smaller than 0.5 mm in diameter in the 
combination group, compared to 51% in pioglitazone group and 42% in budesonide 
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group. Large tumors are significantly inhibited in combination group compared to either 
single agent. Budesonide and pioglitazone have different mechanisms in inhibiting lung 
cancer (Nemenoff  2007; Nemenoff  et al. 2008; Yao et al. 2004). The combination 
effects of  budesonide and pioglitazone were shown to be independent and additive on 
cell growth by using a linear model, which indicated that the two agents functioned 
individually in inhibiting lung tumorigenesis and the overall inhibition was increased due 
to the additive effect (Fu et al. 2011b). 
The drugs tested here for their efficacy on lung cancer chemoprevention, are either 
approved by the FDA to be used on human (i.e., budesonide and pioglitazone), or 
natural agents that are extracted from food (i.e., Polyphenon E and I3C). In this study, 
the two FDA approved drugs were introduced in the same ways as they have been using 
to treat certain diseases- budesonide was introduced through inhalation, while 
pioglitazone was given orally. The two natural drugs were introduced orally, the same 
way as how people take them in daily life. Our results showed that by combining those 
two drugs, the tumor number and tumor load was further reduced by 56% and 90%, 
respectively. The combination of  aerosolized budesonide and oral pioglitazone might be 
a good candidate for clinical trials. 
In this study, we used post-initiation protocol, i.e., all the treatment began after the 
tumor being initiated by carcinogen. Under this protocol, all three chemopreventive 
agents (i.e., I3C, pioglitazone, Polyphenon E) examined for their combination with 
budesonide showed significant inhibitory effects on the tumor size but less effect on the 
tumor number compared with the groups of  testing them as single agent. Similarly, all 
the combinational groups failed to further decrease the tumor number when compared 
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to the budesonide alone treatment group. The inhibitions on the tumor load were 
higher for all combinational groups than that of  any individual treatment group. 
However, the difference was not statistically significant between the combination 
treatment and the budesonide group, mainly due to the strong inhibitory effect by 
budesonide alone. The decrease in tumor load by budesonide only was already 78%. To 
further test the combinational effects, the dose of  budesonide should be decreased. 
5.5  Summary 
In this study, the combinative effects of  aerosolized budesonide with oral 
Polyphenon E, indole-3-carbinol, or pioglitazone were investigated using female A/J 
mice. Aerosolized budesonide inhibited lung adenoma formation. Compared with 
solvent control group, budesonide decreased the tumor multiplicity and the tumor load 
by 56.7% and 78.4%, respectively. Furthermore, aerosol delivery can achieve high 
concentration in the target organ with low chemopreventive agent dose compared to 
other administration routes. Used as a single agent, Polyphenon E, I3C and pioglitazone 
all showed significant inhibition on tumor load. The decrease in tumor load was 82.9% 
by Polyphenon E, 83.2% by I3C, and 63.3% by pioglitazone. No effects on tumor 
multiplicity were achieved. By combining aerosolized budesonide with Polyphenon E, 
indole-3-carbinol or pioglitazone, respectively, the tumor load of  test mice could be 
significantly reduced. Budesonide with polyphenon E decreased tumor multiplicity by 
58.3% and tumor load by 88.8%. For budesonide with I3C, the decrease in tumor 
multiplicity was 42.1%, while the decrease in tumor load was 84.9%. Budesonide and 
pioglitazone showed the most decrease on tumor load among the three combination 
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treatment cases. The decreased in tumor load was 89.6%, while in tumor multiplicity it 
was 55.5%. The three agents used for the combination treatment with budesonide did 
not decrease tumor number. As a result, the combination groups all showed similar 
inhibitory effects on tumor multiplicity as budesonide alone case. Since the three agents 
can significantly inhibit tumor growth, the inhibition on tumor load after combined with 
budesonide was even greater. Among all three combination groups, pioglitazone 
combined with budesonide showed the greatest inhibitions on tumor load, which makes 
them a promising candidate for further investigation. Our result shows that the 
combination of  agents targeting different pathways could be a promising approach in 
lung cancer chemoprevention.  
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Chapter 6  
Review of  Twin-head Electrospray 
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6.1 Introduction 
Electrohydrodynamic spraying (Electrospray, ES) is a method to generate 
monodisperse particles with diameters in the range of  nanometers to micrometers. The 
main advantages of  electrospray include: 
(1) The particles generated by electrospray when it is operated in the stable cone-jet 
mode are in narrow size range. 
(2) The particles are highly charged with the same polarity, which highly decreases 
the particle agglomerations due to mutual repulsion. 
(3) The particles are airborne after generation. Based on the applications, they can 
be either remained in airborne or collected for further process. 
(4) Both liquid solution and suspension can be sprayed. 
(5) By using dual-capillary or tri-capillary, the particles can be modified to form 
multiple layers or contain multi-functional groups. 
Coagulation is the most important interparticle phenomenon for aerosols. It has 
been studied both theoretically and experimentally since 1917 when Smoluchowski 
developed the theory for the collision frequency function for Brownian coagulation. 
The coagulation can be increased when there are attractive electrical forces between 
particles. With the high charge levels achieved by electrospraying, charge-enhanced 
coagulation has been utilized for various applications using systems containing two 
electrospray heads. 
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6.2 Electrostatic Coagulation 
Coagulation of  charged aerosols in the absence of  electrostatic dispersion is 
described in a discrete form by (Zebel 1958):   
∑∑ ∑∑
∞
−∞=
−
=
∞
−∞=
∞
=
−
−
−
− −=
q
i
j q j
q
j
p
i
qp
ji
q
j
qp
ji
qqp
jji
p
i NNβNNβ
t
N 1
1 1
,
,
,
,
2
1
d
d
,                           (6.1) 
 
where N is the number concentration of  the particles made of  i primary particles 
having p charges, i or j is the number of  primary particles, p or q is the number of  
elementary charge units per particle, t is the time, and β is the coagulation coefficient. 
The first term on the right-hand side accounts for the formation of  particles of  size i 
and charge p due to collisions of  particles of  size i - j and number of  charges p - q and 
particles of  size j and number of  charges q, respectively. The second term describes the 
loss of  particles of  size i and charge p by coagulation with any other particle in the 
system. 
The collision rate of  particles carrying charges of  opposite polarities is highly 
enhanced compared to the case of  neutral particles coagulation. Zebel and Fuchs 
derived the coagulation coefficient of  electrically charged (including both unipolar 
charged and bipolar charged) particles by Coulomb force (Fuchs 1964).  
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where qp jiβ
,
,  is the coagulation coefficient of  neutral particles and 
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,
, is the Fuchs 
stability function. For collisions of  particles with opposite sign,  
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where dpi and dpj are the diameters of  the colliding particles, e is the element charge, 
kB is Boltzmann constant, ε is the dielectric constant of  the medium, and T is the 
temperature. For particles of  the opposite sign, κ is negative, qpjiW
,
, is positive and less 
than unity. So qp jiβ
,
, is larger than jiβ , , indicating that the collisions occur more rapidly 
than in the case of  neutral particles. 
6.3 Adhesive Forces between Coagulated Particles  
The interaction forces between two coagulated particles include the electrostatic 
force, the van der Waals force, and the forces arising from the surface tension of  liquid 
films (Hinds 1999a). The above forces depend on both particle properties, such as the 
material, shape, surface roughness, size, and the contact velocity; and environmental 
conditions, such as the relative humidity and temperature.   
Droplets generated by electrospray are highly charged with the same polarity. The 
aggregation among the droplets is negligible due to the mutual repulsion. This is one of  
the advantages of  ES in aerosol generation. In the twin-head electrospray system, 
oppositely charged droplets generated by two electrosprays carried an extremely large 
number of  positive or negative charges. The electrostatic attraction was the main force 
to drag droplets together. The attractive Coulomb force can be estimated from the 
following equation:  
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where Ek is Coulomb constant, q and q’ are the number of  charges on each of  the 
two droplets, and xq is the distance between the two particles. 
The van der Waals forces are effective when two particles are very close to each 
other. The random movements of  electrons surrounding the nucleus of  electrically 
neutral atoms on the surface of  particles induces dipoles, which creates an opposite 
polarity on the surface of  another particle when the two were a few molecular diameters 
apart. The resultant attractive force between two particles can be estimated by the 
following equation: 
212x
AD
Fw = ,                                                             (6.5) 
where A is the Hamaker constant, which depends on the material; D is 
)/(2 2121 RRRR + , with R1 and R2 to be the radius of  the two particles; and x is the 
separation distance that depends on the surface roughness of  the particle and the 
contact surface. 
When there are liquid molecules on the surface of  particles, an attractive force is 
created by the surface tension of  the liquid in the capillary space at the point of  contact. 
Also, the curved liquid surface causes a Laplace pressure, which attracts particles toward 
each other. The force is related to the surface tension of  the liquid, the diameter of  the 
particle, the surface roughness, and the contact angles. 
   92 
6.4 Review of  Designs and Applications of  THES 
This concept of  using two sprays to generate countercharged droplets was first 
proposed in 1965 to study the collision of  two charged droplets (Schneider et al. 1965). 
Electrostatic atomization was used to generate droplets with diameters around 180 µm. 
Two charged droplets were introduced into a Faraday cage, where the charge and 
velocity were measured before the collision. A 4 × 5 camera was used to photograph 
the trajectories of  the two opposite charged droplets. The experimental apparatus is 
shown in Figure 6.1. Their experiments confirmed that the collision rate of  oppositely 
charged droplets was much higher than that of  droplets carrying like charges. However, 
the experimental apparatus could only measure extremely large droplets.  
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Generator
Deflection Plates
Deflection Plates
Faraday
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Figure 6.1 Experimental apparatus for studying the collision between two charged droplets.  (Schneider et 
al. 1965)  
Langer et al. studied the encapsulation process between charged liquid droplets and 
solid particles (Langer and Yamate 1969). They also used electrostatic atomization to 
generate droplets with diameter larger than 1 µm. Despite the loss of  charged droplets 
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on the grounded plate before they entered the encapsulation chamber, a high percentage 
of  encapsulation was observed for droplets larger than 10 µm.  
- D.C.High Voltage+ D.C.High Voltage
Burettes
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Sample Slide
Glass Container
 
Figure 6.2 Electrostatic aerosol encapsulator for aerosols larger than 1 µm.(Langer and Yamate 1969) 
The possibility of  using bipolar coagulation of  particles generated by two sprays in 
powder industry was studied (Borra et al. 1999; Camelot et al. 1999) using the 
experimental setup shown in Figure 6.3. Each of  the two electrosprays generated 
droplets containing one reaction precursor. The coagulation of  two precursor droplets 
created a good mixing of  chemical compounds on a microscale. The droplets produced 
by bipolar coagulation can serve as microreactors to form powders with desired 
composition. Based on their applications in powder production, super micrometer 
droplets are favorable. Moreover, this research was mainly focused on the micromixing 
and microreactor. Limited information on the system characterization and evaluation of  
the coagulation process was provided.  
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Figure 6.3 Experimental apparatus using two electrospray in powder synthesis. (Borra et al. 1999; Camelot 
et al. 1999)  
The interactions between fibers and particles generated by countercharged 
electrospinning and electrospray were studied by Park et al (Park et al. 2008) (Figure 6.4). 
They observed that the stream of  fibers changed their moving direction towards the 
oppositely charged droplets due to the changes in electrostatic forces. However, the 
encountering phenomena between oppositely charged particles generated by the same 
system were hardly observed.  
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Figure 6.4 Experimental setup to study the interaction between counter charged fibers and particles. (Park 
et al. 2008) 
Similar approach was used to manufacture nanomat using electrospinning and 
electrospray (Morozov and Vsevolodov 2007). Here, electrospinning was used to 
generate polymer fibers, while electrospray was used generate ions using a volatile 
solvent to neutralize the charges carried on fibers. The schematic diagram are given in 
Figure 6.5. In their system, the fibers were not neutralized immediately after they 
deposited. Instead, opposite charges accumulated on both side of  the nanomat. As a 
result, the nanofibers collapsed into a film due to electrostatic attraction. 
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Figure 6.5 Schematics of  a device used for the manufacturing of  free and mesh-supported nanofilters 
and nanomats. (Morozov and Vsevolodov 2007) 
A direct observation of  the interaction between the counter-charged droplets 
generated by two electrosprays was done by Almekinders et al.(Almekinders and Jones 
1999). They designed a multi-jet electrohydrodynamic atomizer. By operating two EHD 
atomizers using high voltage with different polarities, the two aerosols were attracted by 
electrostatic force. However, they claimed that “The positive and negative charged 
droplets become spatially distributed such that inter-droplet Coulomb forces are leveled 
out and no droplet coalescence takes place.” There were no characterizations about the 
particle size before and after the mixing. 
6.5 Potential Application as ES Inhaler 
A potential application of  the twin-head electrospray system in pulmonary drug 
delivery is the electrospray inhaler. There are many commercial aerosol generators for 
drug inhalation, such as jet nebulizers, pressurized meter-dose inhalers and dry powder 
inhalers, most of  which generate polydisperse aerosols with drug particles or droplets. It 
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is believed that monodisperse particles are better for target site delivery. The idea of  
using electrospray for target drug inhalation was first recognized by Tang and Gomez 
(Tang and Gomez 1994). Battelle Memorial Institute developed a portable electrospray 
inhaler (Figure 6.6)(Zimlich et al. 1999). A phase I clinical trial and in vitro studies 
showed that the dose efficiency was much higher than commercial inhalers (Gomez 
2002).  
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Figure 6.6 Prototype electrospray aerosol delivery system. (Gomez 2002)  
Since the charges carried by particles might cause particle loss in the oropharyngeal 
region due to image force, they must be neutralized before delivery. In general the 
charge level of  ES-produced particles can be reduced by passing them through an 
environment where bipolar ions were produced via corona discharge, soft X-ray, or 
radioactive materials (Chen et al. 1995; Ebeling et al. 2000; Hogan et al. 2004). Using a 
radioactive source is an effective and reliable way to electrically neutralize charged 
particles (Liu and Pui 1974). However, it is not practical due to safety regulations and 
similar case for soft X-ray, too. So, a corona discharge was used to neutralize the highly 
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charged monodisperse droplets. Corona discharge has been widely used in electrospray 
systems (Borra et al. 2004; Ijsebaert et al. 2001; Lu and Koropchak 2004; Tang and 
Gomez 1994; Tang and Gomez 1995). However, one main drawback of  corona 
discharging is the generation of  ozone during the process, which played a key role in the 
failure of  the clinical trial with human volunteers. Ozone is a highly toxic air pollutant, 
which was shown to be carcinogenic with long-term exposure in animals (Herbert et al. 
1996; Menzel 1984). An alternative choice of  neutralization method, which should be 
safe and convenient to use, is required to replace the corona discharge in the 
electrospray inhaler. In a twin-head electrospray system, monodisperse droplets carrying 
both positive and negative charges are generated separately. Since we can control the 
charge levels on both positive and negative charged particles, the particles could reach 
approximately zero net charge after mixing the two aerosol flows. The coagulation 
between opposite charged particles can also serve as a neutralization process. No 
further neutralization is required. By using two electrosprays, the mass output can also 
be increased. So, the twin-head electrospray could be used as an electrospray inhaler 
after careful design and evaluation.   
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Chapter 7  
Design and Characterization of  a Twin-
head Electrospray (THES) System 
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7.1 Design of  the Twin-head Electrospray System 
A schematic diagram of  the designed twin-head electrospray system is shown in 
Figure 7.1. The system contained two identical electrospray heads and a neutralization 
chamber. In each electrospray head, both single capillary and dual-capillary could be 
used. The inner diameter of  the outer capillary was fixed at 0.046 inches. The outer 
diameter of  the inner capillary was fixed at 1/32 inches, while the inner diameter could 
be chosen from a variety of  choices. The distance between the spray nozzle and the 
counter electrode, which was a metal ring inserted into the top surface of  the 
neutralization chamber, was adjustable. The electrical field was created by applying high 
voltage on the metal spray nozzle while grounding the metal orifice. A plexiglass outer 
case, which was used to hold the spray head, served as the insulation part. Air flow was 
introduced into each spray head chamber from the inlet tube, which was connected at 
90º to the outer case and located above the spray nozzle. The 16 columniform openings 
on the metal plate allowed the aerosol flow to be uniformly distributed surrounding the 
spray nozzle. Then, the air flow carrying the highly charged droplets entered the 
neutralization chamber. One LED light was glued into the case of  each spray head for 
illumination, while a glass window was installed on the other side of  each case. A 
microscope was used to monitor the spray condition through the small window.  
Two coagulation chambers were designed. The first one was named as 90 degree 
chamber, as shown in Figure 7.1(a) and (b). The two electrospray heads were fixed at 
two perpendicular surfaces on the coagulation chamber respectively, with the spray 
nozzle pointing towards the center of  the chamber. The coagulation chamber could 
hold up to four neutralizers (Po210, Nuclespot P-2042, NRD LLC, NY), with two on the 
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top level and two on the bottom level. When four neutralizers were used, the charge 
level carried by droplets could be highly reduced to reach the Boltzmann equilibrium 
charge distribution. Using fewer neutralizers would allow the charge-enhanced 
coagulation to take place inside the chamber. The second chamber was a 180 degree 
chamber. The two spray heads were installed on the side surfaces of  the chamber, with 
the spray nozzles facing each other. Two aerosol flows from each spray head mixed in 
the center of  the coagulation chamber and then exited from the bottom opening. This 
180 degree chamber can hold two neutralizers. The effects of  the design of  chamber, 
mainly the angles between two aerosol flows, on the coagulation process are discussed 
later.  
 
(a) 
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 (b) 
 
(c) 
Figure 7.1 Design of  the twin-head electrospray system. (a) photo of  the system; (b) the 90 degree 
chamber and the spray nozzles; (c) the 180 degree coagulation chamber. 
Neutralizer Holder 
Connected to 
spray head 
Connected to 
spray head 
Neutralizer Holder 
Aerosol Outlet 
   103 
7.2  Experimental Setup and Methods 
7.2.1  Experimental Setup 
Given in  
 
Figure 7.2 is the experimental setup for the size distribution characterization. The 90 
degree chamber was used for most of  the studies, except for section 7.3.5. Sucrose 
(ACS reagent, ≥99.0%, Sigma-Aldrich) was dissolved in isopropanol (IPA) /aqueous 
(4:1 in v/v) solution at the desired concentration. Ammonium acetate (ACS reagent, 
≥99.99%, Sigma-Aldrich) was added into the solution to adjust the conductivity. The 
single capillary with an i.d. of  0.008 inches was used in this part. The liquid feeding flow 
rate was controlled by a syringe pump (PHD 22/2000, Harvard Apparatus, MA). 
Particle-free compressed air was introduced into each spray head at 2.5 lpm. The 
residence time of  particles inside the neutralization chamber was then calculated to be 
0.24 s. During operation, a positive or negative high voltage was applied at the spray 
head via a high voltage DC power supply (Bertan, Series 230, Spellman High Voltage 
Electronics Corp., NY). The sprays were in the stable cone-jet mode for all the 
measurements. When all four neutralizers were presented in the chamber, droplets could 
be neutralized immediately after entering the coagulation chamber to reach the 
Boltzmann equilibrium charge distribution. The electrostatic coagulation of  aerosols 
having the Boltzmann equilibrium charge distribution was negligible compared with 
Brownian coagulation (Adachi et al. 1981). So, four neutralizers were used to 
characterize the size distribution of  particles generated by either single head electrospray 
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or twin-head electrospray without electrostatic coagulation. The size distribution of  
aerosols passing through the chamber was then measured by the scanning mobility 
particle sizer (SMPS). To characterize the coagulation between highly charged particles, 
no neutralizers were used inside the neutralization chamber. An electrostatic precipitator 
was used to remove all charged particles, only particles that collided with other particles 
carrying the same charge number with opposite polarity could penetrate through the 
precipitator. A 25 mm filter holder with glass fiber filter media (Lydall 
Filtration/Seperation, Inc., NH) was connected to the outlet of  the precipitator to 
collect the neutral particles. So, the percentage of  neutral and charged particles can be 
characterized using fluorescence analysis. 
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Figure 7.2  Experimental setup for the size distribution measurement 
7.2.2 Particle Characterizations 
The morphology of  particles was characterized by SEM (Nova NanoSEM 2300, 
FEI).  
A Zeiss Axioskop A1m fluorescence microscope was used to identify the 
composition of  the particles after coagulation. Green fluorescent images were created 
using a GFP filter (31019 GFP FLTR SET), with excitation at 425/40 nm and detection 
at 505/40 nm. For the red channel, a TRITC filter (CZ915 RHODAMINE SET), with 
546/10 nm excitation, and 590 long-pass detection was used. Uranine (Sigma-Aldrich) 
and rhodamine 6G (Sigma-Aldrich) were dissolved in the sucrose solution separately to 
label the particles. During the operation, one spray head was used to spray uranine 
solution, while the other sprays rhodamine solution. No neutralizers were installed for 
this characterization to ensure electrostatic coagulation. The particles exiting the 
chamber were collected on a microslide for imaging.  
To verify the composition of  coagulated particles, an experiment was carried out 
using two drug solutions, 0.1% EGCG/ethanol and 0.1% budesonide/ethanol. Each 
solution was sprayed using one of  the spray head. The size distribution was measured 
using SMPS. After identifying the peak diameter of  coagulated particles, a long DMA 
(model 3081, TSI, MN) was used to classify the particles so that only particles with the 
same electrical mobility as particles of  the peak diameter could penetrate through the 
DMA. An electrostatic precipitator was used to collect the particles exiting from the 
DMA. After collection, the particles were re-dissolved in ethanol. Drug concentrations 
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were characterized using high efficiency liquid chromatography (HPLC). The HP 1100 
series HPLC system was used. The same analyzing methods described in chapter 3.3 
were used. 
7.2.3 Fluorescence Analysis 
Fluorescence analysis was used to characterize the percentage of  neutral and 
charged particles that exited the THES chamber as well as the particle loss at various 
locations of  the ES system. Uranine was the fluorescent tracer for the quantitative 
analysis of  deposited particles. The electrospray solution was prepared by dissolving 0.1% 
(v/v) sucrose and 1 g/l uranine in an isopropanol/water mixture. A filter was connected 
to the exit of  the coagulation chamber to collect particles that passage through the 
chamber.  
After each run, particles deposited at various locations in the ES system were 
recovered by wiping the surface with cotton swabs wetted in a wash solution, which was 
an aqueous solution of  0.001 N ammonium hydroxide. The uranine on the cotton 
swabs was then dissolved in 25 ml of  wash solution. The mass of  the uranine collected 
on the filter was measured by immersing the entire filter medium in 25 ml of  the wash 
solution. The uranine deposited on the wall of  the tubing connecting the ES system 
with the HEPA filter was also recovered by cotton swabs, which were then immersed in 
the same wash solution as the filter. The concentration of  uranine in the various wash 
solutions was measured by a calibrated fluorometer (GloMax®-Multi Jr Single Tube 
Multimode Reader, Promega Corporation, CA). For each experimental run, we further 
checked the mass conservation of  uranine by comparing the amount of  uranine 
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recovered from various locations in the generator with the total amount of  uranine 
sprayed. In general the difference between the sprayed and recovered amounts was 
within 5% of  the total sprayed. 
7.3 Results and Discussion 
7.3.1  Demonstration of  Coagulation in THES 
To study the coagulation process in the THES system, single capillary ES was used 
for both spray heads. Sucrose solutions of  0.1% (v/v) and a conductivity of  115 µS/cm 
were prepared. To simply the problem, the two sprays were operated at the same 
condition except for the polarity of  the high voltage. As a result, the particles generated 
in each spray heads had the same size distribution and average number of  charges of  
either positive or negative polarity. After being emitted from the cone-jet, droplets were 
carried into the coagulation chamber by filtered air at a flow rate of  2.5 lpm. The two 
aerosol flow met after entering the coagulation chamber. The coagulation chamber 
could hold up to four neutralizers at different locations. The charge-enhanced 
coagulation could be controlled by the number and location of  the neutralizers. 
First, the operations of  each spray head were characterized. The size distributions 
of  particles generated by each spray head, as well as by both spray heads, with four 
neutralizers installed are compared in Figure 7.3.  
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Figure 7.3 The size distributions of  particles generated using (a) one spray head using positive voltage; (b) 
the other spray head using negative voltage; (c) both a and b together. All the cases used 4 neutralizers in 
the coagulation chamber. 
The three size distributions shown in Figure 7.3 were similar in shape. The mean 
sizes were 151.3 nm for positive spray, 150.7 nm for negative spray, and 153.7 nm when 
both spray heads were used. The geometric standard deviations (GSD) were all 1.11. 
The particle size generated by electrospray is affected by both the operation and the 
physical properties of  the solution. In our experiments, the same solution was used in 
both sprays, and the operations were set to be the same. The only difference was that 
positive high voltage was applied to one spray head, while negative high voltage was 
applied to the other one. As shown in Figure 7.3 (a) and (b), the size distributions of  
both cases were similar. When the two spray heads were operated together, droplets 
carrying either positive or negative charges were generated and introduced into the 
coagulation chamber at the same time. The droplets were exposed to the bipolar ions as 
soon as they entered the coagulation chamber. The charges carried on the droplets were 
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neutralized by the radioactive material to reach Boltzmann equilibrium charge 
distribution. The electrostatic coagulation of  aerosols having the Boltzmann equilibrium 
charge distribution is negligible compared with Brownian coagulation (Adachi et al. 
1981). As a result, the size distribution was similar to that generated by either positive or 
negative spray, indicating that the coagulation process, both Brownian coagulation and 
electrostatic coagulation, among droplets generated by the THES was negligible when 
the charge level were reduced to Boltzmann equilibrium charge distribution. For the rest 
of  the experiments, the size distribution using twin-head ES obtained with four 
neutralizers was considered as the initial size distribution, and was used for the 
comparison of  the size distributions after charge-enhanced coagulation. 
The size distributions of  particles generated using both spray heads, with four 
neutralizers, two neutralizers on the bottom level, or without neutralizers in the 
coagulation chamber, are shown in Figure 7.4.  
 
Figure 7.4 The size distributions of  particles generated by two spray heads in THES. (a) 4 neutralizers 
were used; (b) 2 neutralizers were used at the bottom level; (c) no neutralizers were used. 
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When four neutralizers were used, as discussed before, the coagulation process was 
negligible. The size distribution remained good monodispersity. By removing the two 
neutralizers at the top level of  the coagulation chamber, the size distribution was 
broadened, while the peak shifted towards larger sizes, as shown in Figure 7.4(b). 
However, there was a shoulder on the left-hand side of  the peak, corresponding to the 
original particles that did not coagulate with others. If  no neutralizers were used (Figure 
7.4(c)), the peak diameter was about the same as the case with two neutralizers, but the 
shape of  the peak was not the same. Figure 7.4(c) had more particles on the right-hand 
side of  the peak, and fewer particles on the left-hand side. The shoulder in Figure 7.4(b) 
was not seen in Figure 7.4(c).  
When there were no neutralizers at the top level of  the coagulation chamber, no 
bipolar ions presented when the two aerosol flows met. The charges carried on the 
droplets increased the collisions among droplets. The final particle size increased due to 
coagulation. Meanwhile, the charge number of  the particles after coagulation also 
decreased to a relatively lower level. As droplets entered the bottom level of  the 
chamber, two neutralizers were used to further neutralize the charges. Further 
coagulation was again negligible. The shoulder on the left-hand side of  the peak 
represented the particles that passed through the chamber without colliding with other 
particles. However, when no neutralizers were in the coagulation chamber, the only way 
to reduce the charges on the droplets was through coagulation. For those droplets that 
did not collide with others, the high charge level increased their chances of  getting loss 
due to deposition. Also, when no neutralizers presented, charge-enhanced coagulation 
was not terminated due to the lower charge level achieved by exposing particles to 
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bipolar ions. As a result, more droplets had the chance to coagulate compared with the 
other two cases. The overall effect ended up with fewer small particles and more large 
particles in the size distribution. 
To verify that the increase in particle size was because the coagulation between 
positive and negative charged droplets generated by the two identical spray heads 
separately, an experiment using two drugs was carried out. Budesonide and 
epigallocatechin-3-gallate (EGCG) were dissolved in ethanol at a concentration of  0.1%. 
The conductivities and liquid feed rate were the same, so that the particles generated by 
the two spray heads were similar. The two drug solutions were sprayed using the THES 
at the same time. The size distributions before and after coagulation are shown in Figure 
7.5(a) and (b). The initial distribution had a peak value of  57.3 nm and GSD of  1.14. 
After coagulation, a second peak with a larger particle size (peak at 73.7 nm) showed up. 
The 74 nm particles were classified using a long DMA, collected using an electrostatic 
precipitator, and re-dissolved in ethanol. The drug concentrations were then analyzed 
using HPLC. The volume percentages of  each drug in the collected particles are given 
in Figure 7.5(c). 48.4% of  the total mass was EGCG, while 51.6% was budesonide. The 
volume ratio of  the two drugs was almost 1:1, indicating that the large particle was a 
combination of  two drug particles of  similar size. 
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Figure 7.5 Verification of  coagulation using budesonide and EGCG. (a) Size distribution of  budesonide 
and EGCG before coagulation (four neutralizers were used); (b) Size distribution of  budesonide and 
EGCG after coagulation (two neutralizers were installed at the bottom level); (c) The total volume of  
budesonide and EGCG in the collected particles with a diameter of  74 nm. Bar, SD. 
The SEM image of  coagulated sucrose particles is given in Figure 7.6(a). All the 
collected particles were spherical in shape after coagulation. One possible explanation 
would be that the solvent was not totally evaporated when the collision happened. Two 
droplets merged into one after the collision, which ended up with a spherical particle 
after solvent evaporated. 
The particles in the fluorescence image were also spherical Figure 7.6 (b), (c) and (d). 
Both green and red particles could be observed separately under corresponding filter. 
By overlaying the two images, most of  the particles overlapped. The particles which 
could be observed under both filters contained both fluorescent tracers, indicating that 
the particles were formed due to the collision between oppositely charged particles. 
However, there were a few particles which only appeared under one filter, which were 
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primary particles that did not collide with others. Most of  the particles were lost inside 
the chamber if  the charge level was not reduced by collisions. So compared with 
coagulated particles, the primary particles were much less concentrated in number. 
 
(a) 
 
(b) 
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(c) 
 
(d) 
Figure 7.6 SEM and fluorescence images of  coagulated particles. (a) SEM image of  sucrose particles after 
coagulation; (b) fluorescence image of  green channel (uranine); (c) fluorescence image of  red channel 
(Rhodamine 6G); (d) fluorescence image of  two channels together 
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7.3.2 Size Evolution Due to Coagulation 
Experiments had been carried out to study the changes in particle size after 
coagulation. Sucrose was dissolved in isopropanol (IPA) /aqueous (4:1 in v/v) solution 
at concentrations of  1% and 0.1%. Ammonium acetate was added into the solution to 
adjust the conductivity.  A capillary with an o.d. of  1/32 inches and an i.d. of  0.008 
inches was used for both spray heads. All the sprays were in the stable cone-jet mode 
for the experiment. The spray condition and spray current were monitored throughout 
the experiment.  
For a given liquid solution, the size of  particles generated by single capillary 
electrospray can be varied by changing the conductivity and the concentration of  the 
solution, and the liquid feed flow rate (Chen and Pui 1997; Ganan-Calvo 1997; Hartman 
et al. 2000). In our experiment, two sucrose concentrations were prepared with different 
conductivities. The solution feed flow rate varied from 0.15 µl/min to 1 µl/min. The 
initial size before coagulation ranged from 17 nm to 710 nm. For all the tested 
conditions, the spray was controlled at the cone-jet mode, in which monodisperse 
particles were generated. The scaling laws of  single capillary ES has been well 
investigated and summarized (Cloupeau and Prunetfoch 1994; de la Mora 2007; Jaworek 
and Krupa 1999; Marginean et al. 2007). It has been shown that for a single capillary ES 
operated in cone-jet mode, the diameter of  generated particle and the spray current 
follow the following equations (Chen et al. 1995; de Juan and de la Mora 1997): 
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where Dp is the diameter of  generated particles, Q is the feed flow rate of  the 
solution, and K is the conductivity of  the solution. 
The relationship between Dp and Q/K for sucrose solutions at 1% and 0.1% are 
shown in Figure 7.7. The spray current I are plotted in Figure 7.8 as a function of  
(QK)1/2. Both Dp and I showed good linear relationship with the corresponding function 
of  Q and K, indicating that the spray was in the cone-jet mode. 
 
 
Figure 7.7  Particle diameter as a function of  liquid feed flow rate and conductivity. (a) 1% sucrose 
solution; (b) 0.1% sucrose solution. Bar, SD. 
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Figure 7.8 Spray current as a function of  solution conductivity and feed flow rate. Bar, SD. 
The size distributions before and after coagulation were measured by SMPS. The 
size distributions before coagulation were measured with four neutralizers in the 
coagulation chamber, while the distribution after coagulation was taken when no 
neutralizers were used. When no neutralizers were used, the droplets remained in high 
charge level until they collided with other highly charged droplets or deposited on the 
wall. When there was no charge reduction process, over 95% of  the particles were lost 
inside the chamber (Fu et al. 2011a). In the THES, the coagulation was enhanced due to 
electrical force. In the meantime, when the two droplets collided, the net charge on the 
newly formed large droplet was much lower than that of  each original one. As a result, 
the droplets after coagulation had more chance to passage through the chamber than 
droplets that did not collide with others. The size distribution after coagulation was 
mainly composed of  particles that had lower charge levels due to the collisions. The 
representative size distributions before and after coagulation are shown in Figure 7.9.  
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Figure 7.9 Size distributions generated by THES with (a) or without (b) electrostatic coagulation. 
For the example shown in Figure 7.9, the primary particle size before coagulation 
was 109 nm, with a GSD of  1.15. After coagulation, the diameters of  particles shifted 
towards larger size with a broader shape. The peak was around 151 nm and the GSD is 
1.33. Note that there was also a peak of  satellites with much smaller sizes (peak around 
10 nm) in Figure 7.9(a). The satellites, which were also charged, were formed during the 
jet breakup process (Chen et al. 1995). When the two aerosol flows entered the 
coagulation chamber, not only the primary droplets, but also the satellites collided due 
to electrostatic attraction. As shown in Figure 7.9, the peak of  original satellites was 
around 10 nm, while the peak of  coagulated satellites was around 13 nm.  
The particle diameters before and after coagulation are shown in a log-log plot 
Figure 7.10. The particle diameter after coagulation can be calculated under the 
following assumptions: 1) the particles were formed due to two spherical particles of  
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the same size, and 2) the particles formed after coagulation were also spherical in shape. 
Thus, the diameter of  coagulated particle was: 
ppc dd ⋅=
3 2 ,                                                                                   (7.3)  
where dp was the original diameter of  particles before coagulation. The theoretical 
relationship was also plotted in Figure 7.10. 
 
Figure 7.10 Particle diameters before (Dp1) and after (Dp2) coagulation. Bar, SD. 
The increase in particle diameter due to coagulation in general followed the 
theoretical calculation in equation (7.3) throughout the tested diameter range from a few 
nanometers to sub-micrometers. For both primary particles and satellites, the peak 
diameters were 26% larger than the diameter before coagulation, doubling the particle 
volume.  
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The shape of  the size distributions after coagulation was broader than the original 
ones. The distributions were composed of  particles which were formed due to 
coagulation among droplets with different sizes. Although the original particles 
generated by ES had a narrow size range, the coagulation process was not guaranteed to 
only happen to particles of  the same size or carrying the same number of  charges. Also, 
there might be collisions of  more than two particles with different charge levels. Efforts 
have been made to fit the size distributions with several peaks corresponding to 
particles formed by coagulation between different numbers of  original particles. 
However, the fitting results could not explain well the reality because the resolution of  
the measured size distribution was not high enough to separate those peaks. 
The initial charge level of  droplets generated by electrospray is very difficult to be 
measured directly. In this study, we estimated the average number of  charges using the 
total number of  particles and the spray current. Assuming that the all the particles 
generated by electrospray had the same diameter, the total number of  particles can be 
calculated by mass conservation. The spray current was measured using a resistance and 
a multimeter (Model 2000 6½-Digit Multimeter, Keithley Instruments, Inc., OH). The 
Rayleigh limit of  corresponding droplets was also calculated as follows: 
( ) 2/13.08 dγε̟qR = ,                                                                                                                   (7.4) 
where γ is the surface tension of  the liquid, ε0 is the vacuum permittivity, and d is the 
droplet diameter. 
The average numbers of  charge of  the droplets generated by electrospray, as well as 
the Rayleigh limits, are shown in Figure 7.11. The number of  charges ranged from a few 
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hundreds to tens of  thousands, depending on the droplet diameters. Note that the 
charges on the droplets were all below Rayleigh limits. 
Although the charges and particle size both covered wide ranges, the electrostatic 
coagulation was observed for all the tested cases. As shown in Figure 7.10, the peak 
diameters after coagulation all followed the calculation based on two-particle collision, 
disregarding the original charge level and particle size. 
 
Figure 7.11 The average numbers of  charge of  the droplets generated by electrospray. Bar, SD. 
7.3.3  Effect of  Charge Level 
One limitation of  single capillary ES is that the diameter of  the generated particles 
and the number of  charges carried on each particle cannot be separately controlled. 
Both the diameter and the charge level are related to the liquid feed flow rate and the 
solution conductivity. Changing either of  them will result in changes in both the size 
and the charge. Dual-capillary ES was proposed to overcome this limitation. In dual-
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capillary ES, by varying the conductivity of  the outer solution while keeping everything 
else the same, particles with the same diameter can be generated to carry different 
number of  charges. In this study, dual-capillary ES were used for both spray heads to 
study the charge effects on the coagulation process in the THES system. 
The inner solution was PEG (Mw=3350)/ethanol solution at concentrations of  1% 
(v/v), with a conductivity of  35 µS/cm. The outer solution was ethanol with different 
conductivities, i.e. 35 µS/cm, 78 µS/cm, 180 µS/cm, and 340 µS/cm. Two feed flow 
rates, 0.5 µl/min and 1 µl/min were used for inner solution, while three feed flow rates, 
1.5 µl/min, 2 µl/min, and 3 µl/min were used to introduce outer solution. 
The initial average number of  charge on the droplets was estimated in the same way 
as discussed previously. In general, for the same liquid feed flow rate, by increasing the 
conductivities of  outer solution, the average number of  charge increased. One example, 
with 1 µl/min of  1% PEG as the inner solution, and 3 µl/min of  outer solution with 
various conductivities, is given in Figure 7.12.  
The size distributions before and after coagulation were obtained using SMPS. Four 
neutralizers were used to neutralize the electric charge so that the distribution without 
coagulation could be measured. The size distributions were similar for the four cases 
with different conductivities of  outer liquid. When the neutralizers were removed, 
coagulation happened, which increased the particle size and broadened the size 
distribution. The distributions are shown in Figure 7.13. 
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Figure 7.12 The average number of  charge on the droplets generated by ES as a function of  the 
conductivities of  outer liquid. The inner liquid was 1% PEG at feed flow rate of  1 µl/min. The outer 
liquid was 3 µl/min ethanol, with different conductivities. Bar, SD. 
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Figure 7.13 Size distributions before (a) and after coagulations (b,c,d,e) generated using dual-capillary 
THES. The inner liquid was 1% PEG/ethanol solution at a conductivity of  35 µS/cm. The outer liquid 
was ethanol, with conductivities of  35 µS/cm (b), 78 µS/cm (c), 180 µS/cm (d), and 340 µS/cm (e). 
Dp (nm)
50 100 150 200 300
dN
/d
lo
gD
p 
(#/
cm
3 )
0
1e+5
2e+5
3e+5
4e+5
5e+5
6e+5
(c)
Dp (nm)
50 100 150 200 300
dN
/d
lo
gD
p 
(#/
cm
3 )
0
1e+5
2e+5
3e+5
4e+5
5e+5
6e+5
(d)
Dp (nm)
50 100 150 200 300
dN
/d
lo
gD
p 
(#/
cm
3 )
0
1e+5
2e+5
3e+5
4e+5
5e+5
(e)
   125 
When the conductivities of  outer solutions increased, the number of  charges 
carried on the droplets also increased. However, the final particle size distributions were 
very alike. The peak diameter was all 156 nm. The GSD slightly increased with the 
charge level. Similar to single capillary ES cases, the increase in peak diameter 
corresponded to the collision between two droplets with the same diameter. The results 
showed that the initial charge level did not have influence on the size distribution after 
coagulation, especially the peak diameter. The increase in particle size after coagulation 
indicated that the incidence of  collisions between two oppositely charged droplets was 
independent with the initial particle size and charge level in the electrospray system. 
Note that even though the spray current varied with operations, the number of  charge 
on ES-generated particles was very high, as shown in Figure 7.11 and Figure 7.12. The 
attractions between oppositely and highly charged particles ensured the collisions. 
However, the size distributions could not provide the information on the percentage of  
particles that collided with others. Also, although the size distribution seems broader as 
the spray current increases, the resolution of  the size distribution was not high enough 
to give the evidence whether the broadness was because of  multi-body collision instead 
of  two-body collision, or because of  the collision between particles with different sizes. 
Even though the size distribution of  particles generated by electrospray was much 
narrower than those given by other aerosol generation techniques, the particle sizes still 
varied in a small range. Besides, the charge distribution was broader than the size 
distribution. The variation in particle size and charge make it complicated to 
characterize the coagulation process in detail. Advanced techniques with high 
resolutions may help resolve this problem. 
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7.3.4 Residual charge 
The ES generated particles are highly charged. As shown in Figure 7.11, for 
different working conditions, the average number of  charges varied from a few 
hundreds to tens of  thousands. The charge distribution of  the main droplets is about 
2.5 times broader than the size distribution (de Juan and de la Mora 1997). The 
collisions between oppositely charged particles in the THES system were not necessarily 
happen to particles with exactly the same charges. As a result, the particles after 
coagulation might still carry a small amount of  charge. But the charge levels were 
greatly decreased. 
To study the fraction of  neutral, negative charged, and positive charged particles 
that exited the THES system, a precipitator with two parallel plates was designed. 
During operation, one plate was connected to high voltage while the other plate was 
grounded. The aerosol flow was introduced into the space between the two plates. A 
simple calibration was carried out to characterize the performance of  the precipitator. 
By using monodisperse sodium chloride particles which were generated using atomizer 
and classified using DMA, the penetration through the precipitator under different 
operation conditions could be calculated. Due to the parallel configuration, the 
diffusion loss of  small size particles was limited. The penetration of  neutral particle 
with diameter of  15 nm and above was over 99.0%. For singly charged particles, at an 
air flow rate of  1.5 lpm, 99.9% of  100 nm particles deposited in the precipitator when 
the applied high voltage was 8 kV. 
Fluorescence measurement was used to quantify the charge fraction. Uranine was 
dissolved in the sucrose solution at a concentration of  1 g/l. When the high voltage was 
   127 
on, positive and negative charged particles were separated and deposited on 
corresponding plates. Neutral particles could survive the precipitator and would be 
collected on a filter (Lydall Filtration/Separation, Inc., NH). After each experiment run, 
the uranine was recovered using an aqueous solution of  0.001 N ammonium hydroxide. 
The concentration of  uranine in the various wash solutions was measured by a 
fluorometer (GloMax®-Multi Jr Single Tube Multimode Reader, Promega Corporation, 
CA).  
For our experiments, the goal of  using precipitator was to collect all the charged 
particles inside the precipitator so that only neutral particles could passage it. The 
voltage applied on one of  the precipitation plate was set at 12 kV, which was the 
maximum value it could handle. Aerosol flow was directly introduced into the plate 
precipitator after exiting the THES at desired flow rate. Three cases were tested. The 
peak diameters after coagulation were 85 nm, 128 nm, and 346 nm, respectively. The 
average numbers of  charge before coagulation were estimated to be 7334, 11269, and 
21068, respectively. Based on the calibration, the air flow rate of  the precipitator was 1 
lpm for collecting 85 nm and 128 nm particles, and 0.3 lpm for collecting 346 nm 
particles. 
The results are compared in Figure 7.14. The peak diameters after coagulation were 
listed in the figure. The initial charge level also increased with the increase in particle 
size. After coagulation, in general, the ratios of  positively and negatively charged 
particles were close to each other, indicating that the aerosols exited from the THES 
were close to zero net charge even when there was no extra neutralization used. The 
ratios of  neutral particles decreased with the increase in particle size and number of  
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charge. For 85 nm particles (after coagulation, initial size 70 nm), 28% of  total particles 
exited from the ES chamber were neutral. For large particle size (346 nm after 
coagulation), the ratio of  neutral particle was less than 5%. The average charges on 
original particles before coagulation were 3 times higher for 346 nm particles than 85 
nm particles. The large variations in the charge number decreased the chance of  
collisions between two particles with the same number of  charge. 
 
Figure 7.14 The persentage of  neutral, positive charged, and negative charged particles that exited from 
the THES after coagulation. Bar, SD. 
7.3.5 180 Degree Coagulation Chamber 
Another version of  the coagulation chamber was designed with the two spray heads 
facing each other. The volume of  the 180 degree chamber was slightly smaller than the 
90 degree chamber. It can only hold two neutralizers. When neutralizers were used, the 
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aerosols were exposed to bipolar ions after they entered the chamber so that 
electrostatic coagulation could be negligible. If  aluminum dummies were installed in 
stead of  radioactive material, the coagulation process was enhanced by electric 
attractions between oppositely charged particles. The 180 degree chamber was 
compared with the 90 degree chamber for the effects on coagulation. 
Another major difference of  the 180 degree chamber was the size of  the orifice. By 
fluorescence analysis, an interesting observation was the particle deposition inside the 
THES chamber. For all the tested cases, heavy deposition on the grounded stainless 
steel orifice plate of  each spray head was observed. Highly charged particles needed to 
penetrate through the orifice, enter the coagulation chamber to collide with other 
particles or be neutralized by radioactive materials. According to our previous study (Fu 
et al. 2011a), an orifice of  small diameter caused more particle loss compared to larger 
orifice. For the 90 degree chamber, the orifice was only 0.25” in diameter. To increase 
the orifice can reduce the particle loss. In the 180 degree chamber, the orifice was 
enlarged to 0.75”, which was the same diameter as the inner diameter of  the spray 
chamber. No obstruction presented between the spray head and the coagulation 
chamber. 
The size distributions using the 180 degree chamber with or without two 
neutralizers in the chamber were shown in Figure 7.15. The spray solution was 1% 
sucrose solution, with a conductivity of  178 µS/cm, and feed flow rate of  0.3 µl/min. 
The same operation conditions of  Figure 7.9 were used for this case. Figure 7.15(a) 
shows that distribution with neutralizers present when the two flows containing 
oppositely charged particles mixed, no charge-enhanced coagulation was observed. The 
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distribution of  the primary peak was similar to the one in Figure 7.9(a), indicating that 
the modification of  the orifice did not affect the operation of  ES. However, by 
increasing the orifice, the number of  satellites that passage the chamber increased, 
which agreed with our previous observation (Fu et al. 2011a). When there were no 
neutralizers in the chamber, particle size increased due to coagulation process. An 
ionizer (P-2031, Po210, NRD LLC., NY) was connected to the outlet of  the spray 
chamber to further neutralize the particles, corresponding to the case of  the degree 
chamber with two neutralizers installed at the bottom level. The size distribution is 
given in Figure 7.15(b). The distribution had two major peaks: one had the same peak 
diameter as that in Figure 7.15(a), corresponding to the droplets that exited the chamber 
without colliding with other droplets; the larger one had the same peak diameter as that 
in Figure 7.9(b), which was formed by coagulated droplets. The primary droplets that 
did not collide with others had more chance to deposit during transportation before 
entering the DMA for size measurement. By connecting the ionizer to the outlet of  the 
chamber, those particles were preserved. By fitting the size distribution with two 
lognormal distributions (Figure 7.16), the ratio of  coagulated particles and primary 
particles that pass through the ES system could be roughly estimated. The fitting results 
are summarized in Table 7.1. The coagulated particles accounted for 70.6% of  the total 
peak area. However, some of  the primary droplets that did not collide with others got 
lost inside the coagulation chamber. So the exact percentage of  coagulated particles 
should be lower than 70.6%. 
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Figure 7.15 Size distribution of  particles generated by THES using the 180 degree chamber. (a) Size 
distribution when two neutralizers were used. (b) Size distribution when no neutralizers were used in the 
chamber. Note that for (b), an ionizer was connected with the aerosol exit of  the chamber to neutralize 
the aerosols. 
 
Figure 7.16 Curve fitting results of  main peak shown in Figure 7.15(b). 
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Table 7.1 Curve fitting results (Data shown in Mean±SD) 
 N0 Dp GSD % of  Area R2 
Peak 1 
1.4228e+06 ± 
84467.3229 
103.585476 ± 
1.27962019 
1.128799 ± 
0.008623 
29.6339310 
0.98566045 
Peak 2 
1.9262e+06 ± 
50704.3288 
144.453532 ± 
1.65624827 
1.163854 ± 
0.008712 
70.3660690 
To study the effects of  the residence time, a metal tube with 1” in diameter and 3’ in 
length was connected to the outlet of  the coagulation chamber. No radioactive material 
was used in this experiment. The size distributions are given in Figure 7.17. The spray 
solution was 1% sucrose solution, with conductivity of  178 uS/cm, and feed flow rate 
of  0.25 µl/min. The size distribution before coagulation (Figure 7.17(a)) had a primary 
peak at 98.2 nm, with a GSD of  1.19. With no neutralizers installed, the particles exiting 
the chamber were directly introduced to SMPS. As shown in Figure 7.17(b), the peak 
diameter increased to 121.9 nm, and the GSD was increased to 1.37. To further increase 
the residence time, the tube was connected and two air flow rates, 5 lpm and 2 lpm were 
used. The residence times were 5.6 s for 5 lpm flow and 13.9 s for 2 lpm flow. The peak 
diameter was not affected by the residence time, while the distributions were slightly 
broader when compared with the case with no tube. The GSD was 1.40 for both flow 
rates (Figure 7.17(c), (d)). However, the peak of  primary particles was not observed for 
all cases when no neutralizers were used. The particles that were highly charged were 
lost during transportation between the coagulation chamber and the SMPS. The 
residence time inside the coagulation chamber was 0.17 s at 5 lpm flow rate. The 
unaltered particle size distribution under different residence times indicating that the 
   133 
characterization time of  coagulation between highly charged particles was much smaller 
than the residence time in the chamber.  
The characteristic time of  charge-enhanced coagulation can be estimated based on 
the following assumptions: (1) the particles were all of  the same size carrying the same 
number of  elementary charge; (2) the number concentration of  positively and negatively 
charged particles was the same; (3) the coagulation happened between two primary 
particles, the collision between particles that already collided with others was negligible; 
(4) the coagulation coefficient β remained constant.  
For simple monodisperse coagulation with a constant value of  β, the number 
concentration N at time t can be calculated as (Hinds 1999b): 
tβN
N
tN
0
0
1
)(
+
= ,                                                       (7.5) 
Based on the assumptions, the number concentration would decrease to N0/2 after 
the electrostatic coagulation. Hence, the characteristic time can be calculated as: 
βN
t
0
1
= ,                                                               (7.6) 
For particles in the continuum regime, the coagulation coefficient is 
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where η is the viscosity of  the medium (which is air in this study). 
For particles in free molecular regime, the collision coefficient can be calculated as: 
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where ρp is the density of  particle. 
The collision coefficient of  charge-enhanced coagulation can be calculated using 
equation 6.2 and 6.3. 
 
 
Figure 7.17 Size distributions of  particles generated using THES with 180 degree chamber. (a) before 
coagulation; (b) after coagulation, exiting the chamber; (c) after coagulation, with 3’ tube, 5 lpm; (d) after 
coagulation, with 3’ tube, 2 lpm. 
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several typical cases are shown in Table 7.2. Droplets generated by electrospray were 
highly charged. At such high number of  charges, the coagulation happened within very 
short period of  time. As given in Table 7.2, the characteristic time was much less than 
the residence time in the coagulation chamber. As a result, further increasing the 
residence time will not show effects on the size distribution after coagulation, as shown 
in Figure 7.17. 
Table 7.2 The characteristic time of  charge-enhanced coagulation happened in the THES 
Particle 
Diameter 
(nm) 
Droplet 
Diameter 
(nm) 
# of  Charge 
Initial Number 
Concentration 
(#/cm3) 
Characteristic Time 
(s) 
22.5 225 1224 1.21e8 4.20e-5 
88.2 409 3198 5.57e9 8.43e-5 
300 1392 25695 6.28e8 7.01e-5 
429.4 1993 63507 1.21e8 4.81e-5 
The evaporation rate of  droplets can be estimated as follows (Hinds 1999c): 

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  for dp > 1.0 µm 
where R is the gas constant (8.314 m3 Pa K-1 mol-1), ρp is the density of  the droplet, dp 
is the diameter of  the droplet, Dv is the diffusion coefficient of  the vapor molecule, M is 
the molar mass of  the solvent, pd is the partial pressure of  vapor at the surface of  the 
droplet, p∞ is the partial pressure of  vapor in the gas surrounding the droplet, but away 
from the immediate surface, Td is the temperature of  the droplet, and T∞ is the 
temperature away from the droplet surface. 
The droplet lifetime for ethanol and water were calculated by Hinds (Hinds 1999c). 
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It was shown that for droplets larger than 1 µm, the lifetime was in the order of  10-4 s 
or larger for ethanol and water. Since the vapor pressure of  IPA is very close to that of  
ethanol, it is reasonable to estimate that the lifetime of  the droplets larger than 1 µm 
generated in the THES was in the order of  10-4 s. As given in Table 7.2, the 
characteristic time of  charge-enhanced coagulation for droplets larger than 1 µm was in 
the order of  10-5 s, which is faster than the evaporation time. As a result, the collision 
happened between two droplets instead of  solid particles. The two droplets merged into 
one large droplet after collision. As shown in SEM image, the particles after coagulation 
were spherical in shape. By using more volatile solvent, when the evaporation rate is 
faster than the coagulation rate, the coagulation may happen between particles. 
7.3.6 Loss in the System 
The particle transmission efficiency through the two coagulation chambers was 
characterized using fluorescence analysis. HEPA filter was connected to the outlet of  
the chamber to collect all the penetrated particles. In this study, one spray head was used 
to spray uranine/sucrose solution, while the other spray head sprayed IPA with a 
conductivity of  70 µS/cm. The transmission efficiency with and without neutralizers 
were compared. In order to compare with the 180 degree chamber, only two 
neutralizers were installed on the top level of  the coagulation chamber for the 90 degree 
chamber. Only one spray head was operated to spray uranine when neutralizers were 
used. When no neutralizers were installed, both spray heads were operated together. In 
this case, the highly charged IPA droplets were source of  ions to neutralize the uranine 
particles. The feed flow rate of  IPA was varied to provide different ion concentrations. 
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The ratio of  the spray current of  IPA and uranine was used as an indicator of  the 
difference in ion concentration. The higher the current ratio, the more ions compared 
to particle concentrations. The particle transmission efficiencies are compared in Figure 
7.18. 
 
Figure 7.18 Particle transmission efficiency through the THES system. Bar, SD. 
For the 90 degree chamber, one spray current ratio was compared to the case with 
the same particle generation condition, and two neutralizers on the top level. By using 
radioactive materials to reduce the charge level, which is the most commonly used 
technology in laboratory research (Liu and Pui 1974), 52.3% of  the particles penetrated 
the system. When the ion with opposite polarity was generated by another spray head at 
a high concentration, the penetration was 44.2%. The coagulation process can achieve 
84.5% effect of  the neutralization by radioactive materials. Due to the small orifice 
diameter, the particle deposition on the orifice was the major source of  loss inside the 
THES system. The size of  the orifice had been greatly increased in the 180 degree 
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coagulation chamber. As a result, for the case with two neutralizers, the particle 
transmission efficiency through the system was 79.0%, which was much higher than the 
same case with the 90 degree chamber. The transmission efficiencies of  using IPA spray 
instead of  neutralizers were slightly lower than the case with neutralizers. For the four 
ion concentrations, the transmission efficiencies were over 60.0%, which were still 
higher than the cases with 90 degree chamber. By decreasing the ion concentrations, the 
particle loss inside the chamber was slightly increased, indicating the decrease in 
collisions between uranine and IPA droplets. For the 180 degree chamber, the spray 
chamber was wide open due to the large orifice. So the particles could be attracted to 
the orifice or even the spray chamber of  IPA spray. When the spray current of  IPA 
increased, although the overall particle transmission efficiency increased, the deposition 
on the IPA spray chamber also increased. This loss could be decreased by using the 90 
degree configuration. A 90 degree chamber with large orifice might achieve even higher 
particle transmission efficiency. 
7.4 Summary 
A twin-head electrospray system was designed with two configurations of  the 
coagulation chamber. The performance was evaluated under different operational 
conditions. The spray head operated in the cone-jet mode could generate monodisperse 
aerosols. By using two or more neutralizers, the charge-enhanced coagulations between 
oppositely charged droplets were negligible. When no neutralizers were included at the 
mixing region of  the two aerosol flows, coagulation happened. The coagulation process 
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was confirmed by the size distribution, fluorescence microscope, and chemical 
composition analysis using HPLC.  
The size change due to coagulation was characterized for particle size ranging from 
10 nm to 710 nm, including both primary particles and satellites. The peak diameter of  
particles after coagulation was about 1.3 times larger than the size before the 
coagulation, indicating that the large particles were formed due to the collision of  two 
oppositely charged primary droplets. The initial droplet size and the charge level did not 
affect the size distributions after coagulation. By using the 180 degree chamber, similar 
size distributions of  coagulated particles were observed. The number of  charges on 
particles was highly reduced due to the coagulation. Only a small portion of  coagulated 
particles are neutral. At least two-thirds of  the particles remained carrying charges after 
coagulation. 
The particle transmission efficiency was characterized for both spray chambers. By 
using two neutralizers, the transmission efficiency was 52.3% for the 90 degree chamber 
and 79.0% for the 180 degree chamber. Compared with the cases with two neutralizers, 
the transmission efficiency of  the experiments without neutralizers was slightly smaller: 
44.2% for the 90 degree chamber and over 60.0% for the 180 degree chamber. The 
design of  twin-head electrospray, which utilized the coagulation between oppositely 
charged particles to reduce the charge level, could achieve almost equivalent particle 
transmission efficiency with that achieved by using radioactive sources to neutralize the 
charge.   
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PLGA-Based Controlled Drug Delivery 
System Generated by a Twin-Head 
Electrospray 
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8.1 Introduction 
Drug delivery systems have evolved from traditional methods to controlled release 
delivery systems. Compared to traditional delivery system (TDS), controlled release drug 
delivery system (CRS) can increase drug effectiveness by maintaining the drug 
concentration in target organs at a desired level while decreasing the side effects caused 
by drug concentration close to the toxic threshold which is often encountered in TDS 
(Freiberg and Zhu 2004; Kumar and Kumar 2001; Kumar et al. 2002; Uhrich et al. 
1999).  
Biodegradable polymers are widely used in CRS to control the release rate and 
protect the drug prior release. A novel method to synthesis drug/polymer system is 
electrohydrodynamic atomization (Electrospray, ES). ES contains a capillary through 
which sprayed liquid is introduced. During operation, high voltage is applied to the 
capillary. When the electrical force is balanced with the surface tension, a stable cone-jet, 
which can generate monodisperse droplets, will form at the tip of  the capillary. 
Electrospray has many advantages in generating drug loaded particles. It has been 
shown that ES can generate particles with the diameters ranging from nanometers to 
micrometers (Chen et al. 1995). The particle size can be easily controlled by varying the 
solution concentration, liquid feed flow rate, and liquid conductivity without degrading 
the particles’ chemical or biological properties (Chen and Pui 1997; Ganan-Calvo 1997; 
Hartman et al. 2000). No high shear force is required. ES-generated particles are nearly 
monodisperse, which can provide uniform release rate. High encapsulation efficiency 
can be achieved by well controlling the spray conditions (Lee et al. 2010; Mei and Chen 
2007). Single capillary ES was first used to generate drug-loaded particles (Hong et al. 
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2008; Kumbar et al. 2007; Valo et al. 2009; Xie and Wang 2007; Xu and Hanna 2006). 
Later, dual-capillary and tri-capillary were developed and studied for their applications in 
controlled drug delivery (Lee et al. 2011; Lee et al. 2010; Xie et al. 2008). Compared to 
the emulsion method, which is the most commonly used and well-studied method in 
drug encapsulation, by using two or three coaxial capillaries, the encapsulation process 
was not limited by the hydrophilic properties of  the polymer and the drug. 
Controlled drug delivery can not only control drug release profile, but also control 
the drug concentration in a specific site. The most effective way in achieving this goal is 
to directly deliver the drug to the target site. One good example would be pulmonary 
drug delivery. ES-generated particles are airborne, which means that they can be directly 
used in pulmonary drug delivery (Ijsebaert et al. 2001; Tang and Gomez 1994).  
The twin-head electrospray (THES) system contained two identical electrospray 
heads which can be operated using either a single capillary or a dual-capillary. The 
THES system provides a way to first generate drug particles separately and then mix 
them for delivery. The particle sizes and concentrations of  each agent can be 
independently controlled. In this study, PLGA-based drug particles were generated 
using the twin-head ES. The drug release profiles were compared with that of  particles 
generated by one dual-capillary ES. 
   143 
8.2 Experiments and Methods 
8.2.1 Materials 
Poly(lactic-co-glycolic acid) (PLGA, molecular weight =5000-15,000, lactide : 
glycolide = 50:50, Sigma-Aldrich, St. Louis, MO) was used as outer coating material. 
Two tested drugs were budesonide and pioglitazone. Acetonitrile (anhydrous, 99.8%, 
Sigma-Aldrich) were used to dissolve both drugs and PLGA.  
8.2.2 Drug Preparation using THES 
A schematic diagram of  the experimental setup is shown in  
 
Figure 8.1. Dual-capillary was used in each spray head. The inner capillary had an i.d. 
of  0.008” and an o.d. of  0.03125”. The outer capillary was manufactured with an i.d. of  
0.046”. The inner and outer solutions were introduced separately using two syringe 
pumps (PHD 2000, Harvard Apparatus, MA). Filtered air was used as carrier gas. 
Positive and negative high voltages were applied to each spray head separately by 
connecting the stainless steel capillary piece with DC power supply (Bertan, Series 230, 
Spellman High Voltage Electronics Corporation, NY). The spray condition was 
monitored via an optical system including an illumination light source, a microscope 
lens (Infinivar CFM-2/S™ Microscope Video Lenses), and a CCD camera (Model 
XCD-SX910CR, SONY). The charge reduction chamber was designed to hold up to 
four spot ionizers (Po210, Nuclespot P-2042, NRD LLC, NY). No neutralizer was 
installed when the two spray heads were all in use, in which case coagulation between 
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oppositely charged droplets served as charge neutralization process. The drug particles 
exiting the chamber were collected on a HEPA filter (Lydall Filtration/Separation, Inc., 
Rochester, NH) for the subsequent test.  
 
 
 
Figure 8.1  A schematic diagram of  the experimental setup 
8.2.3 Characterization 
The diameters of  particles were characterized using scanning mobility particle sizer 
(SMPS). The morphology of  particles was characterized by SEM (Nova NanoSEM 
2300, FEI). 
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8.2.4 In vitro Drug Release Profile Studies 
Particles generated by the THES were collected on high efficiency glass fiber filter. 
After collection, the filter was immersed in a sample vial with 0.5 ml Phosphate Buffer 
Solution (PBS). The sample vial was continually shaken at room temperature. At a 
desired time point, the buffer solution was extracted. Fresh PBS (0.5 ml) was then 
added in the same sample vial for continue release. After the last time point, DMSO was 
used to dissolve the remaining polymer and unreleased drug. 
Drug concentration was measured by high efficiency liquid chromatography 
(HPLC). The HP 1100 series HPLC system was used. The analyzing conditions were 
the same as described in chapter 3.3. 
8.2.5 Release Kinetics 
A biexponential model was used to fit the release profile.  
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where C(t)/C0 is the percentage of  drug released at time t, A1 and A2 are the 
parameters that reflect the portion of  initial drug concentrations contributing to burst 
release and sustained release, respectively. k1 and k2 are the apparent release rate 
constants, from which the half-life of  burst and sustained release can be calculated. 
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8.3 Results and Discussion 
8.3.1 Characterization of  Particles Generated Using Dual-
Capillary THES 
Dual-capillary electrospray is capable of  generating particles in core-shell structure 
with high encapsulation efficiency (Lee et al. 2010; Loscertales et al. 2002; Mei and Chen 
2007; Xie et al. 2008). The dual-capillary ES head contains two coaxially aligned 
capillaries. The core material and the shell material can be separately introduced through 
two liquid channels. The operational modes of  dual-capillary ES and the effects of  
liquid properties on the encapsulation process were studied by Mei et al. (Mei and Chen 
2007; 2008). In order to achieve nearly monodisperse distribution of  generated particles, 
a cone-jet mode is preferred during operation. When the inner and outer liquids are 
miscible or partially miscible, the stable cone-jet can be easily established. In this study, 
to ensure a stable cone-jet mode operation, acetonitrile was used as the solvent for both 
the inner and the outer materials to minimize the interfacial surface tension.  
Two drugs were used as core materials. Budesonide is a synthetic glucocorticoid 
steroid used frequently for the treatment of  asthma. Pioglitazone is a synthetic PPARγ 
ligands used clinically to treat type II diabetes. Each of  them has been shown to have 
inhibitory effects on lung tumorigenesis by either aerosol or oral delivery (Alyaqoub et 
al. 2007; Nemenoff  2007; Wattenberg and Estensen 1997; Wattenberg et al. 2000; 
Wattenberg et al. 1997). In our previous study using A/J mice, by combining 
budesonide and pioglitazone, 90% inhibition was achieved on tumor load. However, 
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budesonide and pioglitazone were administrated by different routes. Budesonide was 
aerosolized using a custom-built atomizer, while pioglitazone was oral delivered by 
gavage. A simple way to conduct the combination treatment would be to introduce both 
drugs together in aerosolized form.  
One spray head with dual-capillary was first used to generate drug/PLGA particles. 
The experiment conditions and average particle diameters are summarized in Table 8.1.  
 
 
Table 8.1 Cases summary and average particle diameters for one spray head experiments 
Case 
Inner Solution 
(Drug/ACN) 
Outer Solution 
(PLGA/ACN) 
Dp 
(nm) 
GSD 
S1 0.1% Budesonide, 1 µl/min 0.5%, 5 µl/min 330 1.19 
S2 0.1% Budesonide, 1 µl/min 1%, 6.25 µl/min 438 1.21 
S3 0.1% Pioglitazone, 1 µl/min 0.5%, 10 µl/min 270 1.20 
S4 
0.1% Budesonide & 0.1% 
Pioglitazone, 1 µl/min 
0.5%, 15 µl/min 414 1.38 
 
The particle size distributions were measured by SMPS. The morphology of  
drug/PLGA particles was characterized by SEM. Figure 8.2 shows representative 
particle size distributions (S1 and S3) and SEM image (case S2). The diameters of  
drug/PLGA particles generated by dual-capillary ES were within a narrow range, with a 
geometric standard deviation (GSD) around 1.2. The SEM image showed that the 
particles were spherical in shape. The particle diameter is related to the solution 
conductivity, liquid feed flow rate and the concentration. In this study, the particle 
diameters were in sub-micrometer ranges. 
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Figure 8.2 Representative particle size distributions (S1 and S3) and SEM image (case S2) of  cases using 
only one spray head 
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ratios were compared for the release profiles. The cases using THES were summarized 
in Table 8.2. 
Table 8.2 Cases summary and average particle diameters for Twin-Head ES experiments 
Case 
Spray 
Head 
Case in 
Table 1 
Inner Solution Outer Solution Dp 
(nm) (Drug/ACN)* (PLGA/ACN) 
D1 
Positive  S1 0.1% Budesonide, 1 µl/min 0.5%, 5 µl/min 
340 
Negative  - 0.5% PLGA, 1 µl/min* -  
D2 
Positive  S1 0.1% Budesonide, 1 µl/min 0.5%, 5 µl/min 
490 
Negative  S2 0.1% Budesonide, 1 µl/min 1%, 6.25 µl/min 
D3 
Positive  S1 0.1% Budesonide, 1 µl/min 0.5%, 5 µl/min 
398 
Negative  S3 0.1% Pioglitazone, 1 µl/min 0.5%, 10 µl/min 
D4 
Positive  S2 0.1% Budesonide, 1 µl/min 1%, 6.25 µl/min 
460 
Negative  S3 0.1% Pioglitazone, 1 µl/min 0.5%, 10 µl/min 
* Except for D1 case, where single capillary was used for spray and the solution was PLGA/ACN. 
When the two identical spray heads were both used, droplets carrying either positive 
or negative charges were generated by the two spray heads, respectively. After emitted 
from the cone-jet, the droplets passed through the grounded orifice and entered the 
coagulation chamber, where the two aerosols met. Due to the electrostatic attractive 
forces, droplets with opposite charges collided with each other, which served as a charge 
neutralization process. After coagulation, the charges carried on the resulted droplets 
were highly reduced, while the droplet diameter increased because two droplets merged 
together to form a larger one. The particle size distribution was broadened due to the 
coagulation process, as shown in Figure 8.3(a). The SEM image showing the 
morphology of  the particles generated by THES is shown in Figure 8.3(b). Unlike the 
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case with only one dual-capillary, by including coagulation between oppositely charged 
particles, the particles were not perfectly spherical. The irregular shape was the result of  
the solvent evaporating during the process of  two spherical particles evolving into one 
spherical particle. 
 
(a) 
 
(b) 
Figure 8.3 Representative size distribution of  D3 and D4 and SEM images of  D3 using twin-head 
electrospray 
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8.3.2 In vitro Release Profile Characterization 
The release profiles of  budesonide/PLGA particles generated by one dual-capillary 
electrospray are shown in Figure 8.4. The concentration and feed flow rate of  inner 
solution of  budesonide were kept as 0.1% (v/v) and 1 µl/min. By varying the 
concentration and feed flow rate of  outer PLGA solution, the release rates were 
changed. In general, the release profile contained a fast burst release which continued 
with sustained release at a slower rate. The release rate decreased with the increase in the 
amount of  polymer. For S1, in which the ratio of  feed flow rate between the inner and 
out solution was 1:5, over 26% of  the total drug released within the first hour. By 
doubling the polymer concentration and increasing the feed flow rate, the release rate 
decreased in S2. The first hour release was 6%. S4 used solution contained both 
budesonide and pioglitazone as inner solution, and PLGA solution at a feed flow rate 
of  15 µl/min as outer solution. The release profile was similar to S2. In both S2 and S4, 
one dual-capillary ES was utilized, so the structures of  generated particles were similar. 
The total amount of  polymer in both cases was close. As a result, the release profiles 
were overlapped with each other. 50% release took place after 5 hrs for S1, 59 hrs for 
both S2 and S4. 
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Figure 8.4 Release profilesof  budesonide/PLGA particles generated by one dual-capillary electrospray. 
Bar, SD. 
Table 8.3 summarized the model parameters obtained by fitting the experimental 
data of  one dual-capillary ES cases with the biexponential model. The release profiled 
could be fitted very well using the biexponential model. As shown in Table 8.3, the 
burst release accounted for 57% for S1, 15% for S2, and 24% for S4. The half-life of  
burst release was 3.1 hr for S1, 5.7 hr for S2, and 7.2 hr for S4. The burst release was 
suppressed by increasing the amount of  PLGA. Also, more PLGA decreased the 
sustained release rate, which was characterized by the half-life (t2(1/2)). 
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Table 8.3 Release kinetics for budesonide/PLGA particles generated by one spray head in THES. (Data 
shown in Mean±SD) 
Cases S1 S2 S4 
A1 0.56965±0.03397 0.15163±0.00996 0.23713±0.02181 
k1 4.40459±0.54717 8.17132±1.34242 10.3339±1.97996 
A2 0.31444±0.03369 0.81680±0.00976 0.76077±0.02269 
k2 72.81541±11.08148 121.86882±2.56211 136.01662±4.81455 
t1(1/2) 3.05238±0.37919 5.66272±0.93030 7.16139±1.37211 
t2(1/2) 50.46108±7.67947 84.45509±1.77554 94.25952±3.33648 
R2 0.99412 0.99935 0.99852 
 
By using THES, two spray heads were operated with high voltage of  different 
polarities simultaneously. In the experimental conditions, the polarity did not affect the 
spray condition. Thus, the solutions for either positive or negative spray were 
interchangeable. Figure 8.5 shows the comparison of  the release profile between THES 
cases and one dual-capillary ES cases. Table 8.4 gives the parameters in the 
biexponential release kinetic model. In D1, one spray head was operated in exactly the 
same condition as S1, while the other spray head sprayed PLGA with feed flow rate of  
1 µl/min. As shown in Figure 8.5 (a), the release rate was slightly decreased compared 
to S1. But the release was still faster than S2. The first hour release was 20% for D1. 
From the kinetic parameters shown in Table 8.4, we can see that the portion accounted 
for burst release (A1) was highly decreased in D1, which might be because the S1 
particles were partially coated by the polymer generated by the other spray head after 
they collided. In case D2, both S1 and S2 were sprayed separately using two identical 
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spray heads at the same time. S1 and S2 both contained budesonide/PLGA, but they 
released at different rates. The combination of  these two cases showed a release rate in 
between (Figure 8.5 (b)), as well as the kinetic parameters (Table 8.4). Particles 
containing both budesonide and pioglitazone can be generated using THES, with 
budesonide introduced to one spray head and pioglitazone introduced to the other one. 
The cases of  D3 and D4 were prepared in such ways. D3 included cases S1 and S3, 
while D4 included cases S2 and S3. Since D3 contained S1, and the total amount of  
polymer in D3 was the same as S4, the release rate of  D3 was compared with that of  S1 
and S4, as shown in Figure 8.5 (c). By spraying S1 and S3 at the same time, the polymer 
contained in each droplet after coagulation was much greater than cases using only one 
ES. As a result, the overall release rate of  D3 was close to that of  S4, which was much 
decreased than that of  S1. However, the initial burst release was still fast, indicating that 
the structure of  the particles after coagulation in D3 was not the same as the core-shall 
structure generated in S4. Similarly, in D4, the total amount of  polymer was almost 
doubled compared with S2, which greatly decreased the release of  budesonide, as 
shown in Figure 8.5 (d). The portion for burst release (A1) was reduced to 11%, and the 
half-life of  sustained release (t2(1/2)) increased to 227 hrs. 
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Figure 8.5 In vitro release profiles of  budesonide/PLGA particles generated by dual-capillary THES. (a) 
D1; (b) D2; (c) D3; (d) D4. Bar, SD.  
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Table 8.4 Release kinetics for budesonide/PLGA particles generated by THES. (Data shown in Mean ± 
SD) 
Cases D1 D2 D3 D4 
A1 0.25245±0.01372 0.25927±0.01365 0.24961±0.02001 0.10521±0.02119 
k1 3.66169±0.54585 3.08294±0.43701 2.76235±0.66191 5.58165±3.23055 
A2 0.63189±0.0137 0.72006±0.0113 0.64816±0.01633 0.8896±0.01803 
k2 63.16622±2.21646 98.25345±2.60958 165.91127±8.61792 327.42528±18.29548 
t1(1/2) 2.53755±0.37827 2.13648±0.30285 1.91431±0.45870 3.86808±2.23877 
t2(1/2) 43.77419±1.53601 68.08964±1.80844 114.97651±5.97222 226.90572±12.67877 
R2 0.99840 0.99872 0.99555 0.9868 
The in vitro release profiles of  pioglitazone are shown in Figure 8.6. Table 8.5 
summarized the corresponding release kinetics based on the biexponential model. When 
only one dual-capillary was used (S3), pioglitazone released rapidly, especially in the first 
few hours. The burst release accounted for 35% (A1) of  total concentrations. Similar to 
budesonide cases, the release rate was decreased when THES was used. D3, which 
sprayed S1 and S3 separately, had the same amount of  PLGA in the final particles as S4. 
The release rate of  D3 was slower than S3, due to the increase of  the mass of  polymer. 
However, D3 released faster than S4, indicating that unlike S4, pioglitazone was not in 
the center of  the particles generated in D3. In fact, the release rate of  D4, which had 
more polymer than S4, was comparable with that of  S4. The parameters of  release 
kinetics for D4 and S4 were close to each other. Although particles of  D4 were larger 
than S4, the thickness of  the polymer layer surrounding pioglitazone was similar to that 
of  particles of  S4, indicating that the mixing in the coagulated particles were incomplete. 
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Figure 8.6 In vitro release profile of  pioglitazone/PLGA particles generated by THES. Bar, SD. 
Table 8.5 Release kinetics for pioglitazone/PLGA particles generated by THES (Data shown in Mean ± 
SD) 
Cases S3 S4 D3 D4 
A1 0.35328±0.0338 0.18841±0.01297 0.20791±0.01128 0.21508±0.00582 
k1 6.51925±1.57474 5.48643±1.05842 24.61033±2.53679 14.69661±0.97091 
A2 0.53359±0.03136 0.75353±0.01006 0.77033±0.01149 0.78087±0.00563 
k2 172.2906±16.9813 379.23512±17.00545 739.34843±41.47648 996.72317±38.54218 
t1(1/2) 4.51783±1.09129 3.80210±0.73349 17.05496±1.75800 10.18475±0.67284 
t2(1/2) 119.39739±11.76804 262.80994±11.78478 512.36846±28.74320 690.72916±26.70973 
R2 0.99061 0.99543 0.99772 0.99867 
 
In the coagulation chamber, the coagulation between droplets containing either 
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to an electrical attraction between charges with opposite polarities. As shown in the 
SEM image (Figure 8.3 (b)), the particles after coagulation were not spherical. A 
reasonable guess would be that by the time coagulation happened, the solvent had not 
been completely evaporated from the droplet. As a result, after two droplets collided, 
the two solutions mixed due to diffusion until all the solvents were evaporated and the 
particles turned into the solid phase. This hypothesis was supported by the release 
profile. For one dual-capillary spray cases, the release rate decreased with the increase in 
polymer mass concentration. In twin-head ES cases, if  the drug/polymer remained in 
the same structure as one spray head cases, the release profile would not be affected. If  
no coagulation took place, or the particles separated after collision, or the particles were 
in solid state, the inner structure of  each particle would still be the same. However, for 
all the THES cases, the release was slower than the corresponding one spray head case. 
The decrease in release rate was associated with the change in particle structure, which 
was the increase in the thickness of  the polymer layer. 
The release mechanisms in polymer-based controlled delivery system are rather 
complicated. Depending on the types of  drug and polymer, one or more mechanisms 
might be involved in the controlled release system, such as diffusion, dissolution, 
swelling, hydrolysis, erosion, osmosis (Siepmann and Siepmann 2008; Uhrich et al. 1999). 
Mathematical modeling of  drug delivery is used to explain the release mechanism and to 
predict the release profile. Numerous models, including mechanistic realistic models and 
empirical/semi-empirical models have been described in the literature (Arifin et al. 2006; 
Narasimhan 2001; Siepmann and Gopferich 2001). In this study, we have tried to fit the 
drug release profiles with several well-defined empirical/semi-empirical models. 
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However, since assumptions have been made for all the models, and each model was 
designed for their special controlled release system, there was no single model that 
could explain all the release data. More characterizations will facilitate the mechanism 
modeling. 
8.3.3 Potential Application of  THES as ES Inhaler 
As discussed in section 7.3.6, the penetration of  the coagulated particles were 44% 
for the 90 degree chamber and over 60% for the 180 degree chamber, which were over 
75% of  the penetration achieved by using radioactive materials. There were strict 
regulations about using radioactive materials. In the THES system, no neutralizers were 
necessary and the particle transmission efficiency still remained at a high level. The 
particles generated by THES were airborne after exiting the system. They can be 
directly used for pulmonary drug delivery studies without further processes.  
The neutralization process is the key issue that obstructs the previous electrospray 
inhaler designed by Battelle Memorial Institute from success. By controlling the 
coagulation process, highly charged particles generated by twin-head electrospray system 
can be neutralized without using extra neutralizer.  
For single drug delivery, one spray head can be used to generate drug particles with 
desired particle size in order to reach a high deposition ratio in the lungs. The drug can 
be coated by polymer to obtain a predesigned release rate if  necessary. The other spray 
head serves as a neutralizer, which can spray either highly volatile organic solvent, or 
drug solution, or even polymer solution. The highly volatile solvent neutralizes drug 
particles without changing the chemical composition or the particle size. If  a drug 
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solution is used in the second spray head, the final aggregates contain primary drug 
particles formed by both spray heads, which will increase the drug mass output. To 
spray polymer solution in the second spray head will further decrease the release rate. 
The collisions between oppositely charged particles neutralize the charges, so that 
neutral drug aggregates are ready for pulmonary delivery.  
Besides the neutralization process, another issue that needs to be considered in 
order to make the electrospray inhaler easy and safe to use was the mass production rate. 
A certain dose of  the drugs is required in order to show effectiveness. One drawback of  
electrospray is its relatively low throughput. The liquid feeding flow rate cannot be 
increased without limitation. Besides optimizing the design of  the electrospray system 
to get high particle transmission efficiency, another possible solution is to use multiple 
spray nozzles. The multiplexed electrospray has already been well studied (Deng and 
Gomez 2007; Deng et al. 2006; Deng et al. 2009). There are already two electrospray 
heads in our twin-head electrospray system; to add more spray nozzles is feasible for the 
electrospray inhaler.  
8.4 Summary 
The twin-head electrospray system was used to generate drug-loaded PLGA 
particles. The particle size distribution, morphology, and in vitro release profile were 
characterized. Dual-capillary ES could produce drug/polymer particles with various 
diameters. By using both spray heads in the THES system, the release rate could be 
further decreased when compared with the release of  particles generated by each spray 
head. The initial burst release was also reduced after coagulation. The decrease in release 
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rate was associated with the increase in the amount of  polymer. The particles generated 
by dual-capillary ES were spherical in shape. After coagulation, the coagulated particles 
were irregular. The change in shape as well as in the release profile indicated that when 
the droplets collided due to electrical attraction, the solvent was not completely 
evaporated. After collision, the two droplets merged while the solvent continued 
evaporating. The non-spherical shape suggested that the two droplets were not well 
mixed when the solvent was completely vaporized. The non-solid state collision ensures 
that the two droplets became one after colliding with each other. The change in release 
profiles provides more evidence for the coagulation process that happened in the THES 
system. The THES also provides the possibility of  developing new electrospray inhalers 
for animal studies as well as human use. 
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Chapter 9  
Dissertation Accomplishments and 
Recommendations for Future Work 
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9.1 Summary of  Accomplishments 
In this dissertation, two spray techniques were studied. First, an animal exposure 
system using spray drying technique was used for the investigation of  chemopreventive 
agents for their inhibitory effects on lung tumorigenesis. Second, a twin-head 
electrospray system, which could be used as a drug delivery system in both the animal 
studies for lung cancer chemoprevention and potentially for humans, was designed and 
evaluated. The accomplishments of  each part of  the study are summarized as follows:  
9.1.1 Aerosol Delivery and Evaluation of  Chemopreventive 
Agents for the Inhibition of  Lung Tumorigenesis  
An aerosol delivery system, containing a custom-build Collison-type atomizer, 
diffusion dryers and/or scrubbers, and a nose-only 12-mice exposure chamber, was 
used to deliver the chemopreventive agents directly to the lung of  mice. Six single 
agents and three groups of  combination treatment were evaluated using female A/J 
mice and postinitiation protocol.  
The six single agents, Polyphenon E, Polyphenon E without EGCG, resveratrol, 
gefitinib, erlotinib, and budesonide, were all administrated via an aerosol route. This 
study showed that Polyphenon E was an effective chemopreventive agent for inducing 
tumor regression and inhibiting tumor growth, while Polyphenon E without EGCG was 
ineffective. EGCG is thought to be the most active component in Polyphenon E, but 
the results of  this study proved that EGCG has to be with other tea catechins to show 
chemopreventive activity on lung tumorigenesis in aerosolized form. Resveratrol, which 
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showed no effects on lung tumorigenesis previously when it was given in diet, inhibit 
tumor growth significantly. HPLC analysis confirmed the existence of  resveratrol in the 
lung, indicating that aerosol delivery could highly improve the bioavailability of  
resveratrol in the lung. Two EGFR inhibitors, gefitinib and erlotinib, inhibited the 
growth of  tumors initiated by either B(a)P or VC. No skin toxicity, which was 
commonly associated with the effectiveness in both animal study and human clinical 
trials, was observed throughout the treatment. Budesonide inhibited tumor multiplicity 
and tumor load. The inhibitory effects increased with the dose. However, higher dosage 
causes severe decrease in body weight. Lower dosages are recommended for future 
testing. 
Through single agent evaluation experiments, the delivery by aerosol of  
chemopreventive agents was demonstrated to be a novel method for providing the 
powerful efficacies in chemoprevention of  lung tumorigenesis. Aerosol delivery can 
decrease the dose, minimize the toxicity, and improve the bioavailability in the lung. The 
inhalation system used in this study is able to provide aerosol with stable size 
distribution which was suitable for a chemoprevention study in mice as well as in men. 
The aerosol delivery is an effective approach of  chemoprevention, which could be 
considered for further studies in animal models as well as clinical trials. 
The combination effects of  aerosolized budesonide with oral Polyphenon E, indole-
3-carbinol, or pioglitazone were investigated using female A/J mice. Aerosolized 
budesonide inhibited lung adenoma formation. Compared to the solvent control group, 
budesonide decreased the tumor multiplicity and the tumor load by 56.7% and 78.4%, 
respectively. Furthermore, aerosol delivery can achieve higher concentration in the lung 
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with low chemopreventive agent dose compared to other administration routes. Used as 
a single agent, Polyphenon E, I3C and pioglitazone all showed significant inhibition on 
the tumor load. The decrease in the tumor load was 82.9% by Polyphenon E, 83.2% by 
I3C, and 63.3% by pioglitazone. No effects on the tumor multiplicity were achieved. By 
combining aerosolized budesonide with Polyphenon E, indole-3-carbinol or 
pioglitazone, respectively, the tumor load of  test mice could be significantly reduced. 
Budesonide with Polyphenon E decreased the tumor load by 88.8%. For budesonide 
with I3C, the decrease in the tumor load was 84.9%. Budesonide and pioglitazone 
showed the most decrease on the tumor load among the three combination treatment 
cases. The decrease in tumor load was 89.6%. The three agents used for combination 
treatment with budesonide alone did not decrease the tumor number. As a result, the 
combination groups all showed similar inhibitory effects on tumor multiplicity as 
budesonide alone case. Among all three combination groups, pioglitazone combined 
with budesonide showed the greatest inhibitions on tumor load, which makes them a 
promising candidate for further investigation. Our result shows that the combination of  
agents targeting different pathways could be a promising approach in lung cancer 
chemoprevention.  
9.1.2 Design and Evaluation of  a Twin-head Electrospray 
System 
A twin-head electrospray system was designed with two configurations of  the 
coagulation chamber. The performance was evaluated under different operational 
conditions. The spray head operated in the cone-jet mode could generate monodisperse 
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aerosols. By using two or more neutralizers, the charge-enhanced coagulations between 
oppositely charged particles were negligible. When no neutralizers were included at the 
mixing region of  the two aerosol flows, coagulation happened. The coagulation process 
was confirmed by the size distribution, fluorescence microscope, and chemical 
composition analysis using HPLC.  
The size change due to coagulation was characterized for particle size ranging from 
10 nm to 710 nm, including both primary particles and satellites. The peak diameter of  
particles after coagulation was about 1.3 times larger than the size before the 
coagulation, indicating that the large particles were formed due to the collision of  two 
oppositely charged initial particles. The initial particle size and the charge level did not 
affect the size distributions after coagulation. By using the 180 degree chamber, similar 
size distributions of  coagulated particles were observed. The number of  charges on 
particles was highly reduced due to the coagulation. Only a small portion of  coagulated 
particles are neutral. At least two-thirds of  the particles remained carrying charges after 
coagulation. 
The particle transmission efficiency was characterized for both spray chambers. By 
using two neutralizers, the transmission efficiency was 52.3% for the 90 degree chamber 
and 79.0% for the 180 degree chamber. Compared with the cases with two neutralizers, 
the transmission efficiency of  the experiments without neutralizers was slightly smaller: 
44.2% for the 90 degree chamber and over 60.0% for the 180 degree chamber. The 
design of  twin-head electrospray, which utilized the coagulation between oppositely 
charged particles as the charge reduction method, could achieve almost equivalent 
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particle transmission efficiency with that achieved by using radioactive sources to 
neutralize the charge.  
The twin-head electrospray system was used to generate drug-loaded PLGA 
particles. The particle size distribution, morphology, and in vitro release profile were 
characterized. Dual-capillary ES could produce drug/polymer particles with various 
diameters. By using both spray heads in the THES system, the release rate could be 
further decreased when compared with the release of  particles generated by each spray 
head. The decrease in release rate was associated with the increase in the amount of  
polymer. The particles generated by dual-capillary ES were spherical. After coagulation, 
the coagulated particles were irregular in shape. The change in shape as well as in the 
release profile indicated that when the droplets collided due to electrical attraction, the 
solvent was not completely evaporated. After collision, the two droplets merged while 
the solvent continued evaporating. The non-spherical shape suggested that the two 
particles were not well mixed when the solvent was completely vaporized. The non-solid 
state collision ensures that the two droplets became one after colliding with each other. 
The change in release profiles provides more evidence for the coagulation process that 
happened in the THES system. The THES also provides the possibility of  developing 
new electrospray inhalers for animal studies as well as human use. 
9.2 Recommendations for Future Research 
The animal exposure system used in this study was proved to be effective in the 
aerosol delivery for lung cancer chemoprevention. Besides investigating more agents 
using aerosol delivery, a more detailed study regarding particle deposition in the lung of  
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mice can provide useful information for the design and improvement of  the aerosol 
generation system. The geometry of  the airway of  mice is much smaller than human. A 
lot of  research has been done regarding the deposition efficiency of  particles with 
various sizes in the lung of  human. Limited information could be found about the 
deposition pattern in the lung of  mice. Since the animal study is the necessary step for 
drug screening, knowing more about the depositions in mice can facilitate the aerosol 
delivery study.  
Besides particle size, other properties of  particles, such as the charge level, the shape 
and morphology, may also affect the deposition and absorption of  the drugs in the lung. 
The deposition efficiency of  the current delivery system can be highly improved if  
more information about the particle deposition is available. The characterization may 
also serve as a reference for human studies. 
In this study, the combination treatment for lung cancer chemoprevention used 
different administration methods for the two combined drugs. Because of  the 
advantages of  aerosol delivery, the drugs for the combination study can all be 
introduced through an aerosol route.  
In the study of  the THES system, the characterizations were mainly focused on the 
size distribution before and after coagulation. Beside the size distribution, the particle 
charge distribution is also important for applications. The initial charge distribution of  
ES generated particles was very difficult to be directly characterized due to the 
extremely high charge level. The charge distribution of  coagulated particles that exited 
from the THES system could be characterized using electrical aerosol analyzer (EAA).  
   170 
The twin-head electrospray was initially designed for animal studies in lung cancer 
chemoprevention. However, due to limited time, this experiment has not been carried 
out. The THES can generate two drug particles separately without interference, which is 
suitable for the combination treatment. Also, the capability of  generating drug/polymer 
particles for controlled release that can directly used for inhalation provides more 
options for future animal exposure studies. 
As mentioned in chapter 8, the twin-head ES can potentially be used as an ES 
inhaler. The inhaler can be easily translated from the design of  THES. The previously 
designed ES inhaler which failed the clinical trial already proved the possibility of  a 
portable ES inhaler. Since the main drawback of  their design has been solved by using 
the twin-head ES, the success in this new ES inhaler is very likely to happen. 
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Abstract 
A new single capillary electrospray aerosol generator has been developed for 
monodisperse particle production with maximal transmission efficiency. The new 
generator consists of  both a spray chamber in a point-to-orifice-plate configuration and 
a charge reduction chamber that can hold up to four Nuclespot ionizers (Model P-2042, 
NRD Inc.). The two chambers are partitioned by an orifice plate. To optimize the 
particle transmission efficiency of  the prototype, a systematic study was performed on 
the generator by varying the system setup and operation. Two key dimensions of  the 
generator setup, the orifice diameter and the distance from the capillary tip to the orifice 
plate, were varied. Fluorescence analysis was applied to characterize the loss of  ES-
generated particles at different locations of  the prototype. It was found that particle loss 
in the generator could be reduced by either increasing the orifice diameter or decreasing 
the distance between the capillary tip and the orifice plate. Increasing either the total 
radioactivity of  the ionizers or the flowrate of  the particle carrier gas also further 
decreased the particle loss in the system. The maximum particle transmission efficiency 
of  88.0% was obtained with the spray chamber fully opened to the charge reduction 
chamber, the capillary tip at the same level as the orifice plate, and four bipolar ionizers 
installed.  
 
 
Keywords: Electrospray generator, particle transmission efficiency, particle loss, 
particle discharge. 
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1. Introduction 
Electrohydrodynamic spraying (i.e., electrospray, ES) uses electric forces to atomize 
liquids. In ES, the liquid flowing out of  a capillary nozzle is forced into fine droplets 
when the local liquid surface tension is overcome by the electric forces at the surface of  
the liquid. The basic forms of  ES include single capillary ES, dual-capillary ES, and tri-
nozzle ES (Chen et al. 1995; Lee et al. 2011; Mei and Chen 2007). The operational mode 
of  single capillary ES has been well investigated and summarized (Cloupeau and 
Prunetfoch 1994; de la Mora 2007; Jaworek and Krupa 1999; Marginean et al. 2007). 
Among all the operational modes, the so-called cone-jet mode, capable of  generating 
monodisperse particles in diameters ranging from nanometers to micrometers, has 
attracted much attention in particle research and applications. Unlike mechanical spray 
techniques, ES can generate particles within a narrow size range, and the particle size 
can be varied by changing the liquid conductivity, liquid flowrate, and solute 
concentration without degrading the particles’ chemical or biological properties (Chen 
and Pui 1997; Ganan-Calvo 1997; Hartman et al. 2000). Examples of  ES applications 
include drug delivery, nanoparticle material synthesis, thin film deposition, and particle 
encapsulation (Chen et al. 1995; Ciach 2007; Jaworek 2007; Jaworek and Sobczyk 2008; 
Mei and Chen 2007; Peltonen et al. 2010). However, the low particle transmission 
efficiency with existing ES systems has not been fully addressed. Based on the 
experimental evaluation previously done by one of  the authors a commercial 
electrospray aerosol generator system typically has only 30-40% particle transmission 
efficiency. This becomes significant for applications in which the mass concentration of  
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particles is critical, such as targeted medicine delivery, particle material synthesis and 
recovery, and nanoparticle toxicity studies. 
The transport behavior of  ES-generated droplets emitted from the jet break-up has 
been investigated (Ganan-Calvo et al. 1994; Gomez and Tang 1994; Hartman et al. 
1999). Most studies on particle transport in ES processes, however, have focused on 
droplet behavior in the spray plume. In the radial direction of  the plume, the spray is at 
first very narrow. Because of  the mutual repulsion of  highly charged droplets, it then 
spreads significantly as droplets move towards the counter electrode. More, it has been 
observed that particles of  smaller sizes move toward the edge of  the spray due to their 
high electrical mobility when compared with particles of  large sizes (Ganan-Calvo et al. 
1994). In the axial direction of  the plume, the velocity of  ES-generated particles is 
mainly attributed to the electric field strength between the capillary and counter 
electrode plate. It is therefore easy for highly-charged droplets to be deposited on the 
counter electrode. The above spray behavior is advantageous for thin film preparation 
via electrospray. However, for aerosol applications, ES-generated particles must remain 
airborne prior to their use. Therefore, the electrical charge level on ES-generated 
particles needs to be reduced for further transportation. In general the charge level of  
ES-produced particles can be reduced by passing them through an environment where 
bipolar ions are produced via corona discharge, soft X-ray, or radioactive materials 
(Chen et al. 1995; Ebeling et al. 2000; Hogan et al. 2004). However, beyond these 
generalizations, information about the particle transmission efficiency of  electrospray 
systems is very limited. In fact, most documented ES systems are not optimized to 
achieve high particle transmission efficiency. Further, to the authors’ knowledge, there 
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has been no thorough investigation into the particle loss in an ES system via variation 
of  the system setup and operational parameters.  
In this study we developed a new single capillary electrospray aerosol system to 
achieve high particle transmission efficiency. The performance of  this new electrospray 
system, especially the particle transmission efficiency, was optimized via variations of  
the system design, operational flowrate of  carrier gas, and strength of  radioactive 
material used. We also modeled the electric field in various system configurations to 
assist in the interpretation of  experimental observations. The modeling results are 
included in the supplemental information.  
2. Experimental Setup and Methods 
The newly designed single-capillary ES aerosol system in this study consisted of  
both spray and particle charge reduction chambers. A point-to-orifice-plate arrangement 
was used in the spray chamber, which was made of  transparent plexiglass. A stainless 
steel capillary with an I.D. of  0.012" and O.D. of  1/32" was fixed on a holding plate 
that was installed at the top of  the spray chamber, with the capillary in line with the 
center of  the orifice plate. The distance between the capillary tip and the orifice plate 
could be adjusted from 0 to 1/4" by inserting 1/32" thick spacers. Plates with orifices 
of  three diameters (1/4", 3/4", and 5/4" D) were tested in the study. All of  the orifice 
plates were 3/16” thick. The transparent plexiglass spray chamber enabled observation 
of  the spray condition via an optical system including an illumination light source, a 
microscope lens (Infinivar CFM-2/S™ Microscope Video Lenses, Edmund Optics Inc., 
Barrington, NJ), and a CCD camera (Model XCD-SX910CR, SONY). The charge 
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reduction chamber was designed to hold up to four spot ionizers (Po210, Nuclespot P-
2042, NRD LLC, Grand Island, NY). A cylindrical opening with a 5/4” diameter was 
the working zone in the charge reduction chamber. The axial distance between the 
upper edge of  the ionizer and the lower surface of  the orifice plate was 5/16”. The 
above distance was chosen to ensure that high energy  particles emitted from Po210 
sources did not reach the tip of  the spray capillary. As a result, the bipolar ions in the 
spray chamber neutralized the particles: no influences on the spray were observed. 
During operation, a positive high voltage was applied at the capillary tube via a high 
voltage DC power supply (Bertan, Series 230, Spellman High Voltage Electronics 
Corporation, Valhalla, NY). The orifice plate and charge reduction chamber were 
electrically grounded. The spray solution was introduced into the capillary tube by a 
syringe pump (PHD 2000, Harvard Apparatus, Holliston, MA). Filtered air was 
introduced into the spray chamber as particle carrier gas. The carrier gas flowrate was 
controlled by a needle valve and monitored by a laminar flow meter. Note that an 
optional flow channel was designed in the system to introduce sheath gas flow around 
the capillary tip when spraying solutions with high surface tension, such as aqueous 
solutions. This option, however, was not needed for this study.  
Figure 1 is a schematic diagram of  the experimental setup. The ES system was 
operated in a stable cone-jet mode to generate monodisperse particles. The liquid feed 
flow rate was fixed at 1 µl/min, and the applied positive voltage was around 4 kV 
relative to the electrically grounded orifice plate. Two flowrates of  particle carrier air 
(1.5 and 6.0 lpm) were tested. At the exit of  the charge reduction chamber, a 47 mm 
filter holder (Millipore, Billerica, MA) with high efficiency particulate air (HEPA) filter 
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media (Lydall Filtration/Seperation, Inc., Rochester, NH) collected all the particles 
exiting from the ES system. 
 
Figure 1  Schematic diagram of  experimental setup to characterize the transmission loss of  particles 
generated by the single-capillary ES system. 
Fluorescence analysis was used to characterize the particle loss at various locations 
of  the ES system (Chen and Pui, 1995). Uranine was the fluorescent tracer for the 
quantitative analysis of  deposited particles. The electrospray solution was prepared by 
dissolving 0.1% (v/v) sucrose and 1 g/l uranine in a 2-propanol/water mixture. Each 
experimental run lasted for 60 min.  
After each run, particles deposited at various locations in the ES system were 
washed off  by an aqueous solution of  0.001 N ammonium hydroxide. The uranine 
deposited on the orifice plate ( PlateM ) was recovered by wiping the surface with cotton 
swabs wetted in the wash solution. The uranine on the cotton swabs was then dissolved 
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in 25 ml of  wash solution. The uranine deposited in the charge reduction chamber 
( ChamberM ) was recovered in the same way. The mass of  the uranine collected on the 
filter was measured by immersing the entire filter medium in 25 ml of  the wash solution. 
The uranine deposited on the wall of  the tubing connecting the ES system with the 
HEPA filter was also recovered by cotton swabs, which were then immersed in the same 
wash solution as the filter. FilterM  thus included the uranine that survived passage 
through the ES system. The concentration of  uranine in the various wash solutions was 
measured by a calibrated fluorometer (GloMax®-Multi Jr Single Tube Multimode 
Reader, Promega Corporation, CA). For each experimental run, we further checked the 
mass conservation of  uranine by comparing the amount of  uranine recovered from 
various locations in the generator with the total amount of  uranine sprayed. In general 
the difference between the sprayed and recovered amounts was within 5% of  the total 
sprayed. 
The transmission efficiency of  ES-produced particles was then calculated by the 
following equation: 
FilterChamberPlate
Filter
MMM
M
η
++
= .                              (1) 
3. Results and Discussion 
ES that operates in the cone-jet mode can generate monodisperse particles with 
diameters varying from nanometers to micrometers. Because particles produced by ES 
are highly charged, significant particle loss in the system is expected, owing to the 
presence of  the strong DC electrical field for the spray and the mutual repulsion among 
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highly charged particles. Reducing the electric charge of  ES-generated particles will help 
keep them airborne. The transmission efficiency of  the studied ES aerosol generator 
was influenced by factors including the system setup configuration, particle carrier gas 
flowrate, and the strength of  the radioactive sources. In this study, the particle 
transmission efficiency was characterized under these factors.   
3.1  Effects of  Orifice Diameter and Capillary-to-Plate Distance  
The orifice ratio, defined as the ratio of  the orifice diameter to the diameter of  the 
charge reduction chamber, was used to characterize the effects of  orifice diameter on 
the transmission efficiency of  the ES generator. Three plates were tested, with orifice 
ratios of  1:5 (plate #1; 1/4" D), 3:5 (plate #2; 3/4" D), and 1:1 (plate #3; 5/4" D). The 
transmission efficiency was characterized at a carrier gas flowrate of  6.0 lpm, with four 
ionizers installed in the charge reduction chamber. No spacer was used for this part of  
the experiment, so the spray capillary tip was at the same level as the upper surface of  
the orifice plate. Figure 2 shows the transmission efficiencies as a function of  the orifice 
ratios.  
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Figure 2  Transmission efficiency and particle loss on the orifice plate for different orifices. 
Under the given experimental conditions, approximately 45.8% of  particles 
generated by the single capillary ES penetrated through the system when plate #1 was 
installed. The transmission efficiency increased with larger orifices. Compared to the 
case with plate #1, the transmission efficiency of  the aerosol generator was almost 
doubled (i.e., 86.2%) by using plate #3. Also shown in Figure 2 is the percentage of  
particles deposited on the orifice plate. With increased orifice diameters, the particle loss 
on the plate decreased from 53.3% for plate #1 to 3.7% for plate #3. 
In addition to the orifice size, another dimension in the system setup was the 
distance between the tip of  the capillary and the upper surface of  the orifice plate. In 
our system the distance could be adjusted by the spacers. The experimental results for 
this part of  the study are shown in Figure 3. Four ionizers were installed in the charge 
reduction chamber of  the ES generator for these experiments. Recall that with no 
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spacer, plate #1 (1/4" D) had a transmission efficiency of  45.8% at a carrier gas 
flowrate of  6.0 lpm. When a 1/4" spacer was installed, the efficiency at the same 
flowrate dropped to 11.0%. For plate #3 (5/4" D), at a gas flowrate of  1.5 lpm, spacers 
of  1/8" and 1/4" thicknesses resulted in transmission efficiencies of  84.9% and 70.1%, 
respectively. When no spacer was installed, the transmission efficiency for plate #3 was 
88.0%. The particle transmission efficiency of  the studied ES generator was again 
decreased by larger distances between the capillary tip and orifice plate.  
 
Figure 3  Effect of  the spacers and orifice plate on transmission efficiency and particle loss on the 
orifice plate.  
For an ES setup in the point-to-orifice-plate configuration, the electrical field is 
present in both the spray and charge reduction chambers. The movement of  ES-
generated droplets results from the flow and electrical fields, the charges on particles, 
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and the gravity of  large particles. In general, because of  the DC electrical field, particles 
generated by ES are highly charged with the same polarity. When the electrical field is 
sufficiently strong, charged droplets are most likely moving in the field direction. When 
no spacer is used (i.e., the tip of  the capillary is in the plane of  the orifice plate), the 
steepest decrease in electrical potential is in the radial direction, from the capillary tip to 
the edge of  the orifice. The gradient of  electrical potential decreases with an increase of  
the orifice diameter. The percentage of  the particles lost on the orifice plate thus 
decreased as the orifice diameter varied from 1/4" to 5/4".  
When a spacer was used, the capillary tip was located above the orifice plate. Highly 
charged droplets generated by ES had to first travel through the spray chamber, pass the 
orifice plate, and enter the charge reduction chamber, where the particle charge level 
could be reduced by exposing them to bipolar ions produced by the radioactive sources 
(Po210). For the case of  the 1/4" D orifice plate, the larger the distance between the 
capillary tip and orifice plate, the longer the distance droplets had to travel. 
Consequently, more droplets were likely deposited on the orifice plate. With the 5/4" D 
orifice plate, the gradient of  the electrical potential was much less than for the case with 
the 1/4" D orifice plate. Therefore, the movement of  charged droplets in the radial 
direction was much slower, giving more time for charge reduction. The result was a 
reduction of  particle deposition on the orifice plate. In fact, with 5/4" D orifice plate, 
most of  the particle loss was in the charge reduction chamber. 
3.2  Effect of  Radioactive Source Strength  
   183 
Particles generated by ES are highly charged, especially when spraying liquids of  
high electrical conductivity. ES-produced particles thus tend to follow the electrical field 
and deposit on the counter electrode (i.e., orifice plate). For applications in which the 
collection or deposition of  particles is essential, the particle collection efficiency can be 
increased by grounding or applying minor voltage of  reverse polarity on the collector, 
consequently decreasing the particle loss. However, some applications, such as aerosol 
drug delivery, require particles to remain airborne. In such applications the above 
methodology will not improve the particle transmission efficiency of  the studied 
generator. To reduce the particle loss due to the electrostatic force, charges on ES-
generated particles must be reduced. Several charge reduction techniques, such as 
corona discharge, radioactive sources, and soft X-ray irradiation, could be applied in ES 
systems. Using a radioactive source is an effective and reliable way to electrically 
neutralize charged particles (Liu and Pui 1974). In this study, 210Po α ionization sources 
(Model P-2042; NRD Inc.) were used in the charge reduction chamber, which could 
simultaneously hold up to four ionizers. The bipolar ion concentration in the chamber, 
N0, which increases with the radioactive strength, can be estimated as follows (Vivas et 
al. 2008): 
VWα
EA
N
r
0
0 = ,                                                 (2) 
where A0 is the activity of  the radioactive source, E is the energy of  the α particles, 
αr is the ion recombination coefficient (1.6 × 10
-12 m3s-1), W is the mean ionization 
potential of  air (35 eV), and V is the volume of  the charge reduction chamber. The 
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original activity of  the Nuclespot ionizers was 5.0 mCi. The actually activity can thus be 
calculated based on the half-life of  210Po, which is 138 days: 
mCitA
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In this part of  study, the effect of  the ion concentration on the particle transmission 
efficiency of  ES-produced particles was studied by varying the number of  sources 
installed in the charge reduction chamber. Figure 4 shows the transmission efficiency of  
the generator as a function of  ion concentration at a carrier gas flowrate of  6.0 lpm. 
The data for the cases with Plate #1 (1/4" D) and #3 (5/4" D) are compared. In both 
cases, the transmission efficiency increased with an increase in bipolar ion concentration. 
When no ionizer was installed, ES-produced particles were more likely to follow the 
electrical field and be deposited on the grounded surfaces (i.e., the surfaces of  the 
orifice plate and the inner surface of  the charge reduction chamber). As a result, the 
measured particle transmission efficiency was less than 5% for both orifice plate cases. 
With only one ionizer in the prototype, the percentage of  ES-produced particles that 
exited the system were 37.4% for the 5/4" D orifice and 13.3% for the 1/4" D orifice, 
respectively. The particle transmission efficiency kept increasing with an increase in 
bipolar ion concentration. When more ionizers were used, the bipolar ion density in the 
charge reduction zone was increased, thus increasing the chance to reduce the charges 
on ES-produced particles. As shown in Figure 4, the particle transmission efficiency was 
doubled when the ion concentration increased from about 4.9 × 108 #/cm3 to over 5.9 
× 108 #/cm3. However, as the ion concentrations increased from 5.9 × 108 #/cm3 to 7.1 
× 108 #/cm3, the particle transmission efficiency increased by less than 10%. The 
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average charges associated with ES-produced particles are directly related to the spray 
current, which remained constant in our study (the sprayed solutions had the same 
electrical conductivity). Thus, for a certain average charge level, there existed a 
minimum ion concentration required to effectively reduce charges on most ES-
produced particles. For the given experimental conditions, to reach over 80% of  the 
highest transmission efficiency, the ion concentration was larger than 5.9 × 108 #/cm3, 
corresponding to more than two ionizers used in the prototype. The half-life of  Po210 is 
about 138 days. Using at least three ionizers with a total radioactivity larger than 4 mCi 
is thus recommended for the studied ES generator.  
 
Figure 4  Transmission efficiency as a function of  bipolar ion concentration. The flow rate of  carrier 
gas was 6 lpm. No spacer was used.  
 Similarly, Figure 5 shows the transmission efficiency of  ES-produced particles as a 
function of  ion concentration for the cases of  (a) the 1/4" D orifice plate with spacers 
and (b) the 5/4" D orifice plate with spacers. For all spacer cases, the transmission 
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efficiency increased with an increase in bipolar ion concentration. Moreover, the 
increases in the transmission efficiencies for the cases when the ion concentration was 
larger than 6 × 108 #/cm3 were all within 5%. For cases with both 1/4" D and 5/4" D 
orifice plates, at a given ion concentration, the use of  a spacer increased the particle loss, 
which is in agreement with the modeling result. Note that the particle transmission 
efficiency did not vary much for the cases using a 5/4" D orifice plate (with/without 
spacers installed). In contrast, a significant difference in the efficiency was observed for 
the cases using a 1/4" D orifice plate (with/without spacers).  
 
(a) 
   187 
 
(b) 
Figure 5 Transmission efficiency as a function of  bipolar ion concentration: (a)  using ¼” orifice 
plate together with spacers and (b) using 5/4” orifice plate together with spacers. 
3.3  Effect of  Carrier Gas Flowrate 
In addition to the bipolar ion concentration, the other factor affecting the charge 
reduction process is the particle residence time in the charge reduction chamber. The 
residence time is controlled by the flowrate of  particle carrier gas. We used particle 
carrier gas flowrates of  1.5 lpm and 6.0 lpm, corresponding to residence times of  1.6 s 
and 0.4 s, respectively. The Reynolds numbers in the ES system were 67 and 267 for 1.5 
lpm and 6.0 lpm flow, respectively, indicating that the flow was mostly laminar in the 
system. Fig. 6a shows the transmission efficiency as a function of  bipolar ion 
concentration for the ES generator with the 1/4" D orifice plate and without a spacer. 
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Fig. 6b is for the system with the 1/4" D orifice plate and a spacer of  1/4” thickness, 
and Fig. 6c is for the 5/4” D orifice plate without a spacer.  
 
(a) 
 
(b) 
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(c) 
Figure 6 Effects of  carrier gas flowrate on transmission efficiency as a function of  bipolar ion 
concentration. (a) 1/4" D orifice plate, no spacer; (b) 1/4" D orifice plate, 1/4" spacer; (c) 5/4" D 
orifice plate, no spacer. 
For the 1/4" D orifice plate, the transmission efficiency at a carrier gas flowrate of  
6.0 lpm was much improved over that at 1.5 lpm. The transmission efficiency for the 
generator with the 1/4" D orifice plate, operated at the 1.5 lpm air flowrate, was less 
than 15%, even with four ionizers installed. However, as indicated in Fig. 6c, the 
improvement between the cases with the 1/4" D orifice plate was not observed with the 
5/4" D orifice plate.   
With the 1/4" D orifice plate installed in the studied ES generator, the spray and 
charge reduction chambers were separated. Charges on ES-generated particles could not 
be efficiently reduced before they entered the charge reduction chamber. The major 
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particle loss for the generator with the 1/4" D orifice plate was thus attributed to 
particle deposition on the orifice plate. By operating the ES system at a high flowrate, 
the gas flow velocity was increased and the particle residence time was decreased, 
leading to less deposition of  charged droplets on the orifice plate. 
The bore of  the spray and charge reduction chambers are each cylinders with an 
inner diameter of  5/4". When the 5/4" D orifice plate was installed in the system, the 
two chambers were effectively merged into one. The distance between the capillary tip 
and the chamber wall was at least 5/8”. Under the given ion concentration, the long 
travel distance increased the chance for particles to be charge-reduced prior to their 
deposition on the orifice plate. At the same time, their residence time was decreased 
when the flowrate of  carrier gas was increased. The chance for ion-particle interaction 
was decreased, leading to an increase in particle loss due to ineffective charge reduction. 
The overall particle transmission efficiency of  the studied system was the result of  the 
two competitive factors described above. Fig. 6c shows that the particle transmission 
efficiencies at two carrier gas flowrates were nearly the same for the system with the 
5/4" D orifice plate, indicating that the carrier gas flowrate did not significantly affect 
the particle transmission. It is possible that the effect of  residence time decrease on the 
transmission efficiency was offset by that of  the long particle travel distance in the 
system prior to their deposition.  
Note that we tried to plot the transmission efficiency as a function of  the Nit value 
since the product of  the ion concentration Ni and residence time t is normally used as 
the key parameter in neutralization/charging theories.  However, no simple correlation 
could be found in all the studied cases, indicating that other factors, for example, spatial 
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distribution of  ions and chamber geometry, play roles in the loss of  ES-generated 
particles.  
3.4  Effect of  Particle Loss on the Size Distribution of  ES-generated 
Particles 
As shown in the previous section, the particle loss in the studied ES system depends 
on the system setup and operation. We wanted to check whether or not the particle loss 
affected the size distribution of  particles generated. We thus characterized the size 
distribution of  particles using a scanning mobility particle sizer (SMPS, Model 3080, TSI 
Inc., St Paul, MN) for various system setups and operating conditions. All the data 
obtained in this part of  the experiment were obtained from systems with four bipolar 
ionizers installed.  
Two typical size distributions are shown in Figure 7. Fig. 7a is the size distribution 
for the case with low particle transmission efficiency (4.0%): the system was operated 
with the 1/4" orifice plate and 1/4" spacer installed (1.5 lpm flowrate). Fig. 7b gives the 
size distribution of  particles generated from the system with high particle transmission 
efficiency (86.2%), with the 5/4" D orifice plate and no spacer installed (6.0 lpm 
flowrate). 
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Figure 7 Particle size distribution generated by the designed ES system: (a) 1/4" D orifice plate, 1/4" 
spacer, 1.5 lpm; (b) 5/4" D orifice plate, no spacer, 6 lpm. 
The geometric mean diameters and geometric standard deviations for the size 
distributions in Fig. 7 were 145.9 nm and 1.20 for Fig. 7a, and 153.7 nm and 1.20 for Fig. 
7b. The primary particle size distributions are similar in shape for all the tested cases. In 
general, the monodispersity of  generated particles remained good, confirming that the 
distribution of  primary particles was not affected in our system optimization for 
maximal particle transmission efficiency. The major difference between the distributions 
was that the case of  high particle transmission efficiency (Fig. 7b) had more particles 
with smaller diameters than the low efficiency case (Fig. 7a). It is known that particles 
generated in ES move with different velocities in the radial direction of  the spray. Due 
to their high electrical mobility,more smaller particles moved toward the edge of  the 
spray than large particles (Ganan-Calvo et al. 1994). As a result, the loss of  smaller 
particles increased significantly when the orifice diameter was decreased. As shown in 
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Fig. 7, more particles with smaller diameters passed through the ES system with the 
5/4”D orifice, while the primary particle size distribution remained similar in shape.  
4. Conclusion 
A prototype single-capillary electrospray aerosol generator in point-to-orifice-plate 
configuration was constructed and optimized to achieve high transmission efficiency of  
produced particles. A systematic study was performed by varying the system setup and 
flowrate operation. Two key dimensions were varied, the orifice diameter of  the counter 
electrode plate and the distance between the capillary tip and the plate. Fluorescence 
analysis was used to quantify the particle loss at different locations of  the prototype 
under various setups and operating conditions. Numerical modeling of  the electrical 
field at different system setups was also performed to assist in interpreting the 
experimental observations. It was found that the particle loss could be significantly 
reduced by increasing the orifice diameter and/or decreasing the distance between the 
capillary tip and orifice plate. The particle transmission efficiency of  the studied ES 
system could be further improved by increasing either the ionizing radioactivity or the 
flowrate of  carrier gas. It was concluded that three radioactive ionizers with a total 
radioactivity larger than 4 mCi would be sufficient for the prototype. The flowrate of  
particle carrier gas more significantly influenced the system with the 1/4" D orifice 
plate than that with the 5/4" D orifice plate, possibly because of  the balance between 
the charge reduction process and particle transportation in the prototype. The quality of  
particles generated by the prototype ES system was also examined by SMPS, and 
measured primary particle peaks were not affected by particle loss. Thus, the prototype 
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generated particles with good monodispersity while achieving high particle transmission 
efficiency. The highest particle transmission efficiency, 88.0%, was achieved with the 
spray chamber fully open to the charge reduction chamber, the capillary tip at the same 
level as the orifice plate, and four bipolar ionizers installed. The knowledge obtained in 
this study provides general guidance for the system setup of  single-capillary electrospray 
to achieve high transmission efficiency. It may also provide basic guidelines for the 
system setup in multiplexing ES. 
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